 
 A PHASE  I/IB TRIAL  OF MK-3475 (PEMBROLIZUMAB)  AND AFATINIB  IN EGFR -
MUTANT  NON- SMALL CELL LUNG  CANCER WITH  RESISTANCE  TO ERLOTINIB  
 
 
Funding  Sources:  Merck  &Co., Inc. 
Boehringer Ingelheim Pharmaceuticals  Inc. (BIPI)  
 
Protocol Number(s):  UCDCC#250 ; 1200.237 (BIPI); 51657 (Merck)  
 
Phase:  1 
 
Principal  Investigator: Jonathan Riess, MD,  MS 
University of California  Davis  Comprehensive Cancer    Center  
4501 X Street, Sacramento,  CA 95817 
     Telephone: (916) 734-3771 
Fax: (916) 734-7946  
jwriess@ucdavis.edu  
 
Co-Investigators: David Gandara, MD 
UC Davis  Comprehensive Cancer  Center  
 4501 X Street, Sacramento, CA 95817 
 Telephone: (916) 734-3771 
Fax: (916) 734-7946  
drgandara@ucdavis.edu  
 
Karen  Kelly,  MD 
UC Davis  Comprehensive Cancer  Center  
4501 X Street, Sacramento,  CA 95817 
Telephone: (916) 734-3771 
 Fax: (916) 734-7946 
karkelly@ucdavis.edu  
 STATISTICAN: Laurel  Beckett,  PhD  
 Division  of Biostatistics,  MS1C  
 University  of California  Davis  
 One Shields A
venue 
Davis,  CA 95616  
labeckett@ucdavis.edu  
 
IND # (Exemption) :                          125235 
 
VERSION NO./VERSION DATE:    Original/October 14, 2014  
 Revision/November 4, 2014 
 Version 1.0/August 4, 2015 
 Version 2.0/ July 26, 2016 
 Version 3.0/September 10, 2018 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 2 of 133 
  
INVESTIGATOR SIGNATURE PAGE  
 
 
Protocol Number: UCDCC#25 0 
 
Protocol Title: A PHASE I/I B TRIAL OF MK -3475 (PEMBROLIZUMAB)  AND AFATINIB 
IN EGFR -MUTANT NON- SMALL CELL LUNG CANCER WITH RESISTANCE TO 
ERLOTINIB  
 
 I have read this protocol and agree that it contains all necessary details for carrying out this study. I will conduct the study as outlined herein and will complete the study within the time designated, in accordance with all stipulations of the protocol and in accordance with Good Clinical Practices, local regulatory requirements, and the Declaration of Helsinki.  
 I will provide copies of the protocol and all pertinent information to all individuals responsible to me who assist in the conduct of this study. I will discuss this material with them to ensure that they are fully informed regarding the study agent(s) and the conduct of the study.     __________________________________ Investigator Name (print)  
  __________________________________ Investigator Signature  
  _____________________ Date  
 
 
  
 
  
 
  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 3 of 133 
 TABLE OF CONTENTS  
 
1.0  TRIAL  SUMMARY  .......................................................................................................... 6  
2.0  TRIAL  DESIGN  ................................................................................................................ 7  
2.1    Trial  Design  ...................................................................................................................... 7  
2.2 Trial  Diagram  ................................................................................................................. 8  
3.0  OBJECTIVE(S)  & HYPOTHESIS(ES)  .......................................................................... 9  
3.1 Primary  Objective & Hypothesis .................................................................................. 9  
3.2 Secondary  Objective & Hypothesis  .............................................................................. 9  
3.3 Exploratory Objectives  ................................................................................................ 10  
4.0  BACKGROUND  & RATIONALE ................................................................................. 10  
4.1 Study Disease  ................................................................................................................ 10  
4.2 MK-3475  ....................................................................................................................... 10  
4.2.1  Pharmaceutical  and Therapeutic Background  ..................................................... 10  
4.2.2  Preclinical  and Clinical  Trial  Data  ...................................................................... 12  
4.3 Afatinib  ......................................................................................................................... 12  
4.3.1  Pharmaceutical  and Therapeutic  ......................................................................... 12  
4.4 Rationale  ....................................................................................................................... 13  
4.4.1  Rationale  for the Trial  and Selected  Subject  Population ..................................... 13  
4.4.2  Rationale  for Dose  Selection/Regimen/Modification  ......................................... 14  
4.4.3  Rationale  for Endpoints  ...................................................................................... 16  
5.0  METHODOLOGY  .......................................................................................................... 18  
5.1.1    Diagnosis/Condition for Entry  into the Trial  ........................................................ 18  
5.1.2    Subject Inclusion Criteria ...................................................................................... 18  
5.1.3  Subject  Exclusion Criteria  .................................................................................. 20  
5.1.4  Trial  Treatments  .................................................................................................. 22  
5.1.5    Dose Selection/Modification  ................................................................................ 24  
5.1.6    Timing of Dose Administration  ............................................................................ 30  
5.1.7    Trial Blinding/Masking ......................................................................................... 30  
5.2    Treatment  Allocation  .................................................................................................... 30  
5.3    Definition  of Dose  Limiting  Toxicities  (DLT)  ............................................................. 31  
5.4    Attribution of Adverse Events  ..................................................................................... 32  
5.5.1    Acceptable Concomitant Medications  .................................................................. 32  
5.5.2    Prohibited Concomitant Medications  .................................................................... 33  
5.6    Rescue Medications  & Supportive  Care  ...................................................................... 34  
5.6.1    Supportive Care Guidelines  .................................................................................. 34  
5.6.2 Rescue medication  for Afatinib  ............................................................................... 38  
5.6.3    Management of Eye  Complications  of Afatinib  ................................................... 38  
5.6.4    Management of expected  adverse  events  .............................................................. 38  
5.6.5    Management of diarrhea and hydration status following treatment with afatinib 38  
5.6.6  Management  recommendations  for dermatological  AEs following treatment  with 
afatinib  39 
5.6.7  Management  of mucositis/stomatitis  .................................................................. 42  
5.7    Diet/Activity/Other  Considerations  ............................................................................. 43  
5.7.1    Diet  ........................................................................................................................ 43  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 4 of 133 
 5.7.2    Contraception  ........................................................................................................ 43  
5.7.3    Use in  Pregnancy  .................................................................................................. 45  
5.7.4    Use in  Nursing Women  ......................................................................................... 46  
5.8    Subject  Withdrawal/Discontinuation Criteria  ............................................................ 46  
5.8.1  Discontinuation of Study Therapy after CR  ....................................................... 47  
5.9    Subject  Replacement  Strategy  ...................................................................................... 47  
5.10  Clinical Criteria  for Early  Trial  Termination  ............................................................ 47  
6.0  TRIAL  FLOW  CHART  .................................................................................................. 48  
7.0  TRIAL  PROCEDURES  .................................................................................................. 51  
7.1    Trial  Procedures  ............................................................................................................ 51  
7.1.1    Administrative Procedures  .................................................................................... 51  
7.1.2    Clinical Procedures/Assessments  .......................................................................... 53  
7.1.3    Laboratory Procedures/Assessments ..................................................................... 59  
7.2    Correlative Studies  ........................................................................................................ 60  
Correlative Studies  .................................................................................................................. 60  
7.2.1    EGFR -directed  Correlative  Studies  ...................................................................... 60  
7.2.3    Immunology Correlates  ........................................................................................ 63  
7.2.4    EGFR & Immunology B iopsy Process ing .......................................................... 64  
7.2.5    Immunology Peripheral Blood Processing ........................................................... 67  
7.3   Withdrawal/Discontinuation  ......................................................................................... 68  
7.4    Visit Requirements ......................................................................................................... 68  
7.4.1   Screening  ............................................................................................................... 68  
7.4.2   Treatment  Period  ................................................................................................... 69  
7.4. 3   Post- Treatment  Visits  ........................................................................................... 69  
7.5    Assessing  and Recording  Adverse Events  ................................................................... 70  
7.5.1    Definition of an Overdose for This Protocol and Reporting of Overdose  ........... 71  
to Merck  ............................................................................................................................ 71  
7.5.2    Reporting of Pregnancy and Lactation  to Merck and BIPI  ................................... 71  
7.5.3    Immediate Reporting of Adverse  Events to Merck and BIPI  ............................... 72  
7.5.4    Protocol-Specific Exceptions to Serious Adverse Event Reporting ..................... 74  
7.5.5  Evaluating Adverse Events  ................................................................................. 75  
7.5.6    Sponsor-Investigator Responsibility for Reporting Adverse  Events  .................... 75  
7.5.7    Safety Reporting Requirements  for IND Exempt Studies  .................................... 75  
8.0  STATISTICAL  ANALYSIS PLAN  ............................................................................... 75  
8.1    Statistical  Analysis Plan  Summary  .............................................................................. 76  
8.2 Correlative Statistical  Analysis Plan  .......................................................................... 77  
9.0  LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL SUPPLIES
................................................................................................................................................... 77  
9.1 Investigational Product:  MK-3475  ............................................................................. 77  
9.1.1  Packaging  and Labeling  Information  .................................................................. 78  
9.1.2    Clinical Supplies Disclosure  ................................................................................. 78  
9.1.3    Storage and Handling Requirements  ..................................................................... 78  
9.1.4    Returns and Reconciliation  ................................................................................... 78  
9.2    Investigational Product:  Afatinib  ................................................................................ 79  
9.2.1    Packaging and Labeling  Information  .................................................................... 79  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 5 of 133 
 9.2.2    Storage Conditions  ................................................................................................ 79  
9.2.3    Drug Accountability .............................................................................................. 79  
10.0  ADMINISTRATIVE  AND REGULATORY DETAILS  ............................................ 80  
10.1  Confidentiality  ......................................................................................................... 80  
10.2  Good Clinical Practice ............................................................................................. 80  
10.3  Patient  Information  and Informed  Consent  ............................................................. 80  
10.4  Records  and Retention............................................................................................. 81  
10.5  Data and Safety  Monitoring .................................................................................... 81  
10.6  Compliance with Trial  Registration  and Results Posting Requirements  ................. 82  
10.7  Quality  Assurance and Control  ............................................................................... 82  
10.8  Registration  Guidelines  ........................................................................................... 83  
10.9  Data Management  ................................................................................................... 84  
11.0  LIST OF REFERENCES  .............................................................................................. 85  
12.0  APPENDICES  ................................................................................................................ 89  
12.1  ECOG P erformance  Status  ...................................................................................... 89  
12.2  Common Terminology Criteria  for Adverse Events V4.0 (CTCAE)  ...................... 90  
12.3  Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria forEvaluating 
Response in Solid  Tumors ................................................................................................ 91  
12.4  New  York  Heart  Association  Classification  of Heart  Failure  ................................. 92  
12.5  List of Potent Inhibitors and Inducers  of P-glycoprotein (MDR1) .......................... 93  
12.6. Liquid Genomics Sample Requisition Form ............................................................ 94  
12.7  Laboratory Tests  ...................................................................................................... 96  
12.8  Evaluating Adverse  Events  ...................................................................................... 97  
12.9  Event of Clinical Interest Guidance Document  ....................................................... 99  
 
           
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 6 of 133 
 1.0  TRIAL  SUMMARY  
 
Abbreviated  Title  MK-3475 and  Afatinib  in EGFR -Mutant  Non-Small  Cell 
Lung Cancer  
Trial  Phase  Phase  I 
Clinical  Indication  The treatment  of subjects  with incurable,  advanced, metastatic  or 
recurrent  non-small  cell lung cancer  with EGFR  activating  
mutations who have  progressive  disease either  clinically  or 
radiographically on erlotinib. 
Trial  Type  Interventional  
Type  of control  N/A 
Test product(s)/Route  of 
administration  Afatinib  (Oral  Tablets)  
MK-3475 (Intravenous) 
Trial  Blinding  Unblinded  Open -label  
Treatment  Groups  • Dose  De-Escalation  of Concurrent  afatinib  + MK-3475  Dose 
Expansion:  
(Cohort A) 
• Concurrent afatinib  + MK-3475  
(Cohort B) 
• Lead  in MK-3475 for 2 cycles followed by C oncurrent afatinib  
+ MK -3475  
Number  of trial  subjects  A minimum  of 9 patients,  if trial is terminated  early  due to 
unacceptable toxicity  and a maximum of 38 patients (18 patients  in 
dose de -escalation  cohort plus 20 in the expansion  cohorts ). 
Estimated  duration  of trial  Approximately 36 months from  the time the first subject 
signs  the informed  consent  until the last subject’s last visit.  
Duration  of Participation  • Patients  will be followed  through  30 days (+/- 5 days)  after 
the last dose of study drugs. 
• All new drug related  events  will be reported  for 30 days after 
the last study drug administration. 
• AEs will be followed  until resolution, return  to baseline, or it  
is deemed  that further recovery  is unlikely. 
• Patients should be contacted by telephone every 12 weeks to 
assess for survival status until  death, withdrawal of consent, or 
the end of the study, whichever occurs first.  
• Each  subject  may receive treatment with MK -3475 for up to 
2 years from  the time  of first dose of MK -3475. 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 7 of 133 
 2.0  TRIAL  DESIGN  
2.1    Trial  Design  
 
This is a prospective, non-randomized, open label  Phase I clinical  trial of intravenous (IV) MK -
3475 (pembrolizumab, Keytruda ®) and afatinib  (oral  tablets)  in subjects  with advanced  or 
metastatic  NSCLC  with EGFR  activating mutations  (exon  19 deletion, exon  21 L858R, G719X, 
L861Q) who have experienced  disease progression on erlotinib, gefitinib  or osimertinib .  It is a 
phase I dose de-escalation  study followed by a phase Ib expansion with  two cohorts for further 
safety  evaluation  and correlative studies of immune  modulation with repeat  biopsy and peripheral 
blood collection.  
 
For the dose de-escalated phase,  patients will receive MK -3475 and afatinib  as outlined in Table 
1 and Section 5.1.5 with escalation  of MK-3475 to the maximum tolerated dose ( MTD ). A 
fixed  dose of MK-3475 (200 mg q3 weeks)  will be tested  in combination with afatinib  starting  
at the FDA approved dose for EGFR -mutated  NSCLC  (40 mg PO daily).  The dose de-
escalation  phase will establish  the MTD  of MK -3475 in combination with afatinib.  
 
Once the MTD  is reached,  patients  will initially  be allocated to  one of two different  arms  at this  
dose: concurrent afatinib  + MK-3475 (Arm  A) or lead in MK-3475 followed by afatinib  
+ MK-3475 (Arm  B) . For Arm A, there  is no lead-in phase.  For Arm B, MK-3475 will be 
given  for 2 cycles  (6 weeks)  as a lead in followed by combination afatinib  and MK-3475. 
Ten patients  will be enrolled  for each cohort (20  patients  total).  These two  expansion cohorts 
will further define toxicities  at the MTD  in order to determine  the recommended phase II dose 
(RP2D) and to assess initial estimates  of efficacy  and examine correlative studies- particularly 
regarding immune  modulation of afatinib  and MK-3475 between  the differing  cohorts.   
 
Subjects  will be evaluated  every  6 weeks  with radiographic imaging  to assess response to 
treatment per  Response Evaluation Criteria  in Solid  Tumors (RECIST)  1.1. Adverse events will 
be monitored throughout the trial and graded  in severity  according  to the guidelines outlined in 
the NCI Common Terminology Criteria  for Adverse Events (CTCAE)  version  
4.0. Treatment  with  MK-3475 and afatinib  will continue until documented disease progression, 
2 years  from  first cycle  of MK-3475 (afatinib  may continue past 2 years), unacceptable adverse 
event(s),  intercurrent  illness  that prevents further  administration  of treatment, investigator’s  
decision  to withdraw the subject,  subject  withdraws consent, pregnancy of the subject,  
noncompliance with trial treatment  or procedure requirements,  or administrative  reasons.  
 After  the end of treatment,  each subject  will be followed for a minimum of 30 days for safety 
monitoring. Subjects  will have post- treatment follow -up for disease  status  until disease 
progression, initiating  a non-study cancer  treatment  (such as chemotherapy, other targeted 
therapy, other treatment for lung cancer), withdrawing consent, or becoming lost to  follow-up 
(progression free survival). 
 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 8 of 133 
 2.2 Trial  Diagram 
 
    
 
  
Advanced  
EGFR -mutant NSCLC; 
Prior erlotinib therapy 
with progressive disease  
Lead in MK-3475  
for 2 cycles  
(Each cycle is 21 days)  
Concurrent Afatinib  
+ 
MK-3475 
(Each cycle is 21 days)  
Disease assessment  
every 6 weeks 
Biopsy at Baseline and at  
6 weeks (after 2 cycles)  
Progressive disease  
RECIST 1.1  
Progressive disease  
RECIST 1.1  
Safety Follow up 
Expansion Cohort B 
Dose De -escalation  
and 
Expansion Cohort A  
Concurrent Afatinib  
+ 
MK-3475 
(Each cycle is 21 days)  
Safety Follow up 
Disease assessment  
every 6 weeks 
Biopsy at Baseline and at  
6 weeks (after 2 cycles)  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 9 of 133 
 Table 1: Dose  De-Escalation  Schema  
 
Dose Leve l Number of Patients Afatinib  
(Daily)  MK- 3475  
(q3 weeks ) 
0 3+ 40 mg D1 200 mg D1 
-1 3+ 30 mg D1 200 mg D1 
-2 3+ 20 mg D1 200 mg D1 
 
 
Dose  Level  0 is the starting  combination dose level  (in bold). If ≥ 2 patients  experience a 
DLT  at dose level  0, the next dose level  will be dose level  -1. If ≥ 2 patients  experience a 
DLT  at dose level  -1, the next  dose level  will be dose level  -2. 
 
The phase I dose de- escalation  portion of the trial will be closed  when  the MTD  or dose level  0 is 
reached  and six patients  have been  treated  at that dose level.  
 
Please see section  5.1.5 for further details  of the dose de- escalation  schema.  
 
 
3.0  OBJECTIVE(S)  & HYPOTHESIS(ES)  
 
3.1 Primary  Objective  & Hypothesis  
 
Objective:  To evaluate the safety  and tolerability  of MK -3475 when given  in combination with  
afatinib  in patients  with advanced  or metastatic  non- small cell lung cancer  with EGFR activating  
mutations  who have progressive disease on erlotinib. 
 
 
Hypothesis: We hypothesize that MK-3475 and afatinib  will be tolerable and that we can 
reach  an effective maximum tolerated  dose (MTD)  and recommended  phase 2 dose (RP2D).  
 
3.2 Secondary  Objective & Hypothesis  
 
Objective: To assess in a preliminary  manner  the efficacy  of this combination (response rate, 
disease control rate and  progression free survival) 
 
Hypothesis : We hypothesize that MK-3475 and afatinib  in combination will be efficacious.  
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 10 of 133 
 3.3 Exploratory Objectives 
 
Objective 1: To determine in an exploratory manner  changes  in PD-L1 expression  in the tumor 
microenvironment and other immune  correlates  in blood and in the tumor microenvironment 
induced by afatinib  with concurrent MK-3475 versus MK-3475 preceding combination 
afatinib/MK -3475. 
 
Objective 2: To determine in an exploratory manner  changes  in EGFR -mutant plasma  DNA  
in response to treatment  with MK-3475 and afatinib.  
 
4.0  BACKGROUND  & RATIONALE  
4.1 Study Disease  
 
Lung  cancer  is the leading  cause of cancer  deaths worldwide due to the majority  of patients  
presenting  with metastatic  disease for which  there  is no cure. In recent  years, advances  in the 
systemic  treatment of non- small cell lung cancer  (NSCLC)  have increased  survival by several  
months and subsets of patients enjoy  prolonged survival beyond two years  (Subramanian  J, et al. 
J Thorac Oncol 7:260-5, 2012).  More efficacious therapies  have been  a direct  result  of our 
increased  understanding and exploitation of the molecular  basis  of lung cancer.  The development 
of inhibitors to the epidermal  growth  factor  receptor  (EGFR)  and the resultant  blockade of its 
signaling  pathway were  the first molecularly  targeted  agents  to improve outcome in this  disease 
(Shepherd FA et  al. N Engl  J Med  353:123-32, 2005).  Patients whose tumors harbor a 
sensitizing  mutation  in EGFR  derive the most benefit  from  EGFR tyrosine kinase inhibitor (TKI)  
therapy  (Mok  TS et al. N Engl  J Med  361:947-57, 2009, Maemondo M. et al. N Engl  J Med  
362:2380-8, 2010).  However,  despite impressive  responses and significantly  prolonged survival 
in this specialized  patient population, all patients  develop resistance to EGFR  TKIs  resulting  in 
tumor progression and death. Concentrated  efforts  to understand the mechanisms  of resistance to 
EGFR -TKIs  are underway. The development of treatment  combinations to overcome or delay 
resistance to erlotinib  represents  a major  unmet need.  
4.2 MK-3475 
4.2.1 P
harmaceutical  and Therapeutic  Background 
 The importance of intact immune  surveillance in controlling outgrowth of neoplastic 
transformation  has been  known for decades [1].  Accumulating evidence shows a correlation 
between  tumor- infiltrating  lymphocytes (TILs) in cancer  tissue  and favorable prognosis in 
various malignancies  [2; 3; 4; 5; 6].  In particular, the presence of CD8+ T- cells and the ratio of 
CD8+  effector  T-cells / FoxP3+ regulatory  T-cells seems  to correlate with improved prognosis 
and long- term survival in many  solid  tumors. 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 11 of 133 
 The PD-1 receptor -ligand  interaction  is a major  pathway hijacked  by tumors  to suppress immune 
control. The normal function of PD -1, expressed  on the cell surface  of activated  T- cells  under 
healthy  conditions, is to down-modulate unwanted or excessive immune re spons es, including 
autoimmune reactions.  PD-1 (encoded  by the  gene  Pdcd1) is an Ig superfamily  member  related  
to CD28 and CTLA -4 which  has been  shown to negatively regulate antigen receptor  signaling  
upon engagement of its  ligands (PD-L1 and/or PD-L2) [7; 8]. The structure  of murine PD-1 has 
been  resolved  [9].  PD-1 and family  members  are type I transmembrane glycoproteins containing 
an Ig Variable- type (V-type)  domain responsible for ligand binding and a cytoplasmic  tail which  
is responsible for the  binding of signaling molecules.  The cytoplasmic  tail of PD -1 contains 2 
tyrosine- based  signaling  motifs,  an immunoreceptor tyrosine- based  inhibition  motif  (ITIM)  and 
an immunoreceptor tyrosine- based  switch  motif  (ITSM).  Following T- cell stimulation,  PD-1 
recruits  the tyrosine phosphatases SHP-1 and SHP -2 to the ITSM  motif  within  its cytoplasmic  
tail, leading  to the dephosphorylation of effector  molecules  such as CD3ζ, PKCθ  and ZAP70  
which  are involved in the CD3 T -cell signaling  cascade [7; 10; 11; 12].  The mechanism  by 
which  PD-1 down modulates T- cell responses is similar  to, but distinct from  that of CTLA -4 as 
both molecules regulate  an overlapping set of signaling proteins [13; 14].  PD- 1 was  shown to be 
expressed  on activated  l ymphocytes including peripheral  CD4+  and CD8+  T-cells,  B-cells,  T regs  
and Natural  Killer  cells [15; 16].  Expression has also been  shown during thymic development  on 
CD4 -CD8 - (double negative) T- cells as well  as subsets of macrophages  and dendritic cells [17].  
The ligands for PD -1 (PD -L1 and PD-L2) are constitutively  expressed  or can  be induced in a 
variety  of cell  types,  including non- hematopoietic  tissues as well  as in various tumors [18; 19; 20; 
13].  Both ligands are type I transmembrane receptors  containing both IgV - and IgC-like domains 
in the extracellular  region  and contain  short cytoplasmic regions  with no known signaling motifs.  
Binding of either  PD-1 ligand to PD-1 inhibits  T- cell  activation  triggered  through the T- cell 
receptor.  PD-L1 is expressed  at low levels  on various non- hematopoietic  tissues,  most notably on 
vascular  endothelium, whereas  PD-L2 protein is only detectably  expressed  on antigen -presenting 
cells found in lymphoid tissue  or chronic inflammatory  environments. PD-L2 is thought to 
control immune  T-cell activati on in lymphoid organs, whereas  PD-L1 serves  to dampen  
unwarranted  T-cell function in peripheral tissues [13].  Although healthy  organs express  little (if 
any) PD-L1, a variety  of cancers  were  demonstrated  to express  abundant levels  of this T- cell 
inhibitor. PD-1 has been  suggested  to regulate  tumor -specific  T-cell expansion in su bjects  with 
melanoma  (MEL) [21].  This suggests that the PD-1/PD- L1 pathway plays  a critical  role in tumor 
immune evasion and should be considered  as an attractive  target  for therapeutic  intervention. 
 
MK-3475 ( Keytruda®, pembrolizumab, and previously known as  SCH 900475) is a potent and 
highly selective humanized monoclonal antibody (mAb)  of the IgG4/kappa isotype designed  to 
directly  block the interaction  between  PD-1 and its  ligands, PD-L1 and PD-L2. MK-3475 has 
recently been approved in the United Stated for the treatment of patients with unresectable or 
metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.  It has also been approved for NSCLC positive for PD- L1 
by the DAK 22C3 antibody after progression on platinum- based chemotherapy , as well as for 
first-line treatment of patients with metastatic (NSCLC whose tumors have high PD -L1 
expression [Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 12 of 133 
 4.2.2 Preclinical  and C linical Trial  Data  
 
Refer  to the Investigator’s Brochure  for MK -3475 Preclinical  and Clinical data.  
4.3 Afatinib  
4.3.1 Pharmaceutical  and Therapeutic  
 
Afatinib  (BIBW2992) is a small molecule,  selective  and irreversible  erbB  family  blocker.  In 
preclinical  models it effectively  inhibits  EGFR,  HER2  and HER4  phosphorylation resulting in  
tumour growth inhibition  and regression  of established  subcutaneous tumors derived from four 
human cell-lines  known to co -express  ErbB  receptors.  
 For the latest  information  on the drug profile  of afatinib, please refer to the current Investigator’s  
Brochure  (IB) (U03 -3218).  All references  in this protocol concerning  afatinib refer  to the free 
base compound afatinib  BI which  is used  as the oral formulation. 
 
Afatinib  is moderately  fast absorbed after oral administration.  Maximum plasma concentrations  
of afatinib  were  achieved  mainly  at 2 to 5 hours after oral drug administration. Afatinib  
maximum  plasma  concentrations  and area under the curve increased  slightly  over- proportional 
with increasing  doses in  the therapeutic  range of 20 -50mg. Moderate to high inter - and intra -
individual differences  in plasma  concentration  were seen.  Afatinib  is highly distributed  out of the 
blood and has a moderate  to high  clearance.  The overall  gMean terminal  half-life at steady  state 
was 37.2 hours in cancer  patients.  Steady  state was reached no later  than 8 days  after  the first 
administration.  The major  route of elimination  of afatinib was via feces.  After  food intake, a 
decreased  systemic  exposure was observed compared  to administration  under fasted  conditions. 
Therefore,  afatinib  should be taken  without food (i.e. food should not be consumed  for at  least 1 
hour before and at least 2 hours after meal).  The PK characteristics  in Caucasian  cancer  patients  
were comparable  to those observed in Japanese cancer  patients.  
 Afa
tinib is bound covalently to proteins to a variable extent  and covalent  protein adducts were the 
major  circulating  metabolites  in the plasma.  Afatinib  did not show relevant inhibition or 
induction of cytochrome P450 isoenzymes, and it appears  unlikely that drug- drug interactions  
based  on this mechanism  will occur.  
 Afatinib  is a substrate of the P- gp transporter.  Concomitant administration  of the potent P- gp 
inhibitor ritonavir did not relevantly  change  the exposure to 40 mg afatinib  when  taken 
simultaneously with or 6 h after afatinib  but increased  the bioavailability  of afatinib  (single dose 
of 20 mg) by 48% and 39% for AUC
0-∞ and Cmax when  given  1 h before afatinib, respectively.  
Pretreatment  with the potent P-gp inducer rifampicin  decreased  the plasma exposure of 40 mg 
afatinib  by 34 % afatinib (AUC 0-∞) and 22 % (C max), respectively.  Caution should be exercised  
when  combining afatinib  with potent P- gp modulators. In pre -clinical studies , afatinib  is not an 
irritant to intact  skin but an ocular  irritant.  Afatinib  is mutagenic  in a single  bacteria strain,  but 
did not show genotoxic potential in vivo when  tested  up to overt toxic/lethal doses. Studies on 
embryo -fetal development in rats and rabbits up to life - threatening  doses have revealed  no 
indication  of teratogenicity.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 13 of 133 
  
Two phase I open label  dose- escalation  studies determined  the MTD  with continuous dosing of 
afatinib  in patients  with advanced  solid  tumors at 40mg and 50mg daily,  respectively ( Ould -
Kaci  M.  Investigator’s  brochure.  Afatinib  (BIBW  2992).  Version  14,  1200.P1 1200. 
P10. 2013, Temple  G, et al. A Phase I open- label  dose escalation  study of continuous once-
daily  oral treatment  with BIBW  2992 in patients  with advanced  solid  tumours.  Trial  
1200.3.  2010.).  Adverse events  (AE) observed  with afatinib  are consistent with those 
reported  for other EGFR  and dual EGFR/HER2  inhibitors. The most frequent investigator  
defined drug- related  AEs   were   associated  with   gastrointestinal  disorders  (including 
diarrhoea, and stomatitis),  skin and subcutaneous tissue  disorders (rash,  dry skin, pruritus, 
acneiform  rash,  acne),  nail  effects,  epistaxis,  fatigue  and  decreased  appetite.  Early  and 
proactive  management  of  diarrhea,  mucositis/stomatitis  and  skin  rash  together  with 
treatment interruptions and  dose reductions is recommended in line with recent  guidelines in the 
management  of common  toxicities  of EGFR  and EGFR/HER2  TKIs  and monoclonal 
antibodies  (Lynch  TJ,  Jr.  et  al.  Oncologist.  2007  May;12(5):610-21.  PubMed  PMID:  
17522250. Lacouture ME et al. Expert  Rev Anticancer Ther.  2013 Jun;13(6):721-8. PubMed 
PMID:  23506519. Yan g JC et al. Expert  Rev Anticancer Ther.  2013 Jun;13(6):729-36. PubMed 
PMID:  23506556. Moy  B, Goss P. Oncologist 1007;12(7):756-65. Giaccone G et al. A  
consensus position from  the EGFRI  dermatologic  toxicity  forum.   ECCO;  Barcelona  
2007). 
 
Refer  to the Investigator’s Brochure  for Afatinib  Preclinical  and Clinical data.  
 
4.4 Rationale 
4.4.1 Rationale for the Trial  and Selected  Subject  Population 
 
The discovery of EGFR  activating  mutations  in NSCLC  and the targeting  of these mutations with  
EGFR -TKIs  represents  a substantial advance in the treatment  of metastatic  NSCLC. EGFR  is a 
member  of the ERBB family  of receptor  tyrosine kinases.  Mutations that render EGFR  
constitutively  active  in NSCLC  are sensitive  to inhibition  with EGFR  tyrosine kinase inhibitors. 
Invariably,  acquired  resistance to erlotinib  develops; more  than 60% of patients experience 
progression within  a year (Rosell  R et al Lancet  Oncol 2012; 13:239-46). New strategies  to 
overcome or circumvent acquired  resistance to EGFR -TKIs  represent  a major unmet need. 
 
Afatinib,  an irreversible  inhibitor of EGFR  and other complexes  formed  by the  ErbB  family of 
hetero - and homo- dimers,  represents  a good first  step in addressing  acquired  resistance to first  
generation  EGFR -TKIs.  Of note, afatinib  is FDA approved as frontline therapy  for use  in patients  
with EGFR -activating  mutations  based  on a significant PFS benefit compared  to platinum based  
chemotherapy  in patients  whose tumors harbor EGFR  activating mutations  (Sequist, LV et al. 
JCO 2013 31:27 3327-34). Additionally, in patients  with EGFR -mutated  cancers  and established  
acquired  resistance to erlotinib,  afatinib  prolongs progression- free survival, with a disease control 
rate of 57% and a 7% response rate (Miller VA et al.  Lancet  Oncol 2012; 13:528-38). 
Combination approaches  with afatinib  appea r more  promising. For example,  the combination of 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 14 of 133 
 afatinib  and cetuximab  has substantially higher response rates  (29% RR) and activity  (100% 
DCR)  (Y. Y. Janjigian et al. Cancer Discovery  2014 4:9; 1036-45) . This combination activity  of 
afatinib/cetuximab  in patients with  acquired  resistance is in contrast  to erlotinib/cetuximab  in this 
setting,  where very little activity  is seen.  Thus afatinib  (as an irreversible  EGFR  inhibitor with 
activity  against mechanisms  such as T790M) is  a more  promising EGFR -TKI to pair with other 
therapeutics  such  as MK-3475. MK-3475 is a potent and highly selective  humanized  mAb  of the 
IgG4/kappa isotype  designed  to directly  block the interaction  between  PD-1 and its  ligands, PD-
L1 and PD-L2. 
 
In preclinical  cell lines  and genetically  engineered  (GEMM)  mouse models EGFR  driven 
tumors expressed  higher levels  of PD-L1 with a more  immunosuppressive tumor 
microenvironment (increased  FoxP3+ T- cells,  decreased  CD8+/CD4+  ratio)  (Akbay EA et al.  
Cancer  discovery 2013; 3:1355-63). Increased PD -L1 expression  was shown across  a range of 
EGFR  activating  mutations  and the EGFR  T790M resistance mutation.  Addition  of an  EGFR -
TKI that decreased EGFR  pathway activity  also decreased PD -L1 expression. The irreversible 
EGFR -TKI WZ004 was more  effective in this regard  than the reversible  EGFR - TKI  gefitinib  in 
preclinical models  with EGFR  T790M (the most common (~60%) EGFR - TKI  resistance 
mutation).  Thus, EGFR mutated  NSCLC  may be  particularly  sensitive  to PD1 antibodies such as 
MK-3475. An irreversible EGFR  inhibitor such as afatinib  may be more effective than the 
reversible EGFR -TKI erlotinib  in this setting.  
 
 
4.4.2 Rationale for Dose  Selection/Regimen/Modification  
 
The dose regimen of 200 mg Q3W of MK -3475 (pembrolizumab) is planned for all urothelial 
cancer trials. Available PK results in subjects with melanoma, NSCLC, and other solid tumor 
types support a lack of meaningful difference in PK exposures obtained at a given dose among tumor types. An open- label  Phase I trial  (PN001) in melanoma subjects is being conducted  to 
evaluate the safety  and clinical  activity  of single  agent  MK-3475.  The dose escalation  portion of 
this trial evaluated three dose levels,  1 mg/kg,  3 mg/kg,  and 10 mg/kg,  administered  every  2 
weeks  (Q2W)  in subjects with advanced  solid  tumors. All three dose levels  were well tolerated  
and no dose- limiting  toxicities  were observed. This first in human  study of MK -3475 showed 
evidence  of target  engagement  and objective evidence of tumor size reduction at all dose levels  (1 
mg/kg,  3 mg/kg  and 10 mg/kg  Q2W).  No MTD has been  identified  to date.  
 In KEYNOTE -001, two randomized cohort evaluations of melanoma subjects receiving 
pembrolizumab at a dose of 2 mg/kg versus 10 mg/kg Q3W have been completed.  The clinical efficacy and safety data demonstrate a lack of clinically important differences in ef ficacy 
response or safety profile at these doses.   For example, in Cohort B2, advanced melanoma 
subjects who had received prior ipilimumab therapy were randomized to receive pembrolizumab at 2 mg/kg versus 10 mg/kg Q3W.  The overall response rate (ORR) was  26% (21/81) in the 
2mg/kg group and 26% (25/79) in the 10 mg/kg group (full analysis set (FAS)).  The proportion of subjects with drug- related adverse events (AEs), grade 3 -5 drug-related AEs, serious drug-
related AEs, death or discontinuation due to an AE was comparable between groups or lower in the 10 mg/kg group.   
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 15 of 133 
 Available pharmacokinetic results in subjects with melanoma, NSCLC, and other solid tumor 
types support a lack of meaningful difference in pharmacokinetic exposures obtained at a given dose among tumor types.  Population PK analysis has been performed and has confirmed the expectation that intrinsic factors do not affect exposure to pembrolizumab to a clinically meaningful extent.  Taken together, these data support the use of lower doses (with similar exposure to 2 mg/kg Q3W) in all solid tumor indications.  2 mg/kg Q3W is being evaluated in NSCLC in PN001, Cohort F30 and PN010, and 200 mg Q3W is being evaluated in head and neck cancer in PN012, which are expected to provide additional data supporting the dose selection.  
 Selection of 200 mg as the appropriate dose for a switch to fixed dosing is based on simulation results indicating that 200 mg will provide exposures that are reasonably consistent with those obtained with 2 mg/kg dose and importantly will maintain individ ual patient exposures within 
the exposure range established in melanoma as associated with maximal clinical response.   A 
population PK model, which characterized the influence of body weight and other patient covariates on exposure, has been developed using available data from 476 subjects from PN001.   The distribution of exposures from the 200 mg fixed dose are predicted to considerably overlap those obtained with the 2 mg/kg dose, with some tendency for individual values to range slightly higher with the  200 mg fixed dose.   The slight increase in PK variability predicted for 
the fixed dose relative to weight -based dosing is not expected to be clinically important given 
that the range of individual exposures is well contained within the range of exposures shown in the melanoma studies of 2 and 10 mg/kg to provide similar efficacy and safety.  The population PK evaluation revealed that there was no significant impact of tumor burden on exposure. In addition, exposure was similar between the NSCLC and melanoma indications. Therefore, there are no anticipated changes in exposure between different tumor types and indication settings.  
 
The rationale for further exploration of 2 mg/kg and comparable doses of pembrolizumab in 
solid tumors is based on: 1) similar efficacy and safety of pembrolizumab when dosed at either 2 
mg/kg or 10 mg/kg Q3W in melanoma patients, 2) the flat exposure-response relationships of pembrolizumab for both efficacy and safety in the dose ranges of 2 mg/kg Q3W to 10 mg/kg Q3W, 3) the lack of effect of tumor burden or indication on distribution behavior of 
pembrolizumab (as assessed by the population PK model) and 4) the assumption that the 
dynamics of pembrolizumab target engagement will not vary meaningfully with tumor type.  
 The choice o f the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on 
simulations performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those 
obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in 
the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual patients exposure in the e xposure range established in melanoma that 
are well tolerated and safe.  
  A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and 
to reduce potential for dosing errors.  A fixed dosing scheme will also reduce complexity in the 
logistical chain at treatment facilities and reduce wastage.  
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 16 of 133 
 Afatinib  will be combined with MK-3475 at the FDA approved single -agent  starting  dose for 
afatinib.  Dose  de-escalation  is permitted  per protocol.  
 
4.4.3 Rationale for Endpoints  
 
This is a phase I dose 3+3 dose de- escalation  study followed by expansion cohorts for safety  and 
correlative studies. Therefore,  the endpoints include determination of MTD,  and recommended  
phase  II  dose  (RP2D)  correlative  and  pharmacokinetic  endpoints  and secondary  efficacy  
endpoints. MTD and RP2D are standard endpoints for phase I dose de -escalation  studies. 
 
• The MTD  is defined  in section  5.1.5. 
 
• The recommended  dose expansion and recommended  phase II dose (RP2D) will be 
determined  by the overall assessment  of the MTD  and toxicities  observed in the dose de-
escalation  portion of this study.  
 
4.4.3.1 Efficacy  Endpoints  
 
• Overall  response rate (ORR).  ORR  is an acceptable measure of clinical  benefit  in 
early  phase clinical  trials  to provide a preliminary signal of activity  to consider later 
phase trials.  
 
• Progression- free survival  (PFS).  PFS is an acceptable measure of assessing  benefit in 
NSCLC  clinical  trials.  
 As this is a 
 phase I study,  our goal is a preliminary  assessment  of a signal  of efficacy as  defined  
in the statistical plan. 
 
4.4.3.2   Biomarker Research  
 
The investigator will conduct biomarker research  on biopsy and blood collected  on trial patients.  
These studies will focus on mechanisms EGFR -TKI resistance and immune correlates.  
 
1. Immunology  Correlates  
 
Immunology correlates will be performed  by collaborators at the Translational Immuno-
Oncology Laboratory Yale University and/ or by the Human  Immune Monitoring Core  at UC 
Davis  as defined  in the protocol. The Human Immune  Monitoring Core  at UC Davis  is under the 
supervision of Emanual Maverakis,  MD. Dr.  Maverakis’  laboratory  is  a  world  renowned  
immunology  laboratory  and  has  the equipment and expertise to conduct the proposed studies. 
The Translational Immuno -Oncology Laboratory at Yale University is under the direction of 
David Rimm MD, Ph.D and Kurt Schalper, MD, Ph.D and has been a leader in the translational 
immuno -oncology of immune checkpoint inhibitors. 
 
a. Biopsy (Biopsy at Baseline  and prior to Cycle  #3): 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 17 of 133 
  
• PD-L1 expression by immunohistochemistry  at  baseline  and  in  repeat  biopsy 
specimens to  assess for changes in PD-L1 expression  in response to treatment  will be 
conducted by Yale Immuno -Oncology under the direction of Kurt Schalper using the 
approved DAKO 22C3 antibody and in addition quantitative IHC assays for PD- L1 if 
tissue permits.  UC Davis may also perform IHC for PD -L1 using the standard DAKO 
22C3 antibody. 
 
• Enumeration and changes  in immune cell subsets by immunohistochemistry  in repeat 
biopsy specimens  in response to treatment will be conducted by Yale Translational 
Immuno- Oncology. 
 
• Whole exome DNA/RNA next generation sequencing and assessment of mutational load 
will be performed by the Broad Institute in Boston. The Broad Institute is a world leader 
in genomic sequencing and analysis. 
 
• RPPA (Reverse Phase Protein Assays) for on -target EGFR pathway inhibition will be 
performed by Theranostics in collaboration with the Mack lab at UC Davis. 
 
b. Peripheral  blood will be collected  at relevant  time points for enumeration of immune  cell 
subsets and changes  in cytokine expression  in response to treatment with  methods including 
Flow  Cytometry  and Luminex  Cytokine Assays by the Human  Immune Monitoring Core  at UC  
Davis.   
 
Plasma PD -L1 DNA/RNA levels will be assayed by Liquid Genomics in a CLIA certified 
laboratory. 
 
2. EGFR Correlates  
a. Biopsy 
The type of EGFR  activating  mutation  and the presence  of EGFR  T790M resistance mutation 
will be performed  per standard of care in a CLIA certified laboratory at the investigators 
discretion  (if previous EGFR T790M mutation  negative or not performed).   
 
Whole exome DNA/RNA next generation sequencing and assessment of mutational load will be performed by the Broad Institute in Boston. The Broad Institute is a world leader in genomic sequencing and analysis.  
 
b. Plasma EGFR -mutant DNA/RNA Levels  
Changes  in plasma  EGFR -mutant DNA /RNA in patients  with EGFR -mutant NSCLC may be 
prognostic for recurrence,  the development of resistance to existing  therapies  and may track 
response or lack of benefit  to existing  treatment  (T. Mok, WCLC  2013). Determination of 
plasma  EGFR -mutant DNA levels  will be conducted at Liquid Genomics in a CLIA certified 
laboratory.  
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 18 of 133 
 c. If tissue permits, analysis for pharmacodynamic markers of on-target EGFR - inhibition  with 
RPPA will be performed by Theranos tics and the Mack lab at UC Davis.  
 
5.0  METHODOLOGY  
 
5.1    Entry  Criteria  
5.1.1    Diagnosis/Condition for Entry  into the Trial  
 
Incurable,  Advanced  and/ or Metastatic/Recurrent Non -Small Cell Lung  Cancer  with EGFR 
Activating  Mutations (Exon 19 del, Exon  21 L858R, L861Q, G719X). Who Have  Radiologic 
and/or Clinically  Progressive  Disease on Erlotinib or Gefitinib  or Osimertinib at any point during 
the patient ’s cancer treatment as determined  by the  Investigator. 
 
5.1.2    Subject Inclusion  Criteria  
 
In order to be eligible  for participation  in this trial, the subject  must: 
 
1.   Be willing  and able to provide written  informed  consent for the  trial. 
 
2.   Be ≥ 18 years  of age  on day of signing informed  consent. 
 
3.   Have a life  expectancy  of at least 3 months. 
 
4.   Have measurable disease  based  on RECIST 1.1. 
 5.   Adequat e archival tissue for determination of EGFR- mutation status and PD -L1 status with a 
leftover cell block (or equivalent) for additional immune correlates from  a tumor lesion  
biopsied in the last 60 days  (prior to signed consent) that has not been previously irradiated 
occurring: 1) after progression on erlotinib and no intervening systemic treatment between 
biopsy and initiation of MK-3475 and afatinib or amenable to repeat  biopsy.  
       If inadequate archival tissue as above, patients must be  willing  to consent for biopsy at 
baseline and an on treatment  biopsy. Patients must also have a tumor in  a location  that in the 
opinion of the investigator  that is amenable to  biopsy or have provided tissue  for PD-L1 and 
other biomarker analysis  from  a newly  obtained formalin fixed  tumor tissue  from  a recent 
biopsy of a tumor lesion  not previously irradiated. No systemic  antineoplastic therapy  may 
be administered  between  the PD- L1 biopsy and initiating  study medication. Fine needle 
aspirates  are not acceptable. Core needle or excisional  biopsies, or resected  tissue  is 
required.  
 
6.   Have a performance status  of 0 or 1 on the ECOG (Zubrod) Performance Scale.  
 
7.   There is no limit to the number of prior treatments  for this  phase I trial. 
8.   Demonstrate adequate organ function as defined  in Table 2, all screening  labs should be 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 19 of 133 
 performed  within  10 days of treatment  initiation.  
 
 
 
Table 2  Adequate Organ  Function Laboratory  Values  
 
Syste m Laborator y Value 
Hematologica l 
Absolut e neutrophi l coun t (ANC ) ≥1,50 0 /mcL 
Platelet s ≥100,00 0 / mcL 
Hemoglobi n ≥9 g/dL or ≥5.6 mmol/L 
Renal  
Serum creatinin e  OR 
Measured or calculateda  creatinin e 
clearance  
(GFR can also be used in place of 
creatinin e or CrCl)  ≤1.5 X uppe r limit of normal (ULN)  OR 
 
≥60 mL/min for subjec t with creatinin e level s > 1.5 X 
institutiona l ULN 
Hepati c 
Serum total bilirubi n ≤ 1.5 X ULN   
 Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 
ULN  
 
AST (S GOT) and ALT (SGPT) ≤ 2.5 X ULN   OR 
< 5 X ULN for subject s with liver metastase s 
Coagulatio n 
 
Internationa l Normalized R atio (INR ) or 
Prothrom bin Time (PT)  
 Activated Partia l Thro mboplastin  
Time 
(aPTT) ≤1.5 X ULN unles s subjec t is receivin g anticoagulan t therapy  
as long as PT or PTT is w ithin therapeuti c range of intende d use of 
anticoagulant s 
≤1.5 X ULN unles s subjec t is receivin g anticoagulan t therapy  
as long as PT or PTT is w ithin therapeuti c range of intende d use of 
anticoagulant s 
aCreatinin e clearance shoul d be calculated per institutiona l standard . 
 
 
9. Female  subject  of childbearing  potential should have a negative  urine  or serum pregnancy 
within  72 hours prior to  receiving  the first  dose of study medication.  If the urine  test is 
positive or cannot be confirmed  as negative,  a serum  pregnancy test  will be  required. 
 
10. Female subjects  of childbearing potential (Section 5.7.2) must be willing  to use an 
adequate method of contraception as outlined in Section 5.7.2 – Contraception, for the 
course of the study through  120 days after the last dose of study medication  (Section  5.7.2). 
 
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the 
subject.  
 
11. Male subjects  of childbearing potential (Section 5.7.1) must  agree  to use an adequate 
method of contraception as outlined in Section 5.7.1 – Contraction, starting  with the  first 
dose of study therapy  through 120 days after the last dose of study therapy.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 20 of 133 
  
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the 
subject.  
 
5.1.3 Subject  Exclusion Criteria  
 
The subject  must be excluded  from  participating  in the trial if the subject:  
1.   Is currently  participating  and receiving study therapy or has participated  in a study of an 
investigational agent and received study therapy or us ed an investigational device within  4 
weeks  of the  first dose of treatment.  
 
2.   Has a diagnosis of immunodeficiency or is receiving  systemic  steroid  therapy  or any other 
form  of immunosuppressive therapy  within  7 days prior to the first dose of trial treatment.  
 
3.  Has a known history of act ive TB  (Bacillus Tuberculosis).  
 
4. Hypersensitivity to pembrolizumab or any of its excipients.  
5. Has had a prior anti -cancer  monoclonal antibody (mAb) within  3 weeks  prior to study Day 1 
or who has not recovered (i.e.,  ≤ Grade 1 or at baseline)  from  adverse events  due to agents 
administered  more  than 4 weeks  earlier.  Denosumab  is allowed  as long as not < 1 week  
prior to study day 1 and not administered  on day of MK -3475 infusion. 
 
6.   Has  had prior chemotherapy  or targeted  small  molecule  therapy within  2 weeks  prior to 
study Day 1 or who has not recovered (i.e.,  ≤ Grade  1 or at baseline)  from  adverse  events  
due to a previously administered  agent.  
 
- Note
:  Subjects  with alopecia or  ≤ Grade 2 neuropathy are an exception  to this criterion 
and may  qualify for the  study.  
 
- Note:  If subject received  major  surgery,  they must have recovered  adequately from  the 
toxicity  and/or complications from the intervention prior to starting therapy.  
 
7.   Has  a known additional malignancy  that is progressing or requires  active treatment.  
Exceptions include basal  cell carcinoma of the skin or squamous cell carcinoma of the 
skin that  has undergone potentially  curative therapy  or in situ cervical  cancer . 
 
8.  Has known active central  nervous system  (CNS) metastases and/or  carcinomatous 
meningitis. Subjects with previously treated brain metastases may participate provided they 
are stable (without evidence of progression  by imaging  for at least two weeks  prior to the 
first dose of trial treatment and any neurologic symptoms  have returned  to baseline),  have 
no evidence of  new or enlarging  brain  metastases,  and are not  using steroids for at  least 7 
days prior to trial treatment.  
 
9.  Has an active autoimmune disease requiring systemic  treatment within  the past 3 months or 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 21 of 133 
 a documented history of clinically  severe autoimmune disease,  or a syndrome that requires  
systemic  steroids or immunosuppressive agents.   Subjects with  vitiligo  or resolved  
childhood asthma/atopy would  be an exception  to this rule. Subjects that require intermittent 
use of bronchodilators or local  steroid  injections would not be excluded  from  the study.   
Subjects  with hypothyroidism stable  on hormone replacement  or Sjorgen’s syndrome will not 
be excluded  from  the study.  
 
10.   Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis. 
Lymphangitic spread  of the  NSCLC  is not exclusionary.  
 
11.   Has  an active infection  requiring  intravenous systemic  therapy.  
 
12. Has  a history or current evidence of any condition, therapy,  or laboratory abnormality that 
might confound the results  of the trial, interfere  with the subject’s  participation for the full 
duration of the trial, or is not in the best interest of  the subject to participate,  in the opinion of 
the treating  investigator. 
 
13. Has  known  psychiatric  or  substance  abuse  disorders  that  would  interfere  with 
cooperation with the requirements  of the trial. 
 
14. History  or  presence  of  clinically  relevant  cardiovascular  abnormalities  such  as 
uncontrolled hypertension, congestive heart  failure  NYHA  classification  of 3 (Refer  to 
APPENDIX 12.4), unstable angina or poorly controlled arrhythmia as  determined by the 
investigator.  Myocardial  infarction  within  6 months prior to enrollment.  
 15.
 Is pregnant or breastfeeding,  or expecting  to conceive  or father  children  within  the 
projected  duration of  the  trial,  starting  with  the  pre-screening  or  screening  visit 
through 120 days after  the last dose of trial  treatment.  
 
16. Has  received  prior therapy  with an anti-PD-1, anti-PD-L1, anti-PD-L2.  
 
17. Known hypersensitivity to afatinib  or the excipients  of any  of the  trial drugs  
 
18. Prior history of receiving afatinib.  
 
19. Has  a known history of Human Immunodeficiency Virus  (HIV) (HIV 1/2  antibodies). 
 
20. Has  known active  Hepatitis  B (e.g., HBsAg  reactive) or  Hepatitis  C (e.g.,  HCV RNA 
[qualitative]  is detected).  
 
21. Has  received  a live  vaccine within  30 days  of planned start of study therapy (See Section 
5.5.2). Note:  Seasonal influenza vaccines for injection are generally inactivated flu vaccines 
and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed. 
 
22. The  presence of poorly controlled gastrointestinal disorders that could affect the  
absorption  of  the  afatinib   (e.g.  Crohn’s  disease,  ulcerative  colitis, chronic  diarrhea,  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 22 of 133 
 malabsorption). 
 
23. Receiving  drugs  known to be strong  inducers or inhibitors of P- glycoprotein  that are known 
to interact  with afatinib  including, but not limited  to: ritonavir, cyclosporine A, 
ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus,  nelfinavir, 
saquinavir, and amiodarone.  Because the lists  of these agents are constantly changing,  it is 
important to regularly  consult a frequently-updated list such as  
http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical  reference  texts  such as  the 
Physicians’  Desk  Reference may  also provide this information.  As part of the 
enrollment/informed consent procedures, the patient  will be counseled  on the risk of 
interactions  with  other  agents, and what to do if new medications need to be prescribed or 
if the patient  is considering a new over-the-counter medicine or herbal product. The subject  
must stop the strong inducer or inhibitor of P-glycoprotein 7 days before  or 5 half lives  
before  study drug administration (whichever timepoint is longer). 
 
24. Major  surgery within 4 weeks before starting study treatment or scheduled for surgery during 
the projected course of the study. 
 25. Radiotherapy within 4 weeks prior to  enrollment , except as follows:  
 i.) Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to enrollment, and  ii.) Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor-investigator prior to enrolling. 
26. Menin geal ca rcinomatosis . 
27. Prior participation in an afatinib cli nical study, even if not assigned to afatinib treatment.  
28. Any history of or concomitant condition that, in the opinion of the Investigator, would 
compromise the patient’s ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug.  
 
5.1.4 Trial  Treatments  
 
The treatment to be used in this trial is outlined below in Table 3. Each  cycle  is 21 days in length.  
Table 3 Trial  Tr
 eatments  
Drug Dose/Potency Dose 
Frequenc y Route of 
Administration Regimen/Treatment 
Period Use 
MK-3475 200 mg Q3W IV infusion Day 1 of each cycle Experimental  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 23 of 133 
 Afatinib * 20 mg,  30 mg, 
or 40 mg  Once daily  Oral Day 1-21 of each 
cycle  Experimental  
The MK-3475  dosing  interval  may be increased  due to toxicity  as described  in Section  5.1.5.3 . 
*Cohort B begins in Cycle 3  
 
Table 4: Dose  De- Escalation  Schema  
Dose Leve l Number of Patients Afatinib  
(Daily) MK-3475  
(q3 weeks ) 
0 3+ 40 mg D1 200 mg D1 
-1 3+ 30 mg D1 200 mg D1 
-2 3+ 20 mg D1 200 mg D1 
Each cycle is 21 days in length.  
  
Dose  De-Escalation  
This treatment will start at dose level  0 (Bold). Afatinib  is an oral agent  that will be given once 
daily  for 21 days per cycle starting  on day 1  of each cycle  before administration  of MK- 
3475. It should be taken  in the morning with 200 mL of water.  Tablets  should be taken  1 
hour before  or 2 hours after meals.  MK-3475 will be given  once every  3 weeks  at a fixed  
dose of 200 mg. Treatment  will be administered  until progression or toxicity  or withdrawal of 
consent as defined  in this protocol. 
 
Cohort A (Arm A) : Dose  Expansion  
 
This treatment  will start at the MTD  determined in  the dose de-escalation  portion of this trial. 
Afatinib  is an oral agent that  will be given  once daily  for 21 days per cycle starting  on day 1 of 
each cycle  before administration  of MK-3475. It should be taken  in the morning with 200 mL of 
water.  Tablets should be taken  1 hour before  or 2 hours after meals.  MK-3475 will be given  
once every  3 weeks.  Treatment  will be administered  until progression or toxicity  or 
withdrawal  of consent  as defined  in this protocol. 
 
Cohort B (Arm B): Dose  Expansion  
 
This t
reatment  will start at the MTD  determined in  the dose de-escalation  portion of this trial. 
MK-3475 will be administered  on Day 1 of each cycle,  which  is q21d in length. Afatinib  is an 
oral agent that  will be given  once daily  for 21 days per cycle  starting  on Cycle 3  Day 1 of each  
cycle  starting prior to  administration  of MK -3475 on day 1. It  should be taken  in the morning 
with 200 mL of water.  Tablets  should be taken  1 hour before  or 2 hours after meals.  MK-
3475 will be given  once every  3 weeks.  Treatment  will be administered  until progression or 
toxicity  or withdrawal of consent as defined  in this protocol. 
 
After the MTD is reached, Cohort A will complete first to further assess toxicity at the MTD of the combination, followed by enrollment in Cohort B. Cohort Assignment is further defined in 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 24 of 133 
 Section 5.2. 
 
  
5.1.5    Dose Selection/Modification  
 
5.1.5.1   Dose  Selection  
 
The rationale for  selection  of doses to be used in this trial is provided in  Section  4.0 – 
Background and Rationale.  
 
MK-3475 will be provided by Merck  at no cost to the patient. 
 
Afatinib will be provided by Boehringer Ingelheim at no cost to the patient. 
 
Subjects  will take a single  oral dose of afatinib  daily  starting  on Day  1 of each cycle,  until the 
development of progressive disease or unacceptable adverse  events.  
 
See section  5.1.5 for Dose  Modifications for afatinib and  MK-3475. See Table 6 for dose 
reduction for afatinib.  
 
5.1.5.2 Dose  De-Escalation 
 
Dose Leve l Number of Patients Afatinib  
(Daily) MK- 3475  
(q3 weeks ) 
0 3+ 40 mg D1 200 mg D1 
-1 3+ 30 mg D1 200 mg D1 
-2 3+ 20 mg D1 200 mg D1 
 
 
Figure  1: Dose  De-Escalation  Schema  
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 25 of 133 
  
 
 
This is a phase I study.  A minimum of 9 patients  (if trial is terminated  early  due to unacceptable 
toxicity  and a maximum of 38 patients  (18 patients in the dose- de- escalation  cohort plus 10 in 
each of the two expansion cohorts) are anticipated  for this  trial. Analysis  of safety  and 
biomarkers will be limited  to patients  who receive active treatment.  
 
The dose- de-escalation  phase will establish  a MTD  recommended  dose of MK -3475 in expansion 
cohorts (A +B). 
 
We plan to enter  3 patients  at Dose  Level  0. If 0/3 or 1/3 patients  experience a DLT  on level  
0, an additional 3 patients  will be accrued  to Level  0, where  2 or more DLTs  will terminate 
that study arm  and we will proceed  to dose level  -1. 
 
If 2 or more patients  have DLTs  at level 0,  patients  will be accrued  at level  -1. If 1/3 patients 
experience a DLT  on level  -1, an additional 3 patients  will be accrued  to Level  -1, where  2 or 
more  DLTs  will require termination of  that study arm while  1 DLT  out of 6 will result  in 
proceeding  with dose level  -1 as the MTD  for the  dose expansion cohorts. 
 If 2 o
r more patients have DLTs at l evel -1, patients will be accrued at l evel -2. If 1/3 patients 
experi ence a DLT on l evel -2, an additiona l 3 patients will be accrued to Leve l -2, w here 2 or 
more D LTs will require termi nation of the st udy wh ile 1 DLT out of 6 w ill result in 
proceed ing w ith dose level -2 as the MTD for the dose expansio n coho rts. 
 
The phase I dose  de-escalation  portion of the  trial will be closed  when  the maximum tolerated 
dose level  (MTD) or dose level  0 is reached  and six patients  have been  treated  at that dose level.  
 
Dose  modifications  for patients  that experience DLT  is described  in section  5.1.5.3.  Once the 
dose is decreased, there will be no dose re- escalation  allowed  for an individual  patient.  
 
 
The recommended  phase II dose (RP2D) will be determined  by the overall assessment of  the 
MTD  and toxicities  observed in the de-dose escalation  and dose expansion portion of this study.  
 
Treat 3 subjects 
at dose leve l 
If (0 or 1)/3 
subjects with DLT  
If ≥2/3 subjects 
with DLT  
Treat 3 more 
subjects  
If (0 or 1)/6 DLT, 
stop, MTD reached  
If ≥2/6 subjects  
with DLT  
Stop, lower dose and 
enroll 3 subjects  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 26 of 133 
  
5.1.5.3   Dose  Modification  
 
Adverse events (both non-serious and serious) associated with pembrolizumab exposure may 
represent an immunologic etiology.  These adverse events may occur shortly after the first dose or several months after the last dose of treatment.  MK-3475 will be withheld  for MK-3475-
related  toxicities  and severe or life- threatening  AEs as per Table 5. See Section 5.6.1 and Events 
of Clinical Interest Guidance Document for supportive care, including use of corticosteroids. 
 
  
 
    
Table 5: Dose  modification  guidelines for MK-3475 related  adverse  events.  
 
 
Toxicity  Hold 
Treatment 
For Grade  Timing for Restarting 
Treatment  Treatment Discontinuation  
Diarrhea/Colitis  2-3 
 Toxicity resolves to Grade 0 -1 Toxicity does not resolve within 12 weeks of last 
dose or inability to reduce corticosteroid to 10 mg 
or less of prednisone or equivalent per day within 
12 weeks  
4 Permanently discontinue  Permanently discontinue  
AST, ALT, or 
Increased Bilirubin  2
 Toxicity resolves to Grade 0 -1 Toxicity does not resolve within 12 weeks of last 
dose 
3-4 Permanently discontinue  
(see exception below)a Permanently discontinue  
Type 1 diabetes mellitus (if new onset) or Hyperglycemia  T1DM or  
3-4 Hold pembrolizumab for new 
onset Type 1 diabetes mellitus or Grade 3 -4 hyperglycemia 
associated with evidence of 
beta cell failure  Resume pembrolizumab when patients are clinically and metabolically stable  
Hypophysitis  
2-4 Toxicity resolves to Grade 0 -
1. Therapy with pembrolizumab can be continued while endocrine replacement  therapy is 
instituted  Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg 
or less of prednisone or equivalent per day within 12 weeks  
Hyperthyroidism  3 Toxicity resolves to Grade 0 -1 Toxicity does not resolve within 12 weeks of last 
dose or inability to reduce corticosteroid to 10 mg 
or less of prednisone or equivalent per day within 
12 weeks  
4 Permanently discontinue  Permanently discontinue  
Hypothyroidism   Therapy with pembrolizumab Therapy with pembrolizumab can be continued 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 27 of 133 
 Toxicity  Hold 
Treatment 
For Grade  Timing for Restarting 
Treatment  Treatment Discontinuation  
can be continued  while 
thyroid replacement therapy is 
instituted  while thyroid replacement therapy is instituted  
 
Infusion Reaction 2b Toxicity resolves to Grade 0 -1  Permanently discontinue if toxicity develops 
despite adequate premedication  
3-4 Permanently discontinue  Permanently discontinue  
Pneumonitis  2 Toxicity resolves to Grade 0 -1 Toxicity does not resolve within 12 weeks of last 
dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 
12 weeks  
3-4 Permanently discontinue  Permanently discontinue  
Renal Failure or Nephritis  2
 Toxicity resolves to Grade 0 -1 Toxicity does not resolve within 12 weeks of last 
dose or  inability to reduce corticosteroid to 10 mg 
or less of prednisone or equivalent per day within 
12 weeks  
3-4 Permanently discontinue  Permanently discontinue  
All Other Drug -
Related Toxicityc 3 or Severe Toxicity resolves to Grade 0 -1 Toxicity does not resolve within 12 weeks of last 
dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 
12 weeks  
4 Permanently discontinue  Permanently discontinue  
Note: Permanently discontinue for any severe or Grade 3 drug -related AE that recurs or any life -threatening event.  
a For patients with liver metastasis who begin treatment with Grade 2 AST or ALT, if AST or ALT increases by greater than or 
equal to 50% relative to baseline and lasts for at least 1 week then patients should be discontinued.  
b If symptoms resolve within one hour of stopping drug infusion, the infusion may be restarted at 50% of the original infusion rate   
(e.g., from 100 mL/hr to 50 mL/hr).  Otherwise dosing will be held until symptoms resolve  and the subject should be 
premedicated  for the next scheduled dose; Refer to Infusion Treatment Guidelines  for further management details.  
c Patients with intolerable or persistent Grade 2 drug -related AE may hold study medication at physician discretion .  Permanently 
discontinue study drug for persistent Grade 2 adverse reactions for which treatment with study drug has been held, that do not 
recover to Grade 0 -1 within 12 weeks of the last dose.  
 
Dosing interruptions are permitted in the case of medical / surgical events or logistical reasons  
not related to study therapy (e.g., elective surgery, unrelated medical events, patient vacation, and/or holidays). Subjects should be placed back on study therapy within 3 weeks of the scheduled interruption, unless otherwise discussed with the Sponsor. The reason for interruption should be documented in the patient's study record.  
Treatment related  toxicities  will be managed  by treatment  interruptions and  subsequent dose 
reductions of afatinib  according to the schedule described in  Table 6. Dose  reductions will apply  
to individual patients  only. Once the dose has been  reduced, it cannot be increased later.  
 To prevent the development of more  severe adverse events,  treatment related  diarrhea, nausea 
and vomiting  or rash should be managed  early  and proactive as described  in Section  5.6. 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 28 of 133 
   
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 29 of 133 
 Table 6. Dose reduction  scheme for Afatinib  
 
 
AE T ype and CTCAE Grade  Action  Dose Reduction S cheme 
Events  related  to study  drug (afatinib):  
 
• Diarrhea  
Grade  2 persisting  for 2 or  more 
consecutive days (48 hours) despite  
adequate anti-diarrheal 
medication/hydration 
• Reduced  renal  function to  ≥ Grade  2 
as measured  by serum  creatinine,  
proteinuria or decrease in glomerular 
filtration rate   of more  than 50% from 
baseline  
• Any drug related  AE Grade  ≥3  
 
• Pause treatment until patient 
has recovered to Grade  ≤1 or 
baseline.1 
 
 
• Resume treatment at reduced dose according to schedule 
opposite. 
 
 
• If patient has  not recovered 
to Grade  ≤1 or baseline1 
within 14  days study  
treatment  must  be 
permanently discontinued.2  
 
• If patient  was receiving  
40 mg,  resume treatment  at a 
dose of 30 mg.  
• If patient  was receiving  
30 mg,  resume treatment  at a 
dose of 20 mg.  
• If patient  was receiving  
20 mg,  discontinue afatinib.  
Acute  onset  and/or  unexplained 
worsening of pulmonary systems 
(dyspnea, cough, fever)  Pause  afatinib  while clinical  
assessment  to exclude  ILD is 
completed. If ILD  is ruled  out as a cause of 
symptoms, grade symptoms 
and relatedness and  report as 
AEs.  If AEs  are not related,  
resume afatinib  at current  dose.  
If AEs  are drug related,  follow 
directions in row above. 
 
If ILD  is confirmed, 
discontinue afatinib  
1  Baseline is defined as the CTCA E Gr ade at the start of treatment. 
2  In the event t hat the patient is deriving obvious c linical benef it according to the i nves tigator’s judgm ent, 
further treatm ent w ith afa tinib w ill be decided by the i nves tigator. 
 
 
In the event  of any unrelated  adverse events,  the investigator  may choose to interrupt the 
afatinib  for up to 14 days,  but no dose reduction  should occur.  If afatinib  is interrupted for 
more  than 14 days,  the decision  to continue with afatinib  will be made by the investigator. 
 
    
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 30 of 133 
 5.1.6    Timing of Dose Administration  
 
Trial  treatment should be administered on Day 1 of  each cycle after all procedures/assessments  
have been  completed  as detailed  on the Trial  Flow  Chart  (Section  6.0).  Trial  treatment may 
be administered  up to 3 days  before  or after the scheduled Day 1  of each  cycle  due to 
administrative  reasons.  
 
All trial treatments  may be administered  on an outpatient basis.  
MK-3475 200 mg will be administered as  a 30 minute  IV infusion every 3 weeks .  Sites should 
make every effort  to target  infusion  timing  to  be  as  close  to  30  minutes  as  possible.    
However, given the variability of infusion pumps, a window of -5 minutes  and +10 minutes  is 
permitted  (i.e., infusion time  is 30 minutes: -5 min/+10 min).  
 
Afatinib  is an oral agent that  will be given  once daily  for 21 days per cycle starting  on day 1 of 
each cycle  before administration  of MK-3475. It should be taken  in the morning with 200 mL of 
water.   
 
The medication  should be taken  at the same  time each day (±  2 hours) without food (at least one 
hour before or at least 2 hours after a meal).  
 
Missed  doses of afatinib can  be made up  during the  same day.  Otherwise,  the dose must be 
skipped and patients  should take the next scheduled dose at the usual time.  Patients  with emesis  
must not take a replacement  dose. A missed  dose of afatinib  should not be taken within  12 
hours of the next dose. 
5.1.7    Trial Blind ing/Masking  
 This is an open- label trial; therefore, the Sponsor-Investigator and subject  will know the 
treatment  administered.  
 
5.2    Treatment  Allocation 
 
Patients  will be enrolled  into the dose de-escalation  protocol until the MTD  is reached.  Then 
patients  will be enrolled  into 2 cohorts for the dose expansion at the recommended  expansion 
dose and RP2D.  Cohort ( Arm) A: will be concurrent  MK-3475 + afatinib  at initiation  of 
treatment  and Cohort ( Arm) B: will be lead in MK-3475 for 2 cycles  followed by concurrent  
MK-3475 and afatinib. The recommended dose for the dose expansion cohorts and RP2D dose 
will be informed  by the  MTD  determined  in the de-dose escalation  phase and assessment  of 
the overall  toxicity  at the  treated  dose levels.  
 
After  the expansion dose (MTD) is determined,  for the expansion phase we will enroll and 
complete Cohort A: Afatinib  + MK-3475 (Concurrent) to further define toxicities at the MTD in 
the dose expansion. After completion of Cohort A, we will enroll patients into Cohort B (lead -in 
MK-3475 followed by combination afatinib and MK-3475 commencing at cycle #3). 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 31 of 133 
 5.3    Definition  of Dose  Limiting  Toxicities  (DLT)  
All toxicities will be graded  using National  Cancer  Institute  (NCI)  CTCAE  Version  4.0. The 
occurrence of any of the following toxicities  during Cycle  1 will be considered  a DLT,  if 
judged by the Investigator to  be possibly, probably or definitely  related  to study drug (either 
afatinib or MK-3475) administration:  
1.          Grade 4 non-hematologic toxicity  (not laboratory).  
 
2.          Grade 4 hematologic toxicity  lasting  ≥14 days.  
 
3.          Grade 3 non- hematologic toxicity  (not laboratory) lasting  > 3 days despite optimal 
supportive care with maximal supportive care for diarrhea  and rash.  See description of 
maximal supportive care for diarrhea  and rash  attributed  to afatinib  below. 
 
4.          Any Grade 3 or Grade 4 non-hematologic laboratory value if: 
 
• Medical  intervention  is required  to treat  the patient,  or 
 
• The abnormality  leads  to hospitalization,  or 
 
• The abnormality  persists as > grade  3 for >1  week.  
 
5.          Febrile neutropenia Grade 3 or Grade  4: 
 
• Grade  3 is defined as  ANC  <1000/mm3 with a single temperature  of >38.3 
degrees  C (101 degrees F)  or a sustained  temperature of ≥38 degrees C  (100.4 
degrees F)  for more  than one  hour 
 
• Grade  4 is defined as  ANC  <1000/mm3 with a single temperature  of >38.3 
degrees  C (101 degrees F)  or a sustained  temperature of ≥38 degrees C  (100.4 
degrees F)  for more  than one  hour, with life -threatening  consequences  and urgent 
intervention indicated.  
 6.          Thrombocytopenia <25,000/mm3 if associated  with: 
 
• A bleeding event  which  does not result  in hemodynamic  instability  but requires  
an elective platelet  transfusion, or 
 
• A life-threatening  bleeding event  which  results  in urgent intervention and 
admission to  an Intensive Care Unit 
 
• Grade  5 toxicity  (i.e. death).  
 
7.         Diarrhea  is an expected  adverse event  from  afatinib.  Diarrhea attributed  to afatinib 
will be considered  a DLT if grade  3 despite maximal medical  management for  > 72 
hours. Maximal medical  management will be defined as anti-diarrheal management that  
includes: loperamide, diphenoxylate and atropine, and tincture  of opium. Grade 4 
diarrhea  will be considered  a DLT.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 32 of 133 
  
8. Acneiform  rash  is an expected  adverse event  from  afatinib.  Acneiform  rash attributed to  
afatinib  will be considered  a DLT  if grade  3 despite maximal medical  management  for 
> 72  hours.  Maximal medical management will  be  defined  as  oral  antibiotic,  
preferably  doxycycline,  cleocin  solution or cream  and topical steroids. In addition an 
asymptomatic/minimally sy mptomatic classic acneifo rm rash will only be considered a  DLT 
if it covers ≥ 50% BSA. Grade  4 rash will be considered  a DLT.  
 
9.  To be evaluable for a DLT, 80% of dose must have been administered in cycle 1 unless a 
DLT occurred.  
 
10.  Delay in starting cycle 2 of  ≥ 14 days due to toxicity related to afatinib and/or MK-3475  
5.4    Attribution of Adverse Events  
Investigators are required to assess whether there is a reasonable possibility that afatinib and/or 
MK-3475 caused or contributed to the adverse event.  The follow ing general guidance may be 
used. 
• Definite – The AE is clearly related  to the study treatment.  
• Probable – The AE is likely related to the study treatment.  
• Possible – The AE may be related  to the study treatment.  
• Unlikely – The AE is doubtfully related to the study treatment.  
      • Unrelated – The AE is clearly NOT related  to the study treatment.  
If an adverse event is attributable (either definite, probable or possible) to MK-3475 and/ or 
afatinib that requires the drug be held the other drug may be continued if it the adverse event is 
not attributable to that drug (either unlikely or unrelated) with approval of the treating physician 
and primary investigator. Exceptions include pneumonitis and grade 2 and above enterocolitis 
(as d efined in this protocol) where both MK-3475 and afatinib must be held.  
 
5.5    Concomitant Medications/Vaccinations  (allowed & prohibited)  
 
Medications  or vaccinations specifically  prohibited in the exclusion  criteria are not allowed 
during the ongoing trial.  If there is  a clinical  indication for one of these  or other medications or 
vaccinations  specifically  prohibited during the trial, discontinuation from trial therapy  or 
vaccination  may be required.  The investigator should discuss any questions regarding  this 
with the Merck  and/or Boehringer Ingelheim.  The final decision  on any supportive therapy or  
vaccination  rests with the investigator and/or the subject's  primary  physician.   
5.5.1    Acceptable Concomitant Medications  
 
All treatments that the investigator  considers necessary  for a subject’s welfare may be 
administered  at the discretion of the investigator  in keeping  with  the community standards of 
medical  care.   
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 33 of 133 
  
All concomitant medications  received  within  28 days before the first dose of trial treatment and  
30  days  after  the  last  dose  of  trial  treatment  should  be  recorded.    Concomitant 
medications  administered  after 30  days  after  the  last  dose  of  trial  treatment should be 
recorded for  SAEs  and Event(s) of clinical interest.  ECIs  guidance document attached within  the 
appendices . 
 
5.5.2    Prohibited Concomitant Medications  
 Subjects  are prohibited from  receiving  the following  therapies  during the Screening  and 
Treatment  Phase (including retreatment  for post- complete  response relapse)  of this trial: 
 
• Antineoplastic  systemic  chemotherapy  or biological therapy  
 
• Immunotherapy not specified  in this protocol 
 
• Chemotherapy  not specified  in this protocol 
 
• Investigational agents  other than MK-3475 and afatinib  
 
• Radiation  therapy  
 
o Note:  Radiation  therapy  to a symptomatic  solitary  lesion  or to the brain  may be  
allowed  at the Investigator’s discretion . 
 
• Live vaccines  within  30 days prior to the first dose of trial treatment and while 
participating  in the trial. Examples  of live vaccines  include, but are not limited  to, the 
following: measles,  mumps,  rubella,  varicella/zoster , yellow  fever,  rabies,  BCG,  and 
typhoid vaccine.  
 
• Systemic g lucocorticoids for any purpose other than to modulate symptoms  from  an 
event  of clinical  interest  of suspected  immunologic etiology.  The use of physiologic  
doses of corticosteroids may be approved after consultation  with the Sponsor-
Investigator. 
 
• Strong  inducers  or  inhibitors  of  P-glycoprotein  that  are  known  to  interact  with 
afatinib  including, but not limited  to: ritonavir, cyclosporine A, ketoconazole, 
itraconazole,  erythromycin, verapamil, quinidine, tacrolimus,  nelfinavir, saquinavir, and 
amiodarone. Because  the lists of these agents  are constantly changing,  it is important to 
regularly  consult a frequently -updated list such as 
http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical  reference  texts  such as the 
Physicians’  Desk  Reference may also provide this information. 
 
Subjects  who, in the assessment  by the investigator, require the use of any of the 
aforementioned treatments  for clinical  management  should be removed  from  the trial. Subjects  
may  receive  other  medications  that  the  investigator  deems  to  be  medically necessary.  
 
The Exclusion Criteria  describes  other medications  which  are prohibited in this trial. There  are no 
prohibited therapies  during the Post- Treatment  Follow -up Phase.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 34 of 133 
 In case of major  surgery  (as judged by the investigator), it is recommended  to stop treatment 
with afatinib  around one week  prior to the surgery,  and to restart  treatment after  complete 
wound healing.  If afatinib  is interrupted for more  than 14 days,  the decision  to continue will be  
made by the  Sponsor- Investigator.  
5.6    Rescue Medications  & Supportive  Care  
5.6.1    Supportive Care  Guidelines  
 
Subjects should receive appropriate supportive care measures as deemed necessary by the 
treating investigator.  Suggested supportive care measures for the management of adverse events 
with potential immunologic etiology are outlined below. Where appropriat e, these guidelines 
include the use of oral or intravenous treatment with corticosteroids as well as additional anti-inflammatory agents if symptoms do not improve with administration of corticosteroids.   Note that several courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is decreased. For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or viral infection, which might require additional supportive care. The treatment guidelines are intended to be applied when the investigator determines the events to be related to pembrolizumab.  
 
Note: if after the evaluation the event is determined not to be related, the investigator does not 
need to follow the treatment guidance (as outlined below). Refer to Section 5.2.1 for dose modification.  
 
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. 
 
• Pneumonitis :  
o For Grade 2 events , treat with systemic corticosteroids. When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.  
o For Grade 3 -4 events , immediately treat with intravenous steroids.  Administer 
additional anti- inflammatory me asures, as needed.  
o Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid administration.  
 
• Diarrhea /Colitis :    
Both   afatinib   and   MK-3475   can   cause   diarrhea.   Subjects   should additionally 
be carefully  monitored for signs  and symptoms  of enterocolitis (such  as diarrhea,  
abdominal pain, blood or mucus in stool, with or without fever)  and of bowel 
perforation (such  as peritoneal  signs  and ileus).    
o All  subjects  who  experience  diarrhea/colitis   should  be  advised  to  drink  liberal 
quantities  of clear  fluids.  If sufficient  oral fluid  intake is not feasible,  fluid and 
electrolytes should  be substituted  via IV infusion. For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis. Diarrhea 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 35 of 133 
 should be managed  aggressively  with anti-diarrheal agents  such as: loperamide, 
diphenoxylate/atropine and tincture  of opium if necessary. For Grade 2 diarrhea/colitis  
that persists greater than 3 days,  administer oral corticosteroids.  
o For Grade 3 or 4 diarrhea/colitis that persists > 1 week, treat with intravenous steroids 
followed by high dose oral steroids.   
o When symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks.  
 
• Management of Acneiform  Rash  – Afatinib  as with other EGFR -inhibitors can cause a 
classic acneiform  rash.  Acneiform  rash attributed  to afatinib  ≥ grade  2 should be  
managed  aggressively  with  cleocin  solution  and  appropriate anti-biotics such  as 
doxycycline. Management for grade  1 acneiform  rash per investigator ’s discretion. 
 
• Type 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA]) or ≥ 
Grade 3 Hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis 
(DKA)  
• For T1DM or Grade 3 -4 Hyperglycemia  
 Insulin replacement therapy is recommended for Type I diabetes mellitus and 
for Grade 3 -4 hyperglycemia associated with metabolic acidosis or ketonuria. 
 Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated hemoglobin, and C-peptide.  
• Hypophysitis : 
o For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.  
o For Grade 3 -4 events, treat with an initial dose of IV corticosteroids followed by 
oral corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered. 
 
• Hyperthyroidism or Hypothyroidism :  
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. 
• Grade 2 hyperthyroidism events (and Grade 2 -4 hypothyroidism): 
 In hyperthyroidism, non- selective beta -blockers (e.g., propranolol) are 
suggested as initial therapy.  
 In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine 
or liothyroinine, is indicated per standard of care. 
• Grade 3 -4 hyperthyroidism  
• Treat with an initial dose of IV corticosteroid followed by oral 
corticosteroids. When symptoms improve to Grade 1 or less, steroid taper 
should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the st eroid dose is tapered.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 36 of 133 
  
• Hepatic : 
• For Grade 2 events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).  
• Treat with IV or oral corticosteroids  
• For Grade 3 -4 events, treat with intravenous corticosteroids for 24 to 48 hours.  
• When symptoms improve to Grade 1 or less, a steroid taper should be started and 
continued over no less than 4 weeks. 
 
• Renal Failure or Nephritis : 
• For Grade 2 events, treat with corticosteroids.  
• For Grade 3 -4 events, treat with systemic corticosteroids.  
• When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.  
 
• Management of Infusion Reactions : 
Signs and symptoms usually develop during or shortly after drug infusion and generally resolve 
completely within 24 hours of completion of infusion.  
 
 
Table 7 shows treatment guidelines for subjects who experience an infusion reaction associated  
with administration  of MK-3475. Please also see Events of Clinical Interest Appendix attached at 
end of protocol for further details. 
 
  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 37 of 133 
 Table 7.  Infusion Reaction  Treatment  Guidelines  
 
NCI CTCA E Grade Treatment Premedicatio n at  
Subsequent D osing  
Grade 1 
Mild reaction ; infusion interruptio n 
not indicated; interventio n not 
indicate d  
Increas e monitoring of vital signs as 
medicall y indicate d until the subjec t is 
deemed m edicall y stabl e in the opinio n 
of the investigator .  
None 
Grade 2 
Require s infusio n interruptio n but 
respond s promptly to 
symptomatic treatment (e.g., 
antihista mines,  NSAIDS , narcotics , 
IV fluids) ; prophylacti c medication s 
indicate d for < =24 hrs  
Stop Infusio n and monito r symptoms. 
Additiona l appropriat e medica l therapy 
may includ e but is not limited to: 
IV fluid s Antihista mines NSAI DS 
Acetam inophe n Narcotic s 
Increas e monitoring of vital signs as 
medicall y indicate d until the subjec t is 
deemed m edicall y stabl e in the opinio n 
of the investigator . 
If symptoms resolv e within one hour of 
stopping drug infusion , the infusio n may 
be restarte d at 50% of the origina l 
infusio n rate (e.g. from 100 mL/hr to 50 
mL/hr). Otherwise dosin g will be held 
until symptoms resolv e and the subjec t 
should be premedicated for the next 
schedule d dose . Subject s who develo p 
Grade 2 toxicit y despit e adequat e 
premedicatio n  shoul d be permanentl y 
discontinue d from furthe r trial 
treat ment administration.   
Subjec t may be premedicate d 
1.5h (± 30 m inutes ) prior to 
infusio n of MK-3475 with: 
 
Diphenhydra mine  50 mg po 
(or equivalen t dose of 
antihista mine). 
 Acetaminophe n  500-1000 
mg 
po (or equivalent dose of 
antipyretic).  
Grades 3 or 4 
Grade 3: 
Prolonge d (i.e., not rapidly 
responsiv e to symptom atic 
medicatio n and/o r brief interruptio n 
of infusion) ; recurrenc e of 
symptoms follo wing initia l 
improve ment; hospitalizatio n 
indicate d for other clinica l sequela e 
(e.g., renal impairment, pulmonary 
infiltrates ) 
 
Grade 4: 
Life-threatening ;  presso r or 
ventilator y suppor t indicat ed  
Stop Infusion.  
Additiona l appropriat e medica l therap y 
may includ e but is not limited to: 
IV fluid s Antihista mines NSAI DS 
Acetam inophe n Narcotic s Oxygen 
Pressor s Corticosteroid s Epinephrine  
 
Increas e monitoring of vital signs as 
medicall y indicate d until the subjec t is 
deemed m edicall y stabl e in the opinio n 
of the investigator . 
Hospitalizatio n  may be indicated . 
Subjec t is permanentl y discontinue d 
from further trial treatment 
administration   
 
No subsequent dosing  
Appropriat e resuscitatio n equip ment shoul d be availabl e in the room and a physicia n readil y availabl e durin g 
the perio d of drug administration. For Furthe r infor mation , pleas e refer to the Co mmon Terminolog y Criteri a 
for Advers e Event s v4.0 (CT CAE) at http://c tep.cancer.go v 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 38 of 133 
   
5.6.2 Rescue medication  for Afatinib  
 
Rescue medications  to reverse the actions of afatinib  are not available.  There is no specific 
antidote for overdosage with afatinib.  Potential adverse  events  should be treated symptomatically.  
Common adverse events  of treatment  with afatinib  with specified management  recommendations  
and/or requirements  include diarrhea,  and rash/acne, paronychia. To improve tolerability  and the 
probability of clinical  benefit, patients  should receive prompt a nd appropriate supportive care at 
the first signs  of symptoms.  Suggested  treatments  for AEs are  described  below.  
5.6.3    Management of Eye  Complications  of Afatinib 
 
Patients  who present  with symptoms of keratitis,  such  as acute or worsening eye inflammation,  
lacrimation,  light sensitivity,  blurred vision, eye pain and/or red eye should be referred  promptly 
to an ophthalmic specialist.  If a diagnosis of ulcerative keratitis  is confirmed, treatment  with  
afatinib  should be interrupted  or discontinued. If  keratitis  is diagnosed, the benefits  and risks  of 
continuing treatment with afatinib  should be carefully considered.  Afatinib  should be used with 
caution  in patients with  a history of keratitis, ulcerative keratitis  or severe dry eye. Contact  lens 
use is a risk factor  for keratitis  and ulceration. 
5.6.4    Management of expected  adverse events  
 
Dermatologic  adverse events,  mucositis /stomatitis and  diarrhea are the most common side- 
effects  associated  with treatment  with  afatinib.  Treatment of  these side- effects  should be 
proactive and should be started  as early  as possible after onset of symptoms. 
 
5.6.5    Management of diarrhea and hydration status following treatment with afatinib  
 Diarrhea  occurs  at a high frequency  and generally  begins  within  2 weeks  of exposure to 
afatinib.  Although usually  mild to moderate, diarrhea may  lead to dehydration and compel 
treatment  modification  or discontinuation, so early  management  is essential  (Table 10). At the  
time of initiation  of treatment with  afatinib  patients  should be given  a supply of loperamide to 
keep  with them  at all times  or access  to afatinib  should be confirmed; and patients should be 
counselled  on the appropriate use. 
 
 
Patients  must be advised  to drink an adequate amount  of fluids to make up for the fluid  lost 
through diarrhea.  (5) 
 
     
 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 39 of 133 
 Table 10: Grade  specific treatment  recommendations  for afatinib  related  diarrhea  
 
Severity 
(CTCAE 
Grading) Descri ption Interven tion Concerning 
Afatinib Treatment  Specific Interven tion 
Mild  
(Grade 1) Increas e of < 4 stools per 
day over b aseline; m ild 
increas e in o stomy output 
compared w ith baseli ne Continue same dose Stop laxatives and advise patient to drink 
at least 8-10 glasses of w ater of clear 
fluids per da y; 
4 mg (2 tablets) of lop eramide to be taken 
immed iately, followed by 2 mg (1 tablet) 
after each loose stool until bowel 
movements cease for 12 hours   
Moderate 
(Grade 2)  Increas e of 4-6 stools per 
day over baseline; IV fluids 
indicated < 24 hours ; 
moderate increase in 
ostomy output comp ared 
with baseline; not 
interferi ng w ith ADL  Continue same dose unless 
Grade 2 diarrhea c ontinues 
for ≥ 2 days ( 48 hours) in 
which case treat ment must 
be interrup ted until 
recovered to ≤ Grade 1 
followed by dose reduction  Continue loperamide; assess f or 
dehydration and electr olyte imbalance; 
consider IV fl uids and electr olyte 
replacement  
Severe 
(Grade 3)  Increas e of ≥ 7 stools per 
day over baseline; 
incontinence; IV fluids >24 
hours ; hospitalization; 
severe increase in ostomy 
output compared with 
baseline; interferi ng with 
ADL  Dose interruption until 
recovered to ≤ Grade 1 
followe d by dose 
reduction*  See Grade 2; plus:  
an infectiou s process s hould be r uled out 
with stoo l cultures; a ggressi ve iv fl uid 
replacement  
≥ 24 hou rs; hospitalizati on to monitor 
progress; c onsider prophylactic an tibiotics 
if patient is also neutropenic;  
Life 
threatening  
(Grade 4)  Life-threatening 
consequences (e.g. 
hemodyn amic collapse)  Dose interruption until 
recovered to ≤ Grade 1 
followed by dose 
reduction*  See Grade 3 
 
* If despite optimal supportive care and a treatment interruption, diarrhea  does not resolve 
to CTC  AE Grade ≤1 within  14 days,  treatment with  afatinib  must be permanently discontinued.  
In the event  that the patient  is deriving obvious clinical  benefit  according  to the investigator’s  
judgment, further treatment  with afatinib  will be decided  in agreement  between the company 
supporter and  the investigator.  
 
5.6.6 Management recommendations  for dermatological AEs following  treatment  with 
afatinib 
 
Dermatologic  AEs of afatinib  include rash,  acne,  dermatitis  acneiform,  and dry skin. General 
recommendations for prophylaxis  are summarized  in Table 11 and  grade -specific treatment  
recommendations are summarized  in Table 12 and 13. For dose adjustment of afatinib  refer  to 
Table 6.  
 
Specific interventions should be reassessed  at least after 2 weeks  or at any worsening of 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 40 of 133 
 symptoms,  in which  case the specific intervention  should be adjusted and, depending on own 
clinical  experience,  early  involvement of a dermatologist should be considered. (4). 
 
 
Table 11: General  recommendations for prophylaxis while  receiving  afatinib  
 
 Personal  hygiene  • Use of gentle soaps  and shampoos  for the body,  e.g. pH5 neutral bath  and shower  
formulations  and tepid  water.  
• Use of very  mild shampoos  for hair  wash.  
• Only  clean  and smooth  towels  are recommended because of potential risk  of 
infection.  The skin should  be patted  dry after a shower, whereas  rubbing the skin 
dry should be avoide d. 
• Fine cotton  clothes  should  be worn instead  of synthetic  material. Shaving  has to be 
done  very carefully.  
• Manicure, i.e. cutting  of nails,  should  be done  straight across  until the  nails  no 
longer  extend  over the fingers  or toes. Cuticles are  not allowed  to be trimmed  
because this procedure increases  the risk of nail  bed infections  
Sun protection  • Sunscreen  should  be applied  daily  to exposed  skin areas  regardless of  season.  
Hypoallergenic sunscreen  with a high SPF (at least SPF30,  PAPA  free, UVA/UVB  
protection),  preferably broad spectrum containing zinc oxide  or titanium dioxide   
are recommended  
• Patients  should  be encouraged  to consequently  stay out of the  sun.  
• Protective  clothing  for sun protection  and wearing  a hat should be recommended.  
Moisturizer  
treatment  • It is important to  moisturize the  skin as soon  as anti-EGFR  therapy is  started.  
• Hypoallergenic moisturizing  creams, ointments  and emollients should  be used 
once  daily  to smooth  the skin and to prevent  and alleviate  skin dryness.  
• Note: avoid  greasy  creams  (e.g. petrolatum,  soft paraffin,  mineral oil based)  and 
topical acne medications  
Prevention of 
paronychia  • Patients  should  keep  their  hands  dry  and  out  of  water  if  ever possible.  
• They  should  avoid  friction  and pressure  on the nail fold as well as picking  or 
manipulating  the nail. 
• Topical  application of  petrolatum  is recommended  around  the nails due  to its 
lubricant  and smoothing  effect  on the  skin.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 41 of 133 
 Table 12:  Grade  specific  treatment  recommendations  of skin reactions  to afatinib  
 
Severity Descri ption Specifi c intervention 
ACNE IFORM RAS H 
Mild  
(Grade 1) Macula r or papular eruptions or 
erythema w ithout associated symptoms Consider topical antibiotics, e.g. 
clindamycin 2% or top ical erythromycin 1% cream of 
metronidazole 0. 75% or top ical nadifloxaci n 1%; 
Isolated scattered lesion: cream preferre d 
Multipl e scattere d areas: lotion preferred  
Moderat e 
(Grade 2) Macula r or papula r eruption s with 
pruritus or other associated symptoms; 
locali zed desquama tion or other lesions 
covering <30% of BS A Topical treatment as for Grade 1 plus short term topical 
steroids, e.g., prednicar bate cream 0. 02% plus an o ral 
antibiotic (for at least 2 w eeks) e.g. Doxy cycline 100mg 
b.i.d. or Minocy cline hydrochlo ride 100m g b.i.d 
Severe  
(Grade 3) Severe, generalize d erythroderma or 
macu lar, popular or vesicular eruption; 
desquam ation c overing ≥30% of BSA ; 
associated w ith pain, disfigurement, 
ulcerati on or desquamation Topical and systemic treatment as for 
Grade 2. 
Consider referra l to d ermatologist 
Consider sy stemic steroids 
Life 
threatening  
(Grade 4) Generalize d exfoliative, ulcerati ve, or 
bullous dermatitis See Grade 3 
Systemic steroids are recomme nded 
EARL Y AND LAT E XER OTIC SKIN REACT IONS - PRURI TUS 
Mild  
(Grade 1) Mild or localize d Topical polidocanol cream. Consider oral antihistamines, 
e.g. diphe nhyd ramine, dim ethindene, cetirizi ne, 
levocetirizi ne, d esloratidine, fexofenadine or clemastine) 
Moderat e 
(Grade 2) Intense or widespread See Grade 1 plus oral antihistamines; Consider topical 
steroids, e.g., topical hydrocortisone 
Severe  
(Grade 3) Intense or widespread and interferi ng 
with activities of daily living (ADL ) See Grade 2. 
XER OSIS ( DRY SKIN) 
Mild  
(Grade 1) Asymptomatic Soap-free shower gel and/or bath oil. Avoid alcoholic 
solutions and soaps . Urea- or gly cerin-based moisturizer. 
In in flammatory lesions c onsider t opical steroids (e.g., 
hydrocortisone cream) 
Moderat e 
(Grade 2) Symp tomatic, not interferi ng with 
ADL  See Grade 1. 
In in flammatory lesions c onsider t opical steroids (e.g., 
hydrocortisone cream) 
Severe  
(Grade 3)  Symptomatic, i nterferi ng with ADL  See Grade 2. 
Topical st eroid s of higher potency (e.g. , prednicarbate, 
mom etasone furoate) Consider oral antibiotics  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 42 of 133 
  
FISSURE S 
Mild  
(Grade 1) Asymptomatic Petroleum jelly, Vaseline® or Aquaphor for 
30 minute s under plastic o cclusion ev ery night, 
followed by a pplicati on of hydrocolloid d ressing; 
antiseptic baths (e.g. potassi um p ermanganate 
therapeu tic baths, final c oncen tration of 1:10 ,000, or 
povidone -iodine b aths) 
Topical applicati on o f  aqueous silver nitrate solu tions 
to fissures 
Moderat e  
(Grade 2) Symp tomatic, not interferi ng 
with 
 See Grade 1. 
Consider oral antibiotics. 
Severe  
(Grade 3) Symp tomatic, Interferi ng with 
ADL See Grade 2. 
1 If Grade 2 rash persist s for ≥7 days despite treatment and is poorly tolerate d by the patient, the investigator may 
choo se to pause treatment up to 14 days fo llowed by a reducti on in the dose of afatinib according to the dose 
reduction scheme in Table 6. 
 
 
5.6.7 Management of mucositis/stomatitis  
 
General  and grade specific recommendations are described  in Table 13. For dose adjustment 
refer to Section  5,2 and for restrictions  on concomitant  therapies  refer  to Section  5.6. 
 
Treatment  is supportive and aimed  at symptom control. These may include atraumatic cleansing  
and rinsing with non- alcoholic  solutions such as normal saline,  diluted  salt and baking soda 
solution (e.g. one- half teaspoonful of salt  and one teaspoon of baking soda in one quart of water  
every  four hours);  avoidance of agents containing iodine, thyme derivatives  and prolonged use of 
hydrogen peroxide; dietary  maneuvers  such as promotion of soft,  non irritating foods like ice-
creams,  mashed/cooked vegetables,  potatoes  and avoidance of spicy, acidic  or irritating  foods 
such as peppers, curries,  chillies,  nuts and alcohol. If the  patient  is unable to swallow  foods or 
liquids, parenteral  fluid  and/or nutritional support may be needed.  Examples  of some of the 
agents  suggested in Table 13 include: topical  analgesics  –viscous lidocaine 2%; mucosal  coating  
agents  - topical  kaolin/pectin; oral antacids,  maltodextrin,  sucralfate;  topical antifungals – 
nystatin  suspension. (adapted  from (8)). 
 
 
 
 
  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 43 of 133 
 Table 13: Grade specific treatment recommendations of study -drug related mucositis/stomatitis  
 
 
Severity  
(CTCAE 
Grading)  Description  Treatment Recommendations  Intervention Concerning 
Afatinib Treatment/Dose 
Modification 
Mild   
(Grade  1) Minimal 
symptoms;  
normal diet Oral rinses  with agents  such as non -
alcoholic mouthwash, normal saline, 
diluted salt and baking soda solution. No change.  
Moderat e  
(Grade 2) Symptomatic,  
but  can  eat and 
swallow 
modified  diet Addition of topical analgesic  
mouth treatments, topical 
corticosteroids, antiviral therapy if  
herpetic infection  confirmed, 
antifungal therapy preferably topical  
on a case  by case basis.  Maintain dose if  
tolerable; Hold  dose if 
intolerable until recovery to grade ≤1, then  restart  
at  the same dose. 
Severe  
(Grade 3) Symptomatic  
and unable to 
adequately 
aliment or 
hydrate  orally  Same as for Grade  2; institute  
additional symptomatic therapy 
(topical or systemic)  as clinically 
indicated  . Hold dose until 
recovery  to  grade ≤1 or 
baseline, then restart at  the 
reduced dose according to 
Section  5.2. 
Life threate ning 
(Grade 4) Symptoms  
associated  
with life - 
threatening 
consequences Same as for Grade  2; institute  
additional symptomatic therapy 
(topical or systemic)  as clinically 
indicated  Hold dose until 
recovery  to  grade ≤1 or  
baseline,  then restart at  
the reduced dose 
according to Section 5.2 
 
5.7    Diet/Activity/Other  Considerations 
 
5.7.1    Diet 
 
Subjects  should maintain  a normal diet unless modifications  are required  to manage  an AE 
such as diarrhea,  nausea or vomiting. 
 Patients  should be advised to avoid any foods known to aggravate  diarrhea.  
 
5.7.2    Contraception 
 
MK-3475 and afatinib may have adverse effects  on a fetus  in utero.   Furthermore,  it is 
not known if MK -3475 has transient  adverse effects  on the composition of sperm.    
For this trial, male subjects will be considered to be of non -reproductive potential if they 
have azoospermia (whether due to having had a vasectomy or due to an underlying medical 
condition).   
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 44 of 133 
 Female subjects will be considered of non -reproductive potent ial if they are either:  
(1) postmenopausal (defined as at least 12 months with no menses without an alternative 
medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) 
level in the postmenopausal range may be used to confirm a post -menopausal state in 
women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.);  
OR  
(2) have  had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or 
bilateral tubal ligation/occlusion, at least 6 weeks prior to screening;  
OR  
(3) has a congenital or acquired condition that prevents childbearing. 
 
Female and male subjects of reproductive potential must agree to avoid becoming pregnant 
or impregnating a partner, respectively, while receiving study drug and for 120 days after the 
last dose of study drug by complying with one of the following:   
(1) practice true abstinence
† from heterosexual activity , if this is the preferred and usual 
lifestyle  
OR  
(2) use (or have their partner use) highly effective methods of contraception during 
heterosexual activity.   
 
Highly effective methods of contraception  for men and women  are‡: 
• Male sterilization (vasectomy).  For female patients, the vasectomized male partner 
should be the only partner  
• Female sterilization  
• intrauterine device (IUD)  (copper or hormonal)  
• vasectomy of a female subject’s male partner  
• Contracep tive subdermal implant (Nexplanon)  
• Hormonal birth control (i.e., contraceptive pill, patch, ring or injection) for subject or for  male patient’s female partner  
 
Combination method (requires use of two of the following):  
• diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide)  
• cervical cap with spermicide (nulliparous women only)   
• contraceptive sponge (nulliparous women only)  
• male condom or female condom (cannot be used together)  
• hormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or progestin-
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 45 of 133 
 only pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous 
contraceptive injection  
 
Unacceptable methods for men and women : 
• Abstinence at certain times of the cycle only, such as during the days of ovulation, after ovulation (based on symptoms or temperature)  
• Pre-ejaculatory withdrawal  
• Condom with spermicidal foam/gel /film/cream/suppository  
• Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository  
 
†Abstinence (relative to heterosexual activity) can be used as the sole method of 
contraception if it is consistently employed as the subject’s preferred and usual lifestyle and 
if considered acceptable by local regulatory agencies and ERCs/IRBs.  Periodic ab stinence 
(e.g., calendar, ovulation, sympto- thermal, post -ovulation methods, etc.) and withdrawal are 
not acceptable methods of contraception.  
‡If a contraceptive method listed above is restricted by local regulations/guidelines, then it 
does not qualify as an acceptable method of contraception for subjects participating at sites 
in this country/region.  
 
Subjects  should be informed that taking the study medication may  involve unknown risks  to the 
fetus  (unborn baby)  if pregnancy  were  to occur  during the study.  In order  to participate in  the 
study they must adhere to the contraception  requirement  (described  above)  for the duration 
of the study and during the follow-up period defined  in section  7.2.2-Reporting of Pregnancy 
and Lactation  to the Sponsor-Investigator, Merck  and Boehringer Ingelheim.  If there  is any 
question that a subject  will not reliably  comply with the requirements for contraception, that 
subject  should not be entered  into the study.  
 
5.7.3    Use in  Pregnancy  
 
If a subject  inadvertently becomes  pregnant while  on treatment  with MK-3475 and afatinib, the 
subject  will immediately be  removed  from  the study.  The site will contact  the subject  at least  
monthly and document the subject’s  status  until the pregnancy has  been  completed  or 
terminated.  The outcome of the pregnancy  will be reported  to the company supporters and 
Investigator to Merck  and Boehringer Ingelheim without delay  and within  24 hours to the 
Sponsor and within 2 working days to Merck if the outcome is a serious adverse experience 
(e.g.,  death,  abortion, congenital anomaly,  or other  disabling or life -threatening complication  to 
the mother or newborn).  The study investigator will make every  effort  to obtain permission  to 
follow the outcome of the pregnancy and report the condition of the fetus  or newborn to the 
company supporters.   If a male  subject impregnates  his female partner  the study personnel at 
the site must be informed  immediately and  the pregnancy reported  to the Sponsor-Investigator 
and to Merck  and followed as described  above and in Section  7.2.2. 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 46 of 133 
 5.7.4    Use in  Nursing  Women 
 
It is unknown whether  MK-3475 is excreted  in human milk.  Since  many  drugs  are excreted in  
human milk,  and because of the potential for serious adverse reactions  in the nursing infant, 
subjects  who are breast -feeding  are not eligible  for enrollment.  
 
5.8    Subject  Withdrawal/Discontinuation Criteria  
 
Subjects  may  withdraw consent at  any time for any reason  or be dropped from  the trial at  the 
discretion  of the investigator should any untoward effect  occur.  In addition, a subject  may be 
withdrawn  by the investigator or the company supporter  if enrollment into  the trial is 
inappropriate, the trial  plan is violated, or for administrative and/or  other safety  reasons.   
Specific details regarding  discontinuation or withdrawal  are provided in Section  7.1.4 – Other  
Procedures.  
 
A subject  must be discontinued from  the trial for any  of the following  reasons: 
• The subject  or legal  representative (such  as a parent  or legal  guardian) withdraws 
consent. 
• Confirmed  radiographic disease progression by RECIST 1.1  
 
Note : A subject  may be granted  an exception  to continue on treatment with confirmed  
radiographic progression if clinically  stable  or clinically  improved by the primary investigator in 
consultation with the sponsor. 
 
• Unacceptable  adverse experiences  as described  in Section  5.2.1.2 
• Intercurrent illness  that prevents  further administration  of treatment 
• Investigator’s decision  to withdraw the subject  
• The subject  has a confirmed  positive serum  pregnancy test 
• Noncompliance with trial treatment  or procedure requirements  
• The subject  is lost to  follow-up 
• Completed  24 months of uninterrupted treatment with MK-3475 or 35 administrations of 
study medication, whichever is later  
Note:  24 months of study medication is calculated  from the date of first dose. 
• Administrative  reasons  
 
The End of Treatment and  Follow-up visit procedures are  listed  in Section  6 (Protocol Flow 
Chart)  and Section  7.1.5 (Visit Requirements).  After  the end of treatment, each  subject  will be  
followed  for  30  days  for  adverse  event  monitoring.   Subjects who discontinue for reasons  
other than progressive disease will have post- treatment follow - up for disease  status  until disease 
progression, initiating a non-study cancer  treatment, withdrawing  consent or becoming  lost to 
follow-up.   
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 47 of 133 
 5.8.1 Discontinuation of Study Therapy after CR  
 
Discontinuation of treatment may be considered for subjects who have attained a confirmed CR that have been treated for at least 24 weeks with pembrolizumab and had at least two treatments 
with pembrolizumab beyond the date when the initial CR was declared.  Subjects who then 
experience radiographic disease progression may be eligible for up to one year of additional treatment with pembrolizumab via the Second Course Phase at the discretion of the investigator if no cancer treatment was administered since t he last dose of pembrolizumab, the subject meets 
the safety parameters listed in the Inclusion/Exclusion criteria, and the trial is open.  Subjects will resume therapy at the same dose and schedule at the time of initial discontinuation.  Additional details are provided in Section 7.1.5.5. 
 
5.9    Subject  Replacement  Strategy  
 
Patients  who consent for the study and do not receive MK -3474 or afatinib  on study will be 
replaced.  
 
Patients  who receive <80%  of the MK-3475 and afatinib infusion in Cycle  1 (e.g.,  because the 
infusion had to be discontinued due to an infusion reaction)  and did not experience a DLT  will 
not be taken  into account  in the assessment  of the overall  DLT  rate for the particular  dose 
level cohort and will need  to be replaced.  
 
5.10  Clinical Criteria  for Early  Trial  Termination  
 
Early  trial termination  will be the result  of the criteria  specified  below: 
 
1.   Quality or quantity of data recording  is inaccurate or incomplete 
 
2.   Poor adherence to protocol and regulatory  requirements  
 
3.   Incidence or severity of  adverse drug  reaction in  this or other studies indicates  a potential 
health  hazard  to subjects  
 
4.   Plans to modify or discontinue the development of the study drug  
 
In the event  of Merck  and Boehringer  Ingelheim  decision  to no longer supply study drug, 
ample  notification  will be provided so that appropriate adjustments  to subject  treatment can be 
made.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 48 of 133 
 6.0  TRIAL  FLOW  CHART  
6.1 Study Flow  Chart  
Trial Period : Screenin g Phas e Treatment Cycles1.9 End of Treatment 
 
 
 
  Main Stud y 
Screenin g (V isit 1) 1 2 3 4 To be repeate d beyond 8 cycles  Discontinuatio n Visit/Safet y 
Follow Up Visit/PFS follow up  5 6 7 8 
Scheduling W indow (D ays)2: -30 to -1 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3  
Infor med Consent  X          
Inclusion/ Exclusio n Criteri a X          
Demographic s  and Medica l History X          
Prior and Conco mitant Medicatio n Review X X X X X X X X X X 
Trial Treat ment Adm inistratio n  X X X X X X X X  
NSCLC D iseas e Details and Prior Treat ment X          
Review Advers e Event s  X X X X X X X X X 
Full Physica l Examinatio n X          
Directe d Physica l Examinatio n  X X X X X X X X  
Vital Signs and Weight12 X X X X X X X X X  
Zubro d Perfor mance Statu s X X X X X X X X X X 
Pregnanc y Test – Urine or Serum β-HCG3,6 X          
PT/INR and aPTT4,6 X5          
CBC with Differentia l6 X5 X X X X X X X X X 
Comprehensiv e  Serum Chemistry Pane l (see 
6 X5 X X X X X X X X X 
Urinalysi s6 X5          
T3, FT4 and TSH6 X5  X  X  X  X X 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 49 of 133 
  
Trial Period : Screenin g Phas e Treatment Cycles1,9 End of Treatment 
Treat ment Cycle/Title : Main Stud y 
Screenin g (V isit 1) 1 2 3 4 To be repeate d beyon d 8 
cycles  Discontinuatio n Visit/Safet y 
Follow Up Visit     5   6   7   8 
Scheduling W indow (D ays)2 -30 to -1  ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3  
Efficac y Measurem ents 
Tumor Imaging7 X   X   X    
Brain Imaging ( MRI or CT  Scan)13 X          
Tumor Biopsies/ Archiva l  Tissue Collection/ Correlativ e Studie s Blood 
Tissu e Collectio n10 X  
(must be within 60 days)    X       
EGFR Mutatio n Testing8 X          
Correlativ e Studie s Blood Collectio n11 X   X   X   X 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 50 of 133 
 1. I n genera l, assessmen ts/procedure s are to be performe d on Day 1 and prior to the fi rst dose of trial t reatment for each cycle unless otherwise specified. 
Treatment cycles are 3 week s (21-days); howeve r the MK- 3475 treatment cycle inter val may be i ncreased due to toxicity according to the dose modification 
guidelines provided. If treatment cycles are increase d all procedures excep t imaging w ill be comp leted accord ing to the Cycle numbe r and not week s on 
treatment, imaging w ill be performe d every 6 week s (± 3 days) from the fi rst dose of trial t reatment regard less of any treatment delays. Weekly (D8 and D15 
+/- 3 days) follow up visits for the first cycle when  starting afatinib  is recommended  (when afatinib is added (Cohort A C1D1 and Cohort B C3D1).  
2. I n genera l, t he wi ndow for each vis it is ± 3 days unless otherw ise specified. 
3. For women  of reproducti ve potential, a urine or serum  pregnancy  test will be performed  within 72 hours  prior  to first dose of trial treatmen t. If 
urine  pregnancy  resu lts cannot  be confirmed  as negati ve, a serum  pregnancy  test, performed  by the local study site labora tory, will be required . 
Pregnancy  tests (serum  and/or urine tests) shou ld be repea ted if requ ired by local guidelines. 
4. Coagula tion factors (PT/INR and aPTT ) should  be monitored closely throughou t the trial for any subjec t receiving anticoagul ant therapy . 
5. Labo ratory tests for screenin g are to be performed withi n 10 days prior to the first dose of trial treatment . 
6. After Cycle 1, lab samp les can be collected up to 72 hours prior to the schedu led time point. Labo ratory results must be know n and accep table prior to dosing. 
7. The initia l tumo r imagin g will be performed within 30 days prior to the first dose of trial treatment . Scan s performed as part of routin e clinica l managemen t 
are accep table for use as the screening scan if they are of diagnos tic quality and perfo rmed within 30 days prior to the f irst dose of trial treatment. On-st udy 
imaging w ill be performed every 6 week s (42 - 7 days) after the fi rst dose of trial treatment or more frequen tly if clinically  indicated. The timing for imaging 
studies shou ld follow calenda r days and should  not be adjus ted for delays in cycle starts or extension o f MK- 3475/ afatin ib cycle frequenc ies. The same 
imag
ing techniqu e shoul d be used in a subjec t throughou t the tria l. CT i ncluding the chest, abdome n and pelvis or PET-CT is required for the baseline 
assessmen t. 
8. P rovide documenta tion o f the subject’s t umor EGF R mutation from a CLIA certified laboratory.  
9. MK-3475 can be administered for up to 2 years. For the dose de -escalation and Cohort (Arm) A (concurrent afatinib and MK -3475) both drugs will be 
administered as outlined in this protocol starting with cycle #1. For cohort B. MK -3475 will be initiated with cycle #1 and afatinib will commence in 
combination with MK -3475 starting with cycle #3.  
10. Tumo r biopsy for immun e and EGF R biomarke r analysis will be performe d prior to Cycle 1 of treatment either on archival tissue or fresh biopsy (within 60 
days) . Repeat bi opsy will be performe d prior to initiation of cycle 3 (42 days (-7 days)) 
11.  Corre lative bl ood draw s for immun e correlates w ill be performe d prior to cycle 1 (- 3 days) , prior to cycle 3 (-3 days), prior to cycle 6 (-3 days) and at 
progression (+/- 5 days) . Corre lative bl ood draw s for plasma tumor cfDNA  will be performe d at baseline, every 2 cycles (+/- 3 days) and at progress ion (+/- 
5 days) . 
12.  Vita l si gns to include temperat ure, pulse, respiratory rate, weight and blood pressure . Height will be measure d at screen ing only. 
13.  Contrast enhanced MRI brain or CT head is recommended. If contrast is contraindicated, a non -contrast enhanced study may be performed.  
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 51 of 133 
 7.0  TRIAL  PROCEDURES  
7.1    Trial  Procedures  
 
The Trial  Flow  Chart  - Section  6.0 summarizes the  trial procedures to be performed  at each 
visit.  Individual trial procedures are described  in detail  below.  It may be necessary  to perform  
these procedures at  unscheduled time points if deemed  clinically  necessary  by the investigator. 
 Furthermore,  additional evaluations/testing may  be deemed  necessary  by the Sponsor- 
Investigator and/or Merck  and/or Boehringer -Ingelheim for reasons  related  to subject  safety. In  
some cases,  such evaluation/testing may  be potentially sensitive  in nature  (e.g., HIV, Hepatitis  
C, etc.),  and thus local  regulations may require that additional informed  consent  be obtained 
from  the subject.  In these cases,  such evaluations/testing will be performed  in accordance  with 
those regulations. 
7.1.1    Administrative Procedures  
 
7.1.1.1   Informed  Consent  
 
The Investigator must obtain  documented consent from  each potential subject  prior to 
participating  in a clinical  trial. 
 
7.1.1.1.1  General Informed  Consent  
 
Consent must be documented by the subject’s dated  signature  or by the subject’s  legally 
acceptable representative’s dated  signature  on a consent form  along  with the dated  signature of 
the person conducting the consent discussion. 
 A copy  of the signed  and dated  consent form  should be given  to the subject before participation  
in the trial. 
 
The initial informed  consent form,  any subsequent revised  written  informed consent form 
and any written  information provided to the subject  must receive the IRB/ERC’s 
approval/favorable opinion in advance of use.   The subject  or his/her legally  acceptable 
representative should be informed  in a timely  manner if new information becomes  available that  
may be relevant  to the subject’s  willingness  to continue participation  in the trial.  The 
communication of this information  will be provided and documented via a revised  consent form  
or addendum to the original consent form  that captures  the subject’s  dated  signature or by the 
subject’s  legally  acceptable representative’s  dated  signature.  
 Specifics  about a trial and the trial population will be added  to the consent form  template at the  
protocol level.  
 The informed consent will adhere to  IRB/ERC requirements,  applicable laws and regulations and 
Sponsor-Investigator requirements.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 52 of 133 
 7.1.1.2   Inclusion/Exclusion  Criteria  
 
All inclusion and exclusion  criteria  will be reviewed  by the investigator or qualified  designee to  
ensure that the subject  qualifies  for the  trial. 
 
7.1.1.3   Medical  History  
 
A medical  history will be obtained by the investigator or qualified  designee.  Medical  history 
will include all  active conditions, and any condition diagnosed within  the prior 10 years  that are 
considered  to be clinically  significant  by the Investigator.  Details  regarding the disease for  
which  the subject  has enrolled  in this study will be recorded separately and  not listed  as medical  
history. 
 
7.1.1.4   Prior and Concomitant Medications  Review  
 
7.1.1.4.1  Prior Medications  
 
The investigator or qualified  designee  will review  prior medication use,  including any protocol-
specified  washout requirement,  and record  prior medication  taken  by the subject within  28 
days before  starting  the trial.  Treatment for  the disease for which  the subject  has enrolled  in this 
study will be recorded  separately  and not listed  as a prior medication.  
 
7.1.1.4.2  Concomitant Medications  
 
The investigator  or qualified  designee will record  medication,  if any, taken  by the subject 
during the trial.  All medications  related  to reportable SAEs  and ECIs  should be recorded  as 
defined  in Section  7.2. 
 
7.1.1.5   Disease  Details  and Treatments  
 
7.1.1.5.1  Disease  Details  
 
The investigator or qualified  designee  will obtain prior and current  details  regarding  disease 
status.  
 
7.1.1.5.2  Prior Treatment  Details  
 The investigator or qualified  designee will review  all prior cancer  treatments including systemic  
treatments,  radiation  and surgeries.  
 
7.1.1.5.3  Subsequent  Anti -Cancer Therapy  Status  
 
The investigator  or qualified  designee will review  all new anti-neoplastic therapy  initiated 
after the last  dose of trial treatment.  If a subject initiates  a new anti-cancer  therapy  within  30 
days after  the last dose of trial treatment,  the 30 day  Safety  Follow-up visit must occur  before the 
first dose of the new therapy.  Once  new anti-cancer  therapy  has been  initiated  the subject will 
move into survival follow-up. 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 53 of 133 
 7.1.1.6   Trial  Compliance (Medication/Diet/Activity/Other)  
 
The study medication  will be given  in accordance  with  the protocol and the instructions of a site  
investigator.  
 
The appropriate number of afatinib  tablets  for 3 weeks  of treatment will be provided to patients  
to be self-administered  at home. 
 
Patients  will be asked  to bring the remaining  trial medication  at the  end of each 3 week to  the 
investigator  site for a compliance check.  The remaining  film- coated  tablets  will be counted by 
the investigator/site staff  and recorded  at the investigator  site. Discrepancies  between  the 
number of tablets  remaining  and the calculated  number of tablets  the patients  should have 
taken  must be documented and explained. At the end of each 3 week,  any remaining medication  
will be collected.  If the patient  is eligible  for further treatment, a  new bottle of study medication  
must be dispensed. 
 
The investigator can withdraw a patient  from  the study in the event  of serious and persistent  
non-compliance which  jeopardizes the patient’s  safety  or render  study results  for this patient  
unacceptable. Patients  who do not attend  a minimum of 75% of scheduled study visits,  unless 
due to exceptional  circumstances,  should be discussed  with the company supporter and  be 
evaluated  for compliance. 
7.1.2    Clinical Proc edures/Assessments  
 
7.1.2.1   Adverse Event  (AE) Monitoring  
 
The investigator  or qualified  designee will assess each subject to evaluate  for potential new or 
worsening AEs as specified  in the Trial  Flow  Chart  and more  frequently if  clinically indicated.  
Adverse experiences  will be graded and  recorded  throughout the study and during the follow-up 
period according  to NCI CTCAE  Version  4.0 (see Section  12.2).  Toxicities will be 
characterized in  terms  regarding  seriousness,  causality,  toxicity  grading,  and action taken  with 
regard  to trial treatment.  
 
For subjects receiving treatment with  MK-3475 all AEs of unknown etiology associated with 
MK-3475 exposure should be evaluated to determine if it is possibly an event of clinical 
interest  (ECI)  of a potentially  immunologic etiology  (termed immune -related adverse events, or 
irAE s).    See the separate ECI guidance document in  the appendix (Section 12.9) regarding  the 
identification,  evaluation  and management  of potential i rAEs . 
 
Refer to section  7.2 for detailed  information  regarding the assessment  and recording  of AEs.  
 
7.1.2.2   Full Physical Exam  
 
The investigator or qualified  designee  will perform  a complete physical  exam  during the 
screening  period.   Clinically  significant abnormal findings should be recorded  as medical 
history. A full  physical  exam  should be performed  during screening,  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 54 of 133 
 7.1.2.3   Directed  Physical Exam  
 
For cycles  that do not require  a full physical  exam  per the Trial  Flow  Chart,  the investigator or 
qualified  designee will perform  a directed  physical  exam  as clinically  indicated  prior to trial 
treatment  administration.  
 
7.1.2.4   Vital  Signs  
 
The investigator or qualified  designee will take vital signs  at screening,  prior to the 
administration  of each dose of trial treatment  (on day 1 prior to MK- 3475) and at treatment  
discontinuation as specified  in the Trial Flow  Chart (Section  6.0).  Vital signs should include 
temperature,  pulse, respiratory rate,  weight  and blood pressure.  Height  will be measured  at 
screening  only. 
 
7.1.2.5   Eastern  Cooperative Oncology Group  (ECOG/Zubrod)  Performance Scale  
 
The  investigator  or  qualified  designee  will  assess  ECOG  status  (see  Section  12.1)  at 
screening,  prior to the administration  of each dose of trial treatment  and discontinuation of trial 
treatment  as specified  in the Trial  Flow  Chart.    
 
7.1.2.6   Tumor  Imaging and Assessment  of Disease  
 
 
For the purposes of this study,  patients  should be re-evaluated  for response  after  cycle  2 (6 
weeks)  and then  every  2 cycles  (6 weeks).  In addition to a baseline scan,  confirmatory  scans 
should also be obtained at least 4 weeks  following  initial documentation of objective response. 
 
RECIST  version 1.1* will be used in this study  for assessment  of tumor  response. While 
either  CT or MRI  may be utilized,  as per RECIST  1.1, CT is the preferred  imaging  technique in 
this study.  
 * As published in the European Journal of Cancer:  
 
• PET- CT At present,  the low dose or attenuation  correction  CT portion of a combined 
PET- CT is  not always  of optimal diagnostic  CT quality for use with RECIST 
measurements.  However,  if the site can document that  the CT performed  as part of a 
PET- CT is of identical diagnostic  quality to a diagnostic CT (with  IV and oral contrast), 
then the CT portion of the PET- CT can be used for RECIST  measurements and  can  be  
used  interchangeably  with  conventional CT  in  accurately  measuring cancer  lesions 
over time.  Note,  however,  that the PET portion of the CT introduces additional data  
which  may  bias  an  investigator  if  it  is  not  routinely or  serially performed.  
 
• Conventional CT and MRI   This guideline has defined  measurability  of lesions on CT 
scan based  on the assumption that CT slice thickness is 5 mm or less.  If CT scans 
have slice thickness greater  than 5 mm, the minimum size for a measurable lesion 
should be twice  the slice thickness.  MRI  is also acceptable in  certain  situations  (e.g. for 
body scans). 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 55 of 133 
  
Definitions  
 
Evaluable for toxicity .  All patients  will be evaluable for toxicity  from  the time of their first 
treatment  with MK-3475 and afatinib.  
 
 
Evaluable for objective response.   Only  those patients  who have measurable disease present  at 
baseline,  have received  at least one cycle  of therapy,  and have had their disease re-evaluated  
will be considered  evaluable for response.  These patients  will have  their response classified  
according to  the definitions stated  below.   (Note: Patients  who exhibit objective disease 
progression prior to  the end of cycle  1 will also be  considered  evaluable.)  
 
 
Evaluable Non- Target  Disease Response .   Patients  who have lesions present at baseline that are 
evaluable but do not meet  the definitions of measurable disease,  have received  at least one cycle  
of therapy,  and have had their disease re-evaluated  will be considered  evaluable for non- target 
disease.  The response assessment  is based  on the presence,  absence,  or unequivocal progression  
of the lesions. 
 
 
Disease Parameters  
 
Measurable  disease .  Measurable lesions are defined  as those that can be accurately measured  
in at least one dimension (longest diameter to  be recorded) as  ≥20 mm by chest  x-ray or  as ≥10 
mm with CT scan, MRI,  or calipers  by clinical  exam.  All tumor measurements  must be recorded  
in millimeters  (or decimal  fractions  of centimeters).  
 
 
Note:  Tumor lesions that are situated  in a previously irradiated  area are measurable if there is 
evidence of growth post-radiation such as increase in size on CT or increase in FDG avidity on 
PET. 
 
Malignant  lymph  nodes.   To be considered pathologically enlarged  and measurable,  a lymph  
node must be ≥15 mm in  short axis  when  assessed  by CT scan (CT scan  slice thickness  
recommended  to be no greater  than 5 mm).  At baseline and in follow-up, only the short axis 
will be measured  and followed. 
 
 
Non-measurable disease .   All other lesions (or sites of disease),  including small lesions  
(longest diameter  <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis),  are 
considered  non- measurable disease.  Bone  lesions,  leptomeningeal disease,  ascites,  
pleural/pericardial effusions, lymphangitis  cutis/pulmonitis, inflammatory  breast  disease,  and 
abdominal masses  (not followed  by CT or MRI),  are considered  as non- measurable.  
 
 
Note:  Cystic  lesions that meet  the criteria  for radiographically defined  simple  cysts should not 
be considered as malignant lesions  (neither  measurable nor  non- measurable)  since they are, by 
definition, simple  cysts.  
 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 56 of 133 
 ‘Cystic  lesions’  thought  to  represent  cystic  metastases  can  be  considered  as 
measurable  lesions, if they meet  the definition  of measurability described  above. However, if 
non-cystic  lesions are present  in the same patient, these  are preferred for selection  as target  
lesions. 
 
Target lesions.   All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total,  representative of  all involved organs, should be identified  as target lesions  and recorded 
and measured at  baseline.  Target  lesions should be selected  on the basis  of their size (lesions 
with the longest diameter),  be representative of  all involved organs, but in addition should be 
those that lend themselves to  reproducible repeated measurements.  It may be the case that, on 
occasion,  the largest  lesion  does not lend itself  to reproducible measurement  in which  
circumstance the next largest lesion  that can be measured reproducibly should be selected.  A 
sum of the diameters (longest  for non-nodal lesions, short axis for nodal lesions) for all target  
lesions will be  calculated  and reported  as the baseline  sum diameters.  If lymph  nodes are to 
be included in the sum, then  only the short axis is  added  into the sum.  The baseline sum 
diameters  will be used as reference  to further characterize any  objective tumor regression  in the 
measurable dimension of the disease.  
 
Non-target  lesions .  All other lesions (or sites of disease)  including any measurable lesions  
over and above the  5 target  lesions should be identified as  non- target  lesions and should also be 
recorded  at baseline.  Measurements of these lesions are not required, but the presence,  absence,  
or in rare cases  unequivocal progression of each should be noted throughout follow-up. 
 
Response Criteria  
 
Evaluation of Target  Lesions 
 
 
Complete  Response (CR) :  Disappearance of  all target  lesions.  Any pathological lymph  nodes 
(whether  target  or non- target)  must have reduction in short axis to 
<10 mm. 
 
 
Partial  Response (PR) :  At least a 30% decrease  in the sum of the diameters  of target  lesions, 
taking as reference the baseline sum diameters.  
 
 
Progressive Disease  (PD) :  At least a 20% increase in  the sum of the diameters  of target  lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative  increase of  20%, the sum must also demonstrate 
an absolute increase of at least 5 mm. (Note:   the appearance of  one or more  new lesions is 
also considered progressions). 
 
 
Stable  Disease (SD) :  Neither  sufficient  shrinkage to qualify for PR nor sufficient  increase to 
qualify for PD, taking  as reference the smallest sum diameters  while on study. 
 
 
 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 57 of 133 
 Evaluation of Non- Target  Lesions 
 
Complete  Response (CR) :    Disappearance of  all non- target  lesions and normalization of tumor 
marker  level.  All lymph  nodes must be non- pathological in  size (<10  mm short axis).  
Note:  If tumor markers  are initially  above the  upper normal limit,  they must normalize  for a 
patient  to be considered  in complete  clinical  response.  
 
 
Non-CR/Non -PD:   Persistence of  one or more  non- target  lesion(s) and/or maintenance  of tumor 
marker  level  above the normal  limits.  
 
 
Progressive Disease (PD) :   Appearance of one or more  new lesions and/or unequivocal 
progression of existing  non- target  lesions.  Unequivocal progression should not normally 
trump  target  lesion  status.   It must be representative of overall disease  status  change,  not a 
single  lesion  increase.  
 
 
Although a clear  progression of “non- target” lesions  only is exceptional, the opinion of the 
treating  physician  should prevail  in such circumstances,  and the progression status should be 
confirmed  at a later time by the review  panel  (or Principal  Investigator). 
 
 
Evaluation of Best  Overall  Response 
 
 
The best overall  response is the best response recorded from  the start of the treatment  until 
disease progression/recurrence (taking as  reference for progressive disease the smallest 
measurements recorded  since the treatment started).  The patient's  best response assignment  will 
depend on the achievement of  both measurement and confirmation  criteria.  
 
 
  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 58 of 133 
 For Patients  with  Measurable Disease  (i.e., Target Disease)  
 
Target  
Lesions  Non-Targe t 
Lesions New  
Lesions Overall  
Response  Best Overall Response  
when Confirmation  is 
Required*  
CR CR No CR >4 wks. Confirmation** 
CR Non-CR/Non - PD No PR >4 wks. Confirmation** 
CR Not evaluated  No PR 
 
PR Non-CR/Non - PD/not evaluated  No PR 
SD Non-CR/Non -PD/not evaluated  No SD Documented at least once 
>4 wks. from baseline** 
PD Any Yes or No  PD 
No prior SD, PR or CR Any PD*** Yes or No  PD 
Any Any Yes PD 
* See RECIST  1.1 manuscript  for further  details  on what  is evidence  of a new lesion.  
** Only  for non-randomized trials  with response  as primary  endpoint. 
*** In exceptional circumstances,  unequivocal progression in non-target  lesions  may be accepted  as 
disease progression. 
Note : Patients  with  a  global  deterioration  of  health  status  requiring  discontinuation  of treatment 
without objective evidence of disease  progression at that time should be reported as “symptomatic  
deterioration.”  Every effort  should be made  to document the objective progression even  after 
discontinuation of treatment.  
 
 
 
For Patients  with  Non -Measurable Disease ( i.e., Non-Target  Disease)  
 
Non-Target  Lesions  New  Lesions  Overall  Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal  PD Yes or No  PD 
Any Yes PD 
*  ’Non-CR/non -PD’ is preferred  over ‘stable  disease’  for non -target  disease  since  SD is   increasingly  used as an 
endpoint  for assessment  of efficacy  in some  trials  so to  assign  
this category  when  no lesions  can be measured  is not advised  
 
 
 
  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 59 of 133 
 Duration of Response  
 
Duration of overall response :  The duration of overall response is measured from  the time  
measurement  criteria  are met for CR or PR (whichever  is first recorded)  until the first  date that 
recurrent  or progressive  disease is objectively documented  (taking  as reference for progressive 
disease the smallest measurements recorded  since the treatment  started).  
 
 
 
The duration of overall  CR is measured  from  the time measurement criteria  are first met for CR  
until the first date that progressive disease is objectively documented. 
 
 
Duration of stable  disease :  Stable  disease is measured from  the start of the treatment until the 
criteria  for progression  are met, taking  as reference the smallest measurements recorded  since  
the treatment  started,  including the baseline measurements.  
 
 
Progression- Free Survival  
 
PFS is  defined  as the duration of time  from  start of treatment  to time  of progression or death, 
whichever  occurs  first. 
 
 
Response Review  
 
Response review  will be done by the  investigator . 
 
 
7.1.3    Laboratory Procedures/Assessments  
 
Details  regarding  specific laboratory procedures/assessments to be performed  in this trial are 
provided below.   
 
7.1.3.1 Laboratory Safety  Evaluations (Hematology, Chemistry  and Urinalysis)  
 
Laboratory  tests for hematology, chemistry,  urinalysis,  and others are specified  in the trial flow 
chart (Section 6) and section 12.7. The total amount of blood/tissue to be drawn/collected  over 
the course of the  trial (from  pre- trial  to post- trial visits),  including approximate blood/tissue 
volumes drawn/collected  by visit and  by sample  type per subject.  
 
Laboratory tests  for screening  or entry  into the Second  Course Phase should be performed 
within  10 days prior to the first dose of treatment. After  Cycle 1,  pre-dose laboratory procedures  
can be conducted up to 72 hours prior to dosing.  Results  must be reviewed  by the investigator or 
qualified  designee and found to be acceptable prior  to each dose of trial treatment.  
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 60 of 133 
 7.2    Correlative Studies  
Correlative Studies  
Study- specific correlatives are outlined below. Remaining extra plasma and tissue after these 
studies are performed may be used for additional  research studies focusing on molecular 
pathways of resistance to EGFR -directed therapy and additional immune markers. 
A Study ID number will  be assigned  to each patient and  will be used in sample  coding instead  
of the name.  The key linking the number with the patient  identity  and clinical outcomes will 
be kept by Dr. Riess  and his research  staff.  This will be kept in a locked  location. 
 
7.2.1    EGFR -directed  Correlative Studies  
7.2.1.1    Plasma EGFR- mutant DNA  
 
Molecular Studies : Blood  
• Plasma DNA/RNA detection of EGFR  and PD- L1 
Prior to each cycle of treatment , two tubes of blood (1 for RNA and 1 for DNA) will be collected 
for EGFR  and PD-L1 DNA and RNA quantification. Tubes will be provided in a collection kit 
from Liquid Genomics. The assay will be performed by Liquid Genomics, which has validated 
DNA and RNA assays for EGFR mutations  and PD- L1 RNA levels. Please see Appendix 12.6 
for tube collection and shipping instructions. 
Please be sure to order kits from Liquid Genomics at the time of study activation (if not already 
available at the site).  
 
7.2.1.2    EGFR-Activating Mutations and Mechanisms of Resistance to EGFR- TKIs on  
Biopsied Tumor Specimens  
 
7.2.1.3   St andar d-of-C are Baseline Bi opsy  
Biopsy of a patient’s tumor upon pr ogression w ith erlotinib to examine EGFR-r esistance 
mechan isms such as EGFR T790M and rule out small cell h istologic transformation is 
considered standa rd- of- care. The biopsied tissue performed at baseline w ill be sent to 
Foundation Medicine (for patients at UC Davis) or equivalent CLIA -certified assay  for 
confirmation of EGFR-muta tion status and determi nation of EGFR- T790 M resistance 
muta tion, following us ual clinical pr ocedu res. If tissue  permits, ot her mechan isms of r esistance 
will be exami ned, prioritizing  MET ampli fication , HER 2 amp lification, PIK3C A specific and 
pathway muta tions , and MEK pathway mutations . (Biopsy must be performed within 60 days 
of consent). 
 
 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 61 of 133 
 7.2.2    Repeat Biopsies for EGFR- mutation Status and Immune Correlates  
In all patients following consent , two bi opsies w ill be a ttempted on st udy: one prior to 
initiation of st udy treatm ent and one after cycle #2 of treatm ent before in itiation of cycle 3. 
This will be approximately w eek 5-6 on st udy (see study calenda r). Patient c onsent for 
biopsies w ill be a st udy requirement. 
 
Biopsies w ill be performed by a qualified prof essional and will be ta ilored to the availab le 
disease targets. Potential bi opsies could include image-gui ded core biopsy , or limited surgical 
or pulmonary interventional biopsy. Im age-guided tumor bi opsies w ill be obtai ned with the 
help of t he Inter ventiona l Radiology or R adiology team by a percutaneou s approach or by the 
assistance of our surgical or pulm onary colleagues . Alternative bi opsy techn iques (e.g. 
transbronchial, skin punc h biopsy ) will be considered if i ndicated a fter di scussion w ith the 
principal investigat
or. W hen a core biopsy is performed, it is prefe rred that a core biopsy 
system be used to obtain at least 3 core  biopsies not less than 22 gauge in diameter and 1 cm 
in length (6 core biopsies is ideal) . 
 If a s ite is d
 eemed appropriate for biopsy with minimal risk to the participant by agreement 
between the investigators and biopsy t eam, a biopsy w ill be a ttempt ed.  The  use  of  imaging  
to  facilitat e biopsies w ill be decided by mem bers of the Inter ventiona l  Radiology or 
Radiology team and ma y include an u ltrasound  (US), a computer  tomography  (CT) s can, 
or a magne tic  resonanc e  imaging (MRI) scan. Should a CT scan be neede d for biopsy , the 
number of scans for each procedu re w ill be limited to the minimum number needed to s afely 
obtain a biop sy. Tumor bi opsies and local anest hesia will be administered only if t hey are 
considered to be of low risk to the participant, as determi ned by the investigators and/or the 
inter ventionist. 
 
Tis
sue Study Requirements on Treatment Listed in Order of Priority  
Test Institution or 
commercial entity  Baseline Biopsy 
(slides)  On Treatment Biopsy 
(Prior to Cycle 3)  
Standard -of-Care 
Genomic Testing in 
CLIA Certified Lab  Investigator Choice Per SOC Guidelines  X 
PD-L1 and QIF Yale Translational 
Immuno- Oncology  5 slides minimum, 10 
slides optimal  5 slides minimum,  
10 slides optimal 
Next Generation 
Sequencing with 
Mutational Load*  Broad Institute  10 slides minimum 20 
slides optimal.  
(RNA later processing 
if available)  10 slides minimum,  
20 slides optimal.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 62 of 133 
 RPPA for on target 
EGFR -inhibition 
(EGFR, p -EGFR, 
pERK, ERK, pAKT, 
AKT) , caspase 3 
cleavage  Theranostics  3-5 unstained slides 3-5 unstained slides 
* Companion blood draw in kit for germline DNA comparison 
 
7.2.2.1    Standard-of- Care Genomic Testing  
 
Tumor biopsy at baseline will be sent for standard molecular testing at a CLIA -certified lab for  
confirmation of  EGFR activating mutation  and to detect  the presence or  absence of an EGFR -
T790M mutation  as well as other resistance mechanisms to EGFR -TKI. When possible, the 
post- TKI specimen will be compared to the diagnostic block to identify treatment- induced 
differences in molecular profiles.  
 
7.2.2.2    PD -L1 and Evaluation of TILS 
The PD -L1 immunohistochemistry will be performed in 3 -5 µm-thick histology preparations 
obtained from conventional biopsy formalin- fixed, paraffin -embedded (FFPE) tissue samples.  
The tumor PD-L1 protein will be tested using the FDA-approved Dako 22C3 assay using 
chromogenic immunohistochemistry in the Yale Path ology Labs or UC Davis under CLIA 
laboratory conditions. The scoring procedure will include the determination of the percentage of positive cells in the tumor by a surgical pathologist using bright field microscopy. The score will be semi -quantitative and determined based on the percentage of positive cells. 
 The level of major TIL subtypes, TIL activation/proliferation and expression of major immune inhibitory receptors will be evaluated using multiplexed quantitative immunofluorescence ( QIF) 
performed in 3-5 µm-thick histology preparations obtained from formalin- fixed, paraffin -
embedded (FFPE) tissue samples , as previously reported (Schalper KA, Brown J, Carvajal-
Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, et al. Objective measurement and clinical significance of TILs in non -small cell lung cancer. J Natl Cancer Inst. 2015;107.) . We will 
perform three multiplexed QIF panels containing the following markers: Panel #1: DAPI/CD4/CD8/CD20; Panel #2: DAPI/CD3/Granzyme -B/Ki -67; and Panel #3: 
DAPI/CD3/PD- 1/TIM -3/LAG -3.  The Yale group has already performed validation of the 
antibodies and combined these markers into multiplexed QIF panel s. Simultaneous 
measurements of the targets will be performed using multispectral imaging and the AQUA® 
method providing continuous fluorescence marker scores. Eventually , quantification of positive 
cells for each marker will also be performed using the Vectra multispectral imaging platform 
with the cell phenotyping tool of the InForm® software; and reported as cell density (number of cells/area unit). See section 7.2.4 for processing and shipping information for the PD-L1 and QIF 
samples.  
 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 63 of 133 
 7.2.2.3    Next -Generation Sequencing with Mutational Load and Reverse -phase protein 
arrays (RPPA)  
 
Next -Generation Sequencing (DNA and RNA - if sufficient  tissue available) of the Stand Up 2 
Cancer (SU2C)  Customized Gene Panel  which is the standard for the Lung Cancer dream team 
with a focus on resistance mechanisms to EGFR-TKI and quantifying mutational load will be 
performed at the Broad Institute. This will be performed at baseline biopsy unless tissue amount is inadequate where it will be perf ormed on the on- treatmen t biopsy. When requested , the Broad 
Institute Samples lab will ship sample collection kits to research site.  A companion blood collection tube will also be provided and should be collected at baseline for germline mutation testing.  
 
Kits are specific for Material Type collected  
i. Labels – FFPE or Frozen Tumors 
ii. Labels – Blood or Buffy Coat Samples 
iii. Matrix Kits – DNA or RNA analytes  
 
1. Researcher fill kit & provides Sample Kit Metadata spreadsheet (example provided).  
2. Kits are shipped back to the Broad Institute Samples lab p er instructions provided in the kits.  
(See Attached Documents). Specimens should be coded with a unique identifier (ie., 
Institution, Clinical Trial Number, patient number and biopsy number in sequence (ie. for patient 1, UCD250-001- 01 (baseline biopsy), UCD250 -001- 02 (on- treatment biopsy), 
UCD250 -001-03 (post progression biopsy). 
 Sample Processing & Data Generation will proceed.  (Turnaround Time is expected to be 5-6 weeks for Exome runs). RNA sequencing will be batched so timeline will be more variable.  
 
7.2.3    Immunology Correlates  
 
Immune correlates  will be performed  by Yale University Translational Immuno -Oncology or 
the Human  Immune Monitoring  Core (HIMC) at  UC Davis  as outlined below. 
 
PD-L1 expression will be assayed  using Merck’s proprietary 22C3 antibody  that is FDA 
approved as a companion diagnostic for pembrolizumab for quantifying PD -L1 expression for 
MK-3475 trials in NSCLC and melanoma including Garon, Edward B. Naiyer A. Rizvi. 
“Pembrolizumab for the Treatment  of Non–Small -Cell Lung Cancer. ” nejm.org.  The New 
England Journal of Medicine. April 19, 2015. 
 
7.2.3.1    Biopsied tumor for PD -L1 Quantification  
 
PD-L1 expression  by immunohistochemistry at baseline and in repeat  biopsy specimens  to 
assess for changes  in PD-L1 expression  in response to treatment  will be conducted  by UC 
Davis or Yale Translational Immuno -Oncology using the FDA approved DAKO 22C3 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 64 of 133 
 antibody and  by quantitative IHC. 
 
7.2.3.2    Biopsied tumor for Tumor Infiltrating Lymphocytes and Subsets and RT -PCR  for 
Immune Markers  
 
In baseline and on treatment  biopsies, the HIMC  at UC Davis or Yale University Immunology 
Core  will quantify changes  in tumor infiltrating  lymphocytes and immune  subsets using IHC for 
T-cell subsets that include CD4, CD8, and Foxp3. Real time-PCR for immune markers  (if tissue  
size permits)  including CD3, PD-1, GranzB, Perforin,  IL-2, IFNg, Tim3, LAG3,  CTLA -4, Foxp3 
will be performed  if adequate tissue  is available.  
 
7.2.4    EGFR & Immunology Bi opsy Process ing   
 
Tumor  tissue  obtai ned  at  each  bi opsy  time  point  will  be  collecte d  by  a representative 
of the st udy team. At the first bi opsy , one o f the cores w ill be subm itted d irectly to Pathology 
for  clinical  interpreta tion  and  report  as  well  as  standa rd  o f  care  molecular  studies.  The 
remaining cores w ill be delivered to UC D avis Research Pathology, Pavilion R oom 2P524 ( or 
corresponding local research lab at other trial sites ) and divi ded into 2 components.  
 At l
east two core biopsies not less than 22 gauge in diameter and 1cm in length or tissue the 
equivalent of core biopsies sufficient to generate at least 20 cut slides should be paraffin 
embedde d and stored in research pathology until ready for processing and shipping . Ideally, 6 
cores per biopsy timepoint should be obtained. At the first timepoint 2 cores should be used for histologic confirmation and standard molecular testing.  2 cores should be paraffin embedded for IHC of PD -L1 and other markers of the tumor immune microenvironment . At UC Davi s, this 
FFPE specimen may also be stored in  the l aboratory o f Dr. Philip M ack or the UC Davis 
HIMC for stor age until sent for further t esting. 
 If available, two  additional cores  should be i mmed iately stored in 2ml of RNA later 
solution (L ife Techno logies) (the tissue porti on should be pr ocessed into pi eces, each l ess 
than 0.5cm
3) for comprehens ive DNA/RNA sequencing at the Broad Institute . The Samples in 
RNAlater solution shou ld be kept refrigerated until processed at  HIMC .  This should b e 
delivered to the Human I mmune M onito ring Core w ith the contact information listed below. If 
not enough cores are obtained DNA/RNA sequencing can be sent of the initial FFPE tissue  
 Specimens  in RNA Later should be shipped on cool packs  (Monday – Thursday only) to: 
 
Human I mm
une Monito ring Core (M averakis Laboratory) 
Depart ment of Dermatol ogy 
UC D avis School of M edicine 
IRC Bl dg., R oom 1630 
2921 St ockton Bl vd.  
Sacram ento CA 95817 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 65 of 133 
 LAB: 916-734- 2156 
 
Tissue from the   secon d  biopsy  timepoint will  be divi ded  into  th e  2 research  component s  
with  th e  procedu res  outli ned above .  Com ponent  1:  at least 2  cores  or enough tissue for 20 
cut slides as specified for initial biopsy  for  FFPE  for  PD-L1 and additional IHC quantifica tion  
by  UC Davis or Yale   and  2: remaining cores in RNA later solution t hen FFPE for 
DNA/RNA sequencing . (If no cores were available for processing with RNA later in the 
initial biopsy, the repeat biopsy should all go through FFPE and not through an RNA later step).     A r esearch H&E slide w ill also be generated and reviewed by a r esearch 
pathologist to conf irm pr esence of tumor.  
 
If there is limited tissue for the baseli ne bi opsy priority should be gi ven to pathologic 
assessm ent and mol ecular  testing  at Res pons e  Genetic s  per standard of care an d then  PD-
L1  t esting  by  the  central  vendor.  For the repeat  biopsy priority should be gi ven for PD-L1 
and additional IHC t esting by the central vendor and UC Davis HIMC . 
 RPP
A will be performed at Theranostics  using their established procedures for FFPE samples 
under their CAP-accredited CLIA laboratory.  Our previous experience with this resource is that, for phosphorylation states of intracellular signaling molecules, the assay is highly quantitative and corr elates with Western blotting analysis conducted at UC Davis.  The following analytes 
will be performed, listed in order of priority (although measured simultaneously): pEGFR, totalEGFR, pERK, totalERK, pAKT, totalAKT , caspase 3 cleavage.  
 
7.2.4.1 Immunohistochemistry and Quantitative Immunofluorescence  
 
Immunohistochemistry and Quantitative Immunofluorescence: Staining for PD -L1, relevant 
immunoproteins and tumor infiltrating immune cells will be performed by the SU2C Immune Core at Yale University  as outlined below.
 Tissue samples will be collected from participants 
who have been properly consented and who have agreed to participate in the research study. Tumor tissues are optimally  suitable for IHC/QIF  studies if fixed in 10% neutral buffered 
formalin (NBF) for 16 -24 hours  and processed into paraffin blocks using clinical -grade 
pathology laboratory conditions.  
1.  Select the tumor block and obtain one Hematoxylin & Eosin (H&E) stained slide for review b y site pathologist to confirm diagnosis and ensure presence of tumor cells.  For in 
situ analyses, there is no lower limit in the amount of tumor cell content.   
 
a. Samples with few tumor cells (<100 -200 cells) may be insufficient for PD -L1 
immunostaining  but should still be submitted for the QIF studies of TILs and other 
stromal markers . 
 
3. If pathologist review is not possible or available at the site, the H&E slides or a digital version may be sent directly to Yale Pathology for initial assessment.  
 
3. Obtain 5 additional serial 4 -5µm thick sections from the reviewed paraffin block and 
place each section in a positively -charged glass histology slide.  Tissues should be cut and 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 66 of 133 
 processed using conventional , clinical -grade in-house histology protocols.  Paraffin dipping 
of slides after sectioning is not recommended.  
4. Collect 5 freshly cut (<5 days) unstained serial section slides from each case, label each 
preparation using the SU2C coding system and place them in a conventional plastic histology slidebox.  Make sure slides are in a firm position to avoid damage during transportation and cover with paper towel prior to packing to prevent movement within the box.  If possible, also include the sectioning order on the label for each slide.  
a.  Whenever feasi ble, blocks should be processed in batch es, and shipped together within 
a 5-day period after sectioning . 
 
5. Include H&E stained preparation together with the 5 unstained sections in the slidebox.  This slide will be digitalized and become available for re view within the SU2C group.  
Specimens should be coded with a unique identifier (ie. institution, trial number, patient number and biopsy  number in sequence (ie. for UC Davis patient 1, UCD250 -001-01 
(baseline biopsy), UCD250 -001-02 (on- treatment biopsy), UCD250 -001-03 (post 
progression biopsy).  6. Seal the slidebox using Parafilm and/or a plastic envelope and wrap with bubble wrap prior to shipping.  Include detailed sender information (with email) and ship using overnight service to:  
 
Attention to: Nikita Mani (nikita.mani@yale.edu).   Backup contact should Nikita be out is Ila Datar (ila.datar@yale.edu) Address: BML112/BML113    Department of Pathology     Yale School of Medicine  
    310 Cedar Street  
    New Haven, CT  06510 Phone 1:  203-737-4205 Phone 2:  203-785-3588 
 
A confirmation of sample reception will be sent via email to the sender within 72 hours.  
 7.  Slides will be stained for IHC and the QIF panels within 5 working days from reception in the lab or stored in appropriately until use and batched to accommodate projects in single experimental runs (whenever possible).  8. Results of the analyzed markers will be provided as continuous scores using fluorescence intensity scores and/or phenotype cell counts.  The turnaround time will depend on the amount of slides and project volume.   
 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 67 of 133 
 7.2.5    Immunology Peripheral Blood Processing 
  
7.2.5.1  Peripheral blood Analysis of Changes in Immune Cell Subsets, T -Cell  Repertoire, 
and Cytokines  
 
 
Flow  cytometry  for immune  cell subsets.  (primarily  T-cell subsets)  will be performed  in the 
Human Immune Monitoring Core (HIMC)  at UC Davis.  Expression levels  determined  by MFIs 
for markers  will be compared  at baseline and on treatment.  
 
These:  subsets will include: 
 
• T cell  subset panel:  CD4, CD8, CD3, CD25, CD127, Foxp3 (ICS) 
 
• T  cell  differentiation  panel:  CD4, CD8, CD3, CD45RA, CCR7 (extras: CD45RO, 
CD44) 
 
• T  cell  exhaustion  panel: CD4, CD8, CD3, PD-L1, PD-1, TIM3, (extras: LAG3, 2B4, 
CD160) 
 
• T cell activation  panel: CD4, CD8,  CD3,  HLA -DR, Fas, GranzB  (ICS),  CD28 (extras:  
ICOS, CD40L,  FasL)  
 
Luminex Assay  for measurement  of cytokines (25 plea)  in plasma  and supernatant after  
activation  with CD3+  CD28 or PMA+Ionomycine will also be performed  in the HIMC  at UC 
Davis. ( http://tools.lifetechnologies.com/content/sfs/manuals/LHC0009_Protocol.pdf).  
 
7.2.5.2   Peripheral Blood Collection  for Changes in Immune  Subsets  
 
From each patient, at the rel evan t time points i ndicated in the st udy calendar, bl ood w ill be 
withdraw n directly into two 10 mL l avende r-toppe d (EDTA coated) tubes. Samples w ill be 
stored and assay s run at the Human I mmune M onito ring Core (D irector: Em anua l Maverakis 
laboratory at UC D avis). 
 
Contact
 informa tion listed below: 
 
Human Immune Monitoring Core (Maverakis Laboratory)  
UC Davis School of Medicine 
IRC Bldg., Room 1630 2921 Stockton Blvd. Sacramento CA 95817 LAB: 916-734-2156 
 
The HIMC l aboratory (D irector: Em anua l Maverakis, MD) is a r esearch l aboratory at UC 
Davis with both i mmunol ogy experti se and the appropriate equipment to carr y out the 
propose d studies. These studies will i nclude: Luminex Cyt okine A ssays to determine changes 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 68 of 133 
 in cytokine pr ofiles in res pons e to treatment and Flow Cytome try to detect changes in 
immune cell s ubsets. 
 
The tubes should be centri fuged as soon as possible at approximately 800 x g for 10 mi nutes. 
Plasma should be transferred to a 15 mL conical tube and centrifuged a secon d time a t 1000 – 
1500 x g for 10 mi nutes.  After the secon d centrifugation, a liquot pl asma in 500 ul a liquots 
into l abeled cr yovials. For peripheral bl ood m ononuc lear cell (P BMC ) preparation, r eplace the 
plasma rem oved with an equa l amount of PBS (Ca and Mg fr ee) in the o riginal lavende r-top 
tubes, and then slowly l ayer it on top o f the 15ml of Fi coll in a 50ml conical tube, followed 
by
 centrifugation at 800 x g for 20 mi nutes w ith the br eak off. The buffy coat, a whitish layer 
of cells between the PBS and Ficoll layers above the r ed bl ood cell l ayer, should be collected 
and transferred into a new 50ml t ube, washed once w ith 50ml of PBS, re- suspende d in an 
appropriate volume of freezing medium and then transferred  into l abeled cr yovials 
(107/ml/vial).  All cr yovials are t hen to be fr ozen as r apidly as possi ble, and stored in a - 70 
degree freezer until batch analysis is f easible by the HI MC. 
 Sites other than UC Davis may store per SOP until ready for shipment to UC Davis HIMC. Please contact Maverakis lab prior to shipment. 
 
 
7.3   Withdrawal/Discontinuation 
 
When  a subject  discontinues/withdraws prior to trial completion, all applicable activities 
scheduled  for the final trial visit should be performed  at the time of discontinuation.  Any 
adverse  events  which  are  present  at  the  time  of  discontinuation/withdrawal should  be 
followed in accordance with the safety  requirements outlined in Section  5.4 Attribution of 
adverse events and Section 7.5 - Assessing  and Recording Adverse Events.  Subjects  who a) 
attain  a CR or b) complete 24  months of treatment  with MK-3475 may discontinue treatment.  
After  discontinuing treatment  following assessment of CR, these subjects  should return  to the 
site for a Safety  Follow-up Visit and  then proceed  to the Follow- Up Period  of the study. 
 
7.4    Visit Requirements  
 
Visit requirements  are outlined  in Section 6.0 - Trial  Flow  Chart.   Specific procedure- related 
details  are provided above in Section  7.1 - Trial  Procedures.  
 
7.4.1   Screening  
 
Visit requirements  are outlined  in Section  6.0 - Trial  Flow  Chart.  Specific  procedure- related 
details  are provided above in Section  7.1 - Trial  Procedures.  
 
Approximately  30  days  prior  to  enrollment,  potential  subjects  will  be  evaluated  to 
determine  that they fulfill  the entry  requirements  as set forth  in Section  5.1.Written consent must  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 69 of 133 
 be  obtained prior  to  performing  any  protocol specific procedure. Results  of a test 
performed  prior to the subject  signing  consent as part of routine clinical management  are 
acceptable in lieu of a screening  test if performed  within  the specified  time frame.  Screening  
procedures are to be completed  within  30 days  prior to the first dose of trial  treatment  except  for 
the following: 
 
Laboratory  tests are to be performed  within  10 days prior to the first dose of trial treatment. For  
women  of reproductive potential,  a urine pregnancy  test will be performed  within  72 
hours prior to first dose of trial treatment.  If urine  pregnancy results  cannot  be confirmed  as 
negative,  a serum  pregnancy test, performed  by the local  study site laboratory, will be 
required.  
 
Tumor imaging  must be performed  within  30 days prior to the first dose of trial treatment.  
 
7.4.2   Treatment  Period  
 
Visit requirements  are outlined  in Section  6.0 - Trial  Flow  Chart.  Specific  procedure- related 
details  are provided above in Section  7.1 - Trial  Procedures.  
 
7.4. 3   Post-Treatment  Visits  
 
7.4.3.1  Sa
fety Follow- Up Visit  
 
The mandatory Safety  Follow -Up Visit should be conducted approximately  30 days after the 
last dose of trial treatment or before the initiation  of a new anti-cancer  treatment, whichever 
comes  first.  All AEs that occur  prior to the Safety  Follow- Up Visit should be recorded.  
Subjects with  an AE of Grade > 1 will be followed until the resolution of the AE  to Grade 0-1  
or  until the beginning of  a new anti-neoplastic  therapy,  return  to baseline,  or it is deemed  
that further recovery  is unlikely, whichever  occurs  first.  SAEs that  occur  within  30 days of the 
end of treatment  or before initiation of a new anti-cancer treatment  should also be followed and 
recorded.   
 
7.4.3.2   Follow- up Visits  
 
Every  effort  should be made to collect  information regarding disease  status  until the start of new 
anti-neoplastic therapy,  disease progression, death, end of the study.  Information regarding 
post-study anti- neoplastic  treatment  will  be collected  if new  treatment  is initiated.  
 
7.4.3.2.1  Survival Follow- up 
 
Once  a  subject  experiences  confirmed  disease  progression  or  starts  a  new  anti-cancer 
therapy,  the subject moves into the survival follow -up phase and should be contacted by 
telephone every  12 weeks  to assess for survival status  until death,  withdrawal  of consent, or the  
end of the study,  whichever occurs first. 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 70 of 133 
 7.5    Assessing  and Recording  Adverse Events  
 
An adverse event  is defined as any untoward medical  occurrence in  a patient  or clinical 
investigation  subject  administered  a pharmaceutical product and which  does not necessarily 
have to have a causal  relationship with  this treatment.  An adverse event  can therefore  be any 
unfavorable and unintended sign (including an abnormal laboratory finding, for example), 
symptom,  or disease temporally associated  with the use of a medicinal product or protocol- 
specified  procedure, whether or not considered  related  to the medicinal product or protocol- 
specified  procedure.   Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity)  of a preexisting  condition that is temporally associated  with the use 
of the Merck’s  and/or B IPI product, is also an adverse  event.  
 
Changes  resulting  from  normal growth  and development that do not vary significantly  in 
frequency  or  severity  from  expected  levels  are  not  to  be  considered  adverse  events. 
Examples of  this may include,  but are not limited  to, teething,  typical  crying  in infants and 
children  and onset of menses or menopause occurring at a physiologically  appropriate time.  
 Merck  product includes any pharmaceutical product,  biological product, device,  diagnostic 
agent  or protocol- specified  procedure, whether investigational (including placebo  or active 
comparator  medication)  or  marketed,  manufactured  by,  licensed  by,  provided  by  or 
distributed  by Merck  for human use. 
 Adver
se events  may occur during the course of the use of Merck  product in clinical trials  or  
prescribed in  clinical  practice, from overdose (whether  accidental  or intentional), from  abuse and 
from  withdrawal.  
 
Progression of the cancer under study is not considered an adverse event.  
 
All adverse events  that occur  after the consent form is signed but before treatment allocation must 
be reported by the investigator if they cause the subject to be excluded from the trial, or are the result  of a protocol- specified  intervention, including washout or  discontinuation of usual therapy,  
diet, placebo  treatment  or a procedure. 
 
From the time  of treatment allocation through 30 days following  cessation  of treatment , all 
adverse events must be reported by the investigator.  Such events will be recorded  at each 
examination on the Adverse Event case report forms/worksheets. The reporting timeframe  for 
adverse events  meeting  any serious criteria  is described  in section  7.5. The investigator will 
make every attempt to follow all subjects with non -serious adverse events for outcome.  
 Adverse events  will not be collected  for subjects  during the pre- screening period  (for 
determination  of  archival  tissue  status)  as  long  as  that  subject  has  not  undergone any 
protocol- specified  procedure or intervention.   If the subject  requires  a blood draw,  fresh 
tumor biopsy etc., the subject  is first required  to provide consent to the main  study and AEs will  
be captured  according  to guidelines for standard  AE reporting. 
 
All adverse events, serious and non-serious, will be collected, documented and reported to the 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 71 of 133 
 company supporter by the investigator on the appropriate CRFs / SAE repo rting forms (BI and 
Merck SAE report form).  
 
For each adverse event, the investigator will provide the onset date, end date, CTC AE grade, treatment required, outcome, seriousness, and action taken with the investigational drug. The investigator will determine the relationship of the investigational drug to all AEs as defined  
below.  Adverse events with onset within first administration of afatinib therapy and 28 days after last administration of afatinib will be considered as on treatment. All AEs, including those persisting after end of study treatm ent must be followed up until they have resolved or have been 
sufficient ly characteriz ed or the principal investigator decides to not further pursue them. Serious 
and non- serious adverse events occurring later than 28 days after last administration of trial 
drugs will only be reported in case they are considered drug- related or trial (procedure) related.  
 
7.5.1    Definition of an Overdose  for This  Protocol and Reporting  of Overdose to Merck  
 
For purposes of this trial, an overdose of pembrolizumab will be defined  as any dose of 1,000 
mg or greater (>5 times the indicated dose). No specific information  is available on the 
treatment  of  overdose of  MK-3475.  Appropriate supportive treatment should be provided if 
clinically  indicated. In the event  of overdose, the subject  should be observed closely  for signs  
of toxicity.   
 
If an adverse event(s)  is associated  with (“results  from”) the overdose of a Merck  product, the 
adverse event(s)  is reported  as a serious adverse event,  even  if no other seriousness criteria  
are met. 
 
If a dose of Merck’s  product meeting  the protocol definition  of overdose is taken  without any 
associated  clinical  symptoms  or abnormal laboratory results,  the overdose is reported  as a 
non-serious Event of Clinical Interest  (ECI),  using the terminology  “accidental  or intentional 
overdose without adverse  effect.”  
 
All reports  of overdose with and without an adverse event  must be reported  within  24 hours to 
the company supporter and within  2 working days  hours to Merck  Global Safety.  (Attn: 
Worldwide Product Safety;  FAX 215 993-1220) 
 
7.5.2    Rep
orting of Pregnancy and Lactation to Merck  and BIPI  
 
Although pregnancy and lactation  are not considered  adverse  events,  it is the responsibility of 
investigators or their designees  to report  any pregnancy or lactation  in a subject (spontaneously 
reported  to them)  that occurs during the trial.  
 
Pregnancy and lactations that occur after the consent form is signed but before treatment allocation must be reported by the investigator if they cause the subject to be excluded from the trial, or are the result of a protocol-specified intervention, including but not limited to washout or 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 72 of 133 
 discontinuation of usual therapy, diet, placebo treatment or a procedure.   
 Pregnancies and lactations that occur from the time of treatment allocation through 120 days 
following cessation  of treatment , or 30 days following the cessation of treatment if the subject  
initiates  new anticancer  therapy,  whichever is earlier  must be reported by the investigator. All 
reported pregnancies  must  be followed to the completion/termination  of the pregnancy.  
Pregnancy  outcomes of spontaneous abortion, missed  abortion,  benign  hydatidiform mole,  
blighted  ovum,  fetal death,  intrauterine death, miscarriage  and stillbirth  must be reported  as 
serious events (Important Medical  Events).   If the pregnancy continues to term,  the outcome 
(health  of infant) must also be reported.  Report pregnancy to BIPI only if it is associated with the 
SAE (including an outcome that meets SAE criteria).  
 
Such  events  must be reported  within  2 working days to Merck  Global Safety.  (Attn: Worldwide 
Product Safety;  FAX  215 993-1220) as well as Boehringer Ingelheim.  
 
7.5.3    Immediate Reporting  of Adverse Events  to Merck  and BIPI  
 
7.5.3.1   Serious  Adverse Events  
 
A serious adverse  event  is any adverse event  occurring  at any dose or during any use of 
Merck’s  product that: 
 
• Results  in death;  
• Is life  threatening; 
• Results  in persistent  or significant disability/incapacity;  
• Results  in or prolongs an existing  inpatient hospitalization;  
• Is a congenital  anomaly/birth defect;  
• Is another  important medical  event  
 
Note:  In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Merck in the same timeframe as 
SAEs to meet certain local requirements. Therefore, these events are cons idered serious by 
Merck for collection purposes. 
 
• Is a new cancer (that is not a condition of the study); 
• Is associated with an overdose. 
 
Refer to Table 12.7 for additional details regarding each of the above criteria. 
 
For the time period beginning when the consent form is signed until treatment allocation, any serious adverse event, or follow up to a serious adverse event, including death due to any cause other than progression of the cancer under study (Section 7.2.3.3 for additional details) that occur s to any subject must be reported within 2 working days to Merck Global Safety if it causes 
the subject to be excluded from the trial, or is the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual t herapy, diet, placebo treatment 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 73 of 133 
 or a procedure. 
 Progression of the cancer under  study is not considered an  adverse event  unless  it results  in 
hospitalization  or death. 
 
For the time period beginning at treatment allocation, through 90 days following cessation of 
treatment, or 30 days following cessation of treatment if the subject initiates  new anti -cancer 
therapy, whichever is earlier, any serious adverse event, or follow up to a serious adverse event, 
including death due to any cause other than progression of cancer under study (reference Section 7.5.4 for additional details), whether or not related to Merck product, must be reported within 2 working days to Merck Global Safety. 
 
Additionally, any serious adverse event,  considered by an investigator who is a qualified 
physician  to be related  to Merck  product that  is brought to  the attention  of the investigator at any  
time following consent through the end of specified safety follow -up period specified in  the 
paragraph  above, or at any time outside of the time period specified in the previous paragraph 
also must be reported immediately  to Merck  Global Safety . 
 
SAE report s and any other relevan t safet y informatio n are to be forwarde d to the Merck  
Globa l Safet y facsimile number : +1-215-993-1220  
 
Assessment of safety laboratory parameters  
A copy  of all 15 Day Reports and Annual Progress  Reports is submitted  as required  by FDA, 
European Union (EU),  Pharmaceutical and  Medical  Devices  agency (PMDA) or other local 
regulators.  Investigators will cross  reference this submission according  to local  regulations to the 
Merck  Investigational Compound Number (IND,  CSA,  etc.) at the time of submission. 
Additionally investigators will submit a copy  of these reports  to Merck  & Co., Inc. (Attn: 
Worldwide Product Safety;  FAX 215 993- 1220) at  the time of submission to FDA.  
 
All subjects  with serious adverse  events  must be followed up for outcome. 
 
The investigator shall report all SAEs and non serious AEs relevant to a reported SAE by fax from the time the informed consent is signed until the trial specified observational period (please 
specify) using  BI IIS SAE form to BI PI Unique Entry Point in accordance with the following 
timelines:  
 
• within five (5 ) calendar days upon receipt of initial  and follow-up SAEs containing at 
least one fatal or immediately life -threatening event; 
• within ten (10) calendar days upon receipt of any other initial and follow- up SAEs.  
 BI Unique Entry point: 
Boehringer Ingleh eim Pharmaceuticals, Inc  
900 Ridgebury Road Ridgefield, CT 06877 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 74 of 133 
 Fax: 1 -203-837-4329 
 
 
7.5.3.2   Events  of Clinical Interest  
 
Selected  non-serious and  serious adverse  events  are also  known as Events  of Clinical Interest 
(ECI)  and must be reported within 2 working days to Merck  Global Safety. (Attn:  Worldwide 
Product Safety;  FAX 215 993-1220) 
 
For the time period beginning when the consent form is signed until treatment allocation, any 
ECI, or follow up to an ECI, that occurs to any subject must be reported within 2 working days to Merck Global Safety if it causes the subject to be excluded from the trial, or is the result of a protocol-specified intervention including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure.  
 For the time period beginning at treatment allocation through 90 days following cessation of treatment, or 30 days following cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier, any ECI, or follow up to an ECI, whether or not related to Merck product, must be reported within 24 hours to Merck Global Safety.  Events of clinical interest  for this  trial include: 
 
1. an overdose of Merck  product, as defined in Section  7.2.1 - Definition of an Overdose for 
This Protocol and Reporting of Overdose to Merck , that is not associated with  clinical 
symptoms  or abnormal laboratory results.  
 
2. an elevated  AST  or ALT  lab value that is greater  than or equal  to 3X the upper limit of 
normal and an elevated total  bilirubin lab  value that is greater  than  or equal  to 2X the upper 
limit of normal and, at the same time,  an alkaline  phosphatase lab value that is less than 2X 
the upper limit of normal, as determined  by way of protocol- specified laboratory  testing  or 
unscheduled laboratory testing.* 
 
*Note:    These criteria  are based  upon available  regulatory guidance documents. The purpose of 
the criteria is  to specify  a threshold of abnormal hepatic tests  that may require an additional 
evaluation  for  an  underlying  etiology.     
 7.5.4    Protocol- Specific Exceptions to Serious Adverse Event Reporting  
 
Efficacy endpoints as outlined in this section will not be reported to Merck as described in 
Section 7.5.3 .- Immediate Reporting of Ad verse Events to Merck  and BIPI , unless there is 
evidence suggesting a causal relationship between the drug and the event. Any such event will be submitted to Merck Global Safety within 2 working days either by electronic or paper media  Specifically, the suspected/actual events covered in this exception include any event that is 
disease progression of the cancer under study.  
 The Sponsor will monitor unblinded aggregated efficacy endpoint events and safety data to 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 75 of 133 
 ensure the safety of the subjects in the trial. Any suspected endpoint which upon review is not 
progression of the cancer under study will be forwarded to Merck Global Safety as a SAE within 2 working days of determination that the event is not progression of the cancer under study  All the reports specified in this section will also be submitted to BIPI according to SAE reporting timeframe in section 7.5.3.1.   Hospitalization related to convenience (e.g. transportation issues etc.) will not be considered a SAE.
 
7.5.5 Evaluating Adverse Events  
 
An investigator  who  is a qualified  physician  will evaluate all  adverse events  according to  the 
NCI Common Terminology for Adverse Events (CTCAE),  version 4.0. Any adverse event 
which  changes CTCAE  grade over the course of a given  episode will have each change of grade 
recorded  on the adverse  event case report forms/worksheets. 
 
All adverse events  regardless  of CTCAE  grade  must  also be evaluated  for seriousness.  
 
7.5.6    Sponsor -Investigator Responsibility  for Reporting  Adverse  Events  
 
All Adverse Events will be reported  to regulatory authorities, IRB/IECs  and investigators  in 
accordance with all applicable laws and regulations.  
 
7.5.7    Safety  Reporting  Requirements  for IND Exempt Studies  
 For Investigator Sponsored IND Exempt Studies there are some reporting requirements for the 
FDA in accordance with the guidance set forth in 21 CFR 314.80. 
 
Post-marketing 15- Day ‘Alert Report’  
The Sponsor-Investigator is required to notify the FDA of each adverse drug experience that is 
both serious and unexpected and is assessed by the investigator to be possibly related to study 
treatment as soon as possible but in no case later than 15 calendar days of initial receipt of the information.  An unexpected adverse event is one that is not already described in the Investigator Brochure.  Such reports (2 copies) are to be submitted to the FDA at the following address: Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266. 
 All 15 -Day Alert Reports submitted to the FDA by the Sponsor-Investigator must also be faxed 
to Merck.  
 
 
8.0  STATIS TICAL  ANALYSIS PLAN  
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 76 of 133 
 8.1    Statistical  Analysis Plan  Summary  
 
This is a phase I /Ib study.  A minimum of 9 patients , if trial is terminated  early  due to 
unacceptable toxicity  and a maximum of 38 patients (18 patients in the dose de- escalation  cohort 
plus 10 in  each  of the two expansion cohorts) are anticipated  for this  trial. Analysis  of safety  and 
biomarkers will be limited  to patients  who receive active treatment.  
 
The dose de -escalation  phase will establish  a MTD  recommended  dose of MK -3475 in 
combination with lead  in MK-3475 followed by the  combination or concurrent afatinib/MK - 
3475. 
 
We plan to enter  3 patients  at Dose  Level  0. If 0/3 or 1/3 patients  experience a DLT  on level  
0, an additional 3 patients  will be accrued  to Level  0, where  2 or more DLTs  will terminate  
that study arm  and we will proceed  to dose level  -1. 
 
 
If 2 or more patients  have DLTs  at level 0,  patients  will be accrued  at level  -1. If 1/3 patients 
experience a DLT  on level  -1, an additional 3 patients  will be accrued  to Level  -1, where  2 or 
more  DLTs  will require  termination of  that study arm while  1 DLT  out of 6 will result  in 
proceeding  with dose level  -1 as the MTD  for the  dose expansion cohorts. 
 If 2 or
 more patients have DLTs at l evel -1, patients will be accrued at l evel -2. I f 1/3 patients 
experi ence a DLT on l evel -2, an additiona l 3 pa tients will be accrued to Level -2, w here 2 o r 
more D LTs will require termi nation o f the st udy wh ile 1 DLT out o f 6 will result in 
proceed ing w ith dose level -2 as the MTD for the dose expans ion cohort s. 
 
The phase I de-dose escalation  portion of the trial will be closed  when  the maximum  tolerated 
dose level  (MTD) or dose level  0 is reached  and six patients  have been  treated  at that dose level.  
 
Please see section  5.1.4.2 for further details.  
 
 
All patients  at a given  dose level  who have not experienced  DLT,  must be observed for a 
minimum of 21 days or until completion  of their first cycle  of therapy  before the dose level can  
be escalated.  Treatment  will continue in an individual patient  at the same dose level  if no DLT is 
observed and if benefit  is observed. There will be no dose escalation  allowed  for an individual  
patient.  
 
 
The recommended  phase II dose (RP2D) will be determined  by the overall assessment of  the 
MTD  and toxicities  observed in the de-dose escalation  and dose expansion portion of this study.  
 
The baseline assumption is that single  agent  afatinib  yields  a response rate of 10% in  this setting , 
and a response rate of 10% or less would not warrant further study. A response rate of 40% or 
greater would justify further study with a larger sample size. With  10 patients enrolled  in cohort A 
expansion arm, we will declare  this combination lacking  promise if fewer  than 3 patients  respond, 
and potentially worthy of further study if 3 or more patients respond. If the true response rate is 
10%, the chance of having 3 or more patients respond is 7%. If the true response rate is 40%, the 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 77 of 133 
 chance of having 3 or more patients respond is 83%. 
 If 3 or m ore patients  respond, the response rate, toxicity,  and progression -free survival will be 
evaluated  to decide  if larger  randomized studies are warranted  in this disease.  Descriptive 
summaries will be provided for each of these summary measures (numbers and proportion responding, number and proportion with specific type and grade of toxicities, Kaplan- Meier plot and 
life-table summary of progression- free survival.) As stated  earlier,  a “pick the winner” approach  
between  cohort A and  cohort B based  on toxicity : RR,  PFS and  changes  in PDL1  expression  will 
decide which  dosing scheme to take further.  It is assumed  that a true RR >40% would be 
sufficient  to recommend  such development, provided safety  and tolerability  are also acceptable.  
 
8.2 Correlative Statistical  Analysis Plan  
 
Plasma  EGFR -mutant DNA/RNA levels,  PDL1  expression  by IHC  at baseline and in repeat 
biopsy specimens  as well  as the other EGFR  and immune  biomarkers proposed will be evaluated  
in exploratory manner.  A focus is on comparison between  changes  in PD-L1 expression  
comparing  arm A (concurrent  afatinib/MK -3475) and arm B (lead  in MK-3475). Descriptive 
associations  with response rate and PFS will be performed.  All molecular  and other secondary 
evaluations will be considered  for exploratory  analyses  and in view  of the limited  sample -size 
and the exploratory nature of these analyses,  any p-values  reported  will not be adjusted  for 
multiple  comparisons, and any such  analyses  will be stated  carefully  as being  hypothesis-
generating.  
 
Standard  descriptive methods will be used to summarize  the baseline levels  and changes  in 
baseline levels  will allow  us to examine whether  observed patterns  are consistent with 
hypothesized patterns. If the  combination is not found to have sufficient  activity,  these patterns  
may help explain  the lack of activity.  If sufficient  activity  is found, then patients who experience 
an objective response will be compared  to those who did not in terms  of these correlates.  
 
  
9.0  LABELING,  PACKAGING,  STORAGE  AND RETURN OF CLINICAL SUPPLIES  
 
9.1 Investigational Product:  MK-3475 
 
The investigator shall take responsibility for and shall  take all steps  to maintain  appropriate 
records  and ensure appropriate supply, storage,  handling, distribution  and usage of 
investigational product in accordance with the protocol and any applicable laws and regulations. 
 
Clinical Supplies will be provided by Merck  at no cost to subjects  as summarized  below.  
 
Product Descriptions  
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 78 of 133 
 Product  Name  & Potency  Dosage  Form  
MK-3475 100 mg/  4mL  Solution  for In fusion 
 
 
 
Instructions on preparation are provided with Merck pharmacy manual. 
9.1.1 Packaging and Labeling  Information 
 
Clinical  supplies  will  be  affixed  with  a  clinical  label  in  accordance  with  regulatory 
requirements.  
 
9.1.2    Clinical Supplies  Disclosure  
 
This trial is open- label; therefore,  the subject,  the trial site personnel, the Sponsor- Investigator 
and/or designee are not blinded to treatment. Drug  identity  (name,  strength)  is included in the 
label  text; random code/disclosure envelopes or lists  are not provided. 
 
9.1.3    Storage and Handling  Requirements  
 
Clinical supplies must  be stored  in a secure,  limited -access location  under the storage conditions 
specified  on the label.  
 
Receipt  and dispensing of trial medication  must be recorded  by an authorized person at the trial 
site. 
 
Clinical supplies may not be used for any  purpose other than that stated  in the protocol. 
 
 
9.1.4    Returns  and Reconciliation 
 
The investigator is responsible for keeping accurate records of the clinical supplies received from 
Merck or designee, the amount dispensed to and returned by the subjects and the amount remaining at the conclusion of the trial.  
 
Upon com pletion or term ination of the study, all unused and/or partially used investigational 
product will be destroyed at the site per institutional policy. It is the Investigator’s responsibility 
to 
arrange for disposal of all empty containers, provided that procedures for proper disposal have 
been established according to applicable federal, state, local and institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 79 of 133 
 9.2    Investigational Product:  Afati nib 
 
9.2.1    Packaging and Labeling  Information 
 
Medication  numbers will be unique to each bottle and will be used for tracking  purposes 
only. 
 
Afatinib  will be supplied as film- coated  tablets.  Available  dosage strengths  will be 20, 30 and 
40 mg. Tablets  will be supplied in HDPE,  child -resistant,  tamper -evident bottles.  
 
Bottles/boxes  will be labelled  according  to local  regulations and will include the following as a  
minimum;  
 
• Study number [UCDCC#250 + 1200.237] 
• Product name (Afatinib)  
• Contents of the bottle  (number of tablets)  
• Tablet  strength  (mg)  
• Batch  number 
• Medication  number 
• Use-by date  
• Storage  information 
• Instructions for use  
• Sponsor-Investigator name and address  
• A statement  that the medication  is for clinical  study use only 
• A caution  statement  
 
A new bottle  of medication  will be dispensed on day 1 of each course,  regardless  of the 
number of tablets  remaining in  the bottle  from  the previous course.  The patient  will initially 
receive one bottle  of 20, 30 or 40 mg  tablets  and in the event  that dose reduction  is necessary the 
patient  will return  to the clinic  and new  medication  will be dispensed. 
 
9.2.2    Storage Conditions  
 
Afatinib  must be stored  in the original package in  order to protect  from  light.  Film- coated tablets  
are humidity- sensitive; therefore,  bottles  must be kept tightly  closed  to protect  from moisture.  
Tablets  must be stored  according to label  instructions. 
 
9.2.3    Drug Accountability  
 Afatinib,  which  will be provided by Boehringer  Ingelheim  Pharmaceuticals, Inc, at no cost to 
subject,  will be kept in a secure,  limited  access  storage  area under the storage  conditions. Where 
necessary,  a temperature log  must be maintained  to make certain  that the drug supplies are 
stored  at the correct  temperature.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 80 of 133 
  
The responsible person must maintain records  of the product’s delivery to  the study site, the 
inventory at the site, the use by each patient,  and the return  to the Boehringer  Ingelheim  (BIPI)  
or alternative  disposition of unused product(s). Returned or unused study drug will be destroyed 
at site per site’s SOP.  
 
These records  will include dates,  quantities,  batch/serial  numbers, expiry  (‘use  by’) dates, and  
the unique code numbers assigned  to the investigational product(s) and study patients. The 
responsible person will maintain  records  that document adequately  that the patients  were 
provided the doses specified  by the clinical  study protocol and  reconcile all  investigational 
product(s) received  from  Boehringer Ingelheim  (BIPI) . The  responsible person  must verify  that 
all unused or partially  used drug supplies have been  returned  by the  clinical study patient.  
 
10.0  ADMINISTRATIVE  AND REGULATORY DETAILS  
 
10.1  Confidentiality  
 
In order to maintain  patient  privacy, all study reports  and communications will identify  the 
patient by  initials  and the assigned  patient number.   Data capture records  and drug 
accountability records  will be stored  in secure cabinets  in the UCD Office of Clinical Research .  
Medical  records  of patients  will be maintained  in strict confidence according  to legal  
requirements.  The investigator will grant  monitor(s) and auditor(s) from  Merck/BI PI or its 
designees  and regulatory authority(ies) access  to the patient’s  original medical  records  for 
verification of data gathered  on the data capture records  and to audit the data collection process.  
The patient’s  confidentiality  will be maintained and will not be made publicly available to the 
extent  permitted  by the  applicable laws and regulations. 
 
 
 
10.2  Good Clinical Practice  
 
The study will be conducted  in accordance with  the International Conference on Harmoniz ation  
(ICH)  for Good Clinical Practice (GCP)  and the appropriate regulatory requirement(s).  The 
investigator  will be thoroughly familiar  with the appropriate use of the drug as described  in the 
protocol and  Investigator’s Brochure.  Essential  clinical  documents will be maintained to  
demonstrate the validity  of the study and the integrity  of the data collected.  Master  files  should 
be established  at the beginning of the study, maintained  for the duration of the  study and retained  
according  to the appropriate regulations. 
 
10.3  Patient  Information and Informed  Consent  
 After  the study has been  fully explained,  written  informed  consent will be obtained from 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 81 of 133 
 either  the patient  or his guardian or legal  representative prior to study participation.   The 
method of obtaining and documenting the informed  consent and the contents  of the consent will 
comply with  ICH-GCP  and all applicable regulatory requirement(s).  In accordance  with UCD 
OCR  policy an original signed  and dated  participant Informed  Consent document will reside  in a 
secured  location  within  the UCD OCR .  Copies of the signed  and dated  Informed Consent 
document will be provided to the study participant and  UCD Health  System Information  
Management for  inclusion  in the participant’s UCD  Health  System  Medical Record  or per  
participating  site’s  policies.  
 
10.4  Records  and Retention  
 
The investigator will maintain  all study records  according to  ICH-GCP  and applicable 
regulatory requirement(s).  
 
10.5  Data and Safety Monitoring  
 
In addition to the requirements  for adverse  event  reporting as outlined in Section  7.5, this 
protocol is also subject  to the UC Davis  Cancer  Center’s  (UCDCC)  Data and Safety  Monitoring 
Plan.  The UCDCC  is committed to  pursuing high-quality patient -oriented clinical  research  and 
has established  mechanisms to  ensure both scientific  rigor  and patient safety  in the conduct of 
clinical  research  studies. The UCDCC  relies  on a multi- tiered committee  system  that reviews  
and monitors all cancer  clinical  trials  and ensures the safety of  its participants,  in compliance 
with institutional and federal  requirements  on adverse event (AE)  reporting, verification  of data 
accuracy,  and adherence to  protocol eligibility requirements,  treatment guidelines, and related  
matters.  The Scientific  Review  Committee (SRC)  assumes  overall  oversight of cancer  
studies, with assistance and input from  two independent, but interacting,  committees: the 
Quality  Assurance  Committee  and the Data Safety  Monitoring Committee. A  multi- level  review  
system  strengthens  the ability  of the UCDCC  to fulfill its mission  in conducting high quality 
clinical  cancer  research.  
 
As per University of California Davis  Cancer  Center  (UCDCC)  Office of Clinical Research 
(OCR )  SOP  AM  506:  Protocol  Specific  Meetings,  the  principal  investigator  (PI)  and 
clinical  research  coordinator (CRC) meet  at least monthly for ongoing study  information,  to 
discuss patient  data and adverse events  and to determine  if dose escalation  is warranted, 
when  applicable.  Because this  is a phase I study,  a meeting  and/or conference call  will take 
place  when  the  last  subject  on  each  cohort  completes  DLT  (dose- limiting  toxicity) 
assessment.  The meeting  and/or call will update the attendees  of the current  status  of the 
study and will include investigators  from  all participating centers,  and, if necessary, 
representatives  from  the drug provider or financial  supporter.   All serious  adverse events 
experienced  by study subjects  will be discussed  and appropriate action  taken.  If serious 
adverse events  occur  between  these meetings  and/or calls,  all investigators will be informed by 
email.  
 
According  to the UCDCC  Data and Safety  Monitoring Plan (DSMP),  any new serious 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 82 of 133 
 adverse  events  related  to the drugs being  used on this trial are reviewed  monthly by the UCDCC  
Data and Safety  Monitoring Committee  (DSMC) and any applicable changes  to the study are 
recommended  to the PI, if  necessary.  
 
The UCDCC  Scientific  Review  Committee (SRC)  determines  if a UCDCC Data and Safety 
Monitoring Board  (DSMB)  is required.  If required, the DSMC  will appoint a DSMB.  The 
DSMB  is responsible for  reviewing  study accrual logs,  adverse event  information and dose 
escalation  meeting  minutes  (where applicable)  to ensure subject  safety  and compliance with 
protocol defined  guidelines.  
 
10.6  Compliance  with  Trial  Registration and Results  Posting  Requirements  
 
Under the terms  of the Food and Drug  Administration  Modernization Act (FDAMA)  and the 
Food and Drug  Administration  Amendments Act (FDAAA),  the Sponsor of the trial is  solely 
responsible for determining  whether the trial and its results  are subject  to the requirements for 
submission to the Clinical  Trials  Data Bank, http://www.clinicaltrials.gov.  Information posted 
will allow subjects  to identify  potentially  appropriate trials  for their disease  conditions and 
pursue participation by  calling  a central  contact  number for further information on appropriate 
trial locations and trial site contact  information. 
 10.7  Qua 
lity Assurance and Control 
 
Quality  assurance audits of select  patients  and source documents may be conducted by the UC  
Davis  Comprehensive Cancer  Center  Quality  Assurance  Committee  as outlined in the UC  
Davis  Cancer  Center  Data and Safety  Monitoring plan. 
 
 
Quality  control will be maintained  by the OCR  Quality  Assurance team  according to  OCR  
policy. 
 
  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 83 of 133 
 10.8  Registration Guidelines  
 
A.       Before  registration,  the site study coordinator should check  to make  sure that the 
corresponding Investigational Drug  Service or equivalent has investigational product(s) in 
stock. 
 
B.        Registrations  must  be made through the Office of Clinical Research  (OCR ) of the 
University of California,  Davis  Comprehensive Cancer  Center  between the hours of 9am and 
3pm (Pacific Time),  Monday through Friday  (except  holidays).  Documentation of current  
IRB approval of this protocol must be on file prior to registration  of patients. 
 C.        Pre-study laboratory tests,  scans,  and x-rays,  must be completed prior to registration, 
within  the time frame  specified  in the protocol.  The eligibility checklist must be completed. 
Patients  must sign an informed consent prior to registration.  
 
D.        Patients  may be registered  up to 72 hours prior to treatment  initiation.  The signed 
consent, completed  checklist and reports from  all pre-study laboratory  tests,  scans  and x-rays 
must be faxed  to UC Davis  OCR  in order to register  the patient. The UC Davis  Protocol 
Coordinator will review  these documents and fax a registration  confirmation within  3 hours. 
 
E.        If the patient is  to be registered the  same day as the proposed treatment  start date,  the UC  
Davis  Study Coordinator must be notified  by fax 24 hrs prior to proposed treatment  start date  
that the site has a patient  to register.  
 
F.        The Study Coordinator will verify  that the patient  is eligible,  that pre-study tests have 
been  completed,  and that the forms  are complete.  The Study Coordinator will then register the  
patient  and assign  a patient  accession  number.  The Study Coordinator will fax back  a 
registration  confirmation  including the patient  accession  number within  3 hours. 
 
G.        A patient  failing  to meet  all protocol requirements  may not be registered.  If you have any  
questions regarding  eligibility,  contact  the coordinating site PI or Study Coordinator. 
 NOTE:  Administration of  study medication  may  not be initiated  until the registration 
confirmation  has been  received.  
 
  
P r o d ucts :  M K- 3 4 7 5 / A f a ti ni b P r o t oc ol V ersi o n 3. 0  
 Ve r si on D ate : 0 9/ 1 0/ 1 8 
P a g e 8 4  of 1 3 3  
 1 0. 9   D at a M a n a ge me nt 
 
All  data  will   be c ollecte d   usi n g U C  Da vis  data  c ollecti o n  f or ms.  A n y  a n d  all   s o urce 
d oc u me ntati o n s h o ul d be mai ntai ne d.  
 
   S U B MI T  WI T HI N  2 4 H O U R S O F R E GI S T R A TI O N:  
Patie nt  Re gistrati o n  F or m  
 
   S U B MI T  WI T HI N  1 4 D A Y S O F R E GI S T R A TI O N:  I n --- H o us e P re --- Stu d y E val u ati o n  F or m  
(I H --- 1 0 2) 
 
   S U B MI T  WI T HI N  7 D A Y S O F S C R E E NI N G  F AI L U R E:  Patie nt  Scr ee n  Fail ure  F or m  
 
   S U B MI T  WI T H  1 4 D A Y S O F C Y C L E  C O M P L E TI O N:  A d vers e E ve nt/ Dr u g Relati o ns hi p  
F or m  
 
   S U B MI T  WI T HI N  1 4 D A Y S O F E N D  O F E A C H  T R E A T M E N T  C Y C L E:  I n --- H o us e 
Treat me nt  C ycle  F or m  (I H --- 2 0 1) 
 
   S U B MI T  WI T HI N  1 4 D A Y S O F E A C H  R E S P O N S E  A S S E S S M E N T:  T u m or Meas ure m e nt  
L o g  
 
   S U B MI T  WI T HI N  1 4 D A Y S O F O F F T R E A T M E N T:  
Off Tr eat me nt/I n  F oll o w- u p/ Off St u d y/ E x pirati o n  F or m  (I H --- 3 0 1) 
 
   S U B MI T  WI T HI N  1 4 D A Y S O F K N O W L E D G E  O F D E A T H  I F P A TI E N T  I S  S TI L L  O N 
S T U D Y  O R  3 0 – D A Y S I F O F F S T U D Y:   
Off Tr eat me nt/I n  F oll o w- u p/ Off St u d y/ E x pirati o n  F or m  (I H --- 3 0 1) 
 
   S U B MI T  WI T HI N  2 D A Y S O F K N O W L E D G E  O F P R O T O C O L  D E VI A TI O N:  N otice  of 
Pr ot oc ol De viati o n  
 
   S U B MI T  WI T HI N  1 4 D A Y S O F E A C H  R E Q UI R E D  F O L L OW--- U P E N C O U N T E R:  
Foll o w --- U p F or m  (I H --- 3 0 2) 
 
   A L L  S E RI O U S  A D V E R S E  E V E N T S  M U S T  B E  R E P O R T E D  A S O U T LI N E D  I N  T H E  
P R O T O C O L.  
 
 
 
  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 85 of 133 
 11.0  LIST OF REFERENCES  
 
1. Disis  ML.  Immune regulation of cancer.  J Clin  Oncol  2010; 28(29):4531-8. 
 
2. Dong  H,  Strome SE, Salomao  DR, Tamura H,  Hirano  F,  Flies  DB, et al. Tumor- 
associated  B7-H1 promotes T-cell apoptosis: a potential mechanism  of immune  evasion. 
Nat Med 2002;8(8):793-800. 
 
 
3. Sharpe AH, Freeman  GJ. The B7-CD28  superfamily.  Nature 2002;2:116-26. 
 
4. Brown  JA, Dorfman  DM,  Ma F-R, Sullivan  EL, Munoz O,  Wood CR, et  al. Blockade of 
programmed death-1 ligands on dendritic cells enhances  T cell activation  and cytokine 
production. J Immunol 2003;170:1257-66. 
 
5. Francisco  LM, Sage  PT, Sharpe AH. The PD-1 pathway in tolerance  and autoimmunity.  
Immunol Rev 2010;236:219-42. 
 6. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute  ML, Cheville  JC, et al. PD-1 
expressed  by tumor- infiltrating  immune  cells and is associated  with poor outcome for 
patients  with renal  cell carcinoma.  Clin Caner  Res 2007;13(6):1757-61. 
 
7. Talmadge JE, Donkor M, Scholar  E. Inflammatory  cell infiltration  of tumors: Jekyll  or 
Hyde.  Cancer  Metastasis  Rev 2007;26:373-400. 
 
8. Usubütün A,  Ayhan  A, Uygur  MC, zen H, klu C, acan S. Prognostic factors  in renal cell 
carcinoma.  J Exp  Clin  Cancer  Res 1998;17(1):77-81. 
 
9. Al-Shibli KI, Donnem T, Al-Saad  S, Persson  M, Bremnes  RM,  Busund L- T. Prognostic 
effect  of epithelial and stromal symphocyte  infiltration  in non- small cell lung cancer. 
Clin Cancer  Res 2008;14(16):5220-7. 
 
10.  Deschoolmeester  V, Baay  M, Van Marck  E, Weyler  J, Vermeulen  p, Lardon F, et al. 
Tumor infiltrating  lymphocytes:  an intriguing  player  in the survival of colorectal  cancer  
patients.  BMC  Immunol 2010;11:19. 
 
11.  Diez  M,  Pollán  M,  Enriquez  JM,  Dominguez  P,  Santana  A,  Tobaruela  E,  et  al. 
Histopathologic  prognostic  score  in  colorectal  adenocarcinomas.  Anticancer  Res 
1998;18:689-94. 
 
12.  Galon  J, Costes  A, Sanchez -Cabo  F, Kirilovsky  A, Mlecnik  B, Lagorce -Pagès  C, et al. 
Type,  density,  and location  of immune  cells within  human colorectal  tumors predict  
clinical  outcome. Science  2006;313:1960-4. 
 
13. Hiraoka N. Tumor- infiltrating  lymphocytes and hepatocellular carcinoma:  molecular 
biology. Int J Clin  Oncol 2010;15:544-51. 
 
14. Nobili C, Degrate L, Caprotti R,  Franciosi  C, Leone  BE, Trezzi  R, et al. Prolonged survival 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 86 of 133 
 of a patient  affected  by pancreatic adenocarcinoma with massive  lymphocyte and  
dendritic  cell  infiltration  after  interleukin -2 immunotherapy. Report  of  a  case. Tumori  
2008;94:426-30. 
 
15.  Hodi FS,  Dranoff G.  The biologic importance of tumor- infiltrating  lymphocytes. J Cutan  
Pathol 2010;37(Suppl 1):48-53. 
 
 
16.  Kloor   M.   Lymphocyte  infiltration   and   prognosis   in   colorectal   cancer.   Lancet  
2009;10(840):841. 
 
17. Hillen F, Baeten  CIM,  van de Winkel A, Creytens  D, van der Schaft  DWJ, 
Winnepenninckx V, et al. Leukocyte infiltration  and tumor cell plasticity are  parameters of  
aggressiveness  in  primary  cutaneous  melanoma.  Cancer  Immunol Immunother  
2008;57:97-106. 
 
18.  Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, et al. Prognostic implications  of 
type and  density  of  tumour- infiltrating  lymphocytes in  gastric  cancer.  Br J Cancer  
2008;99(10):1704-11. 
 
19.  Leffers  N, Gooden MJM,  de Jong RA, Hoogeboom B- N, ten Hoor KA, Hollema  H, et al.   
Prognostic   significance  of   tumor- infiltrating  T-lymphocytes  in   primary   and 
metastatic  lesions  of  advanced  stage  ovarian  cancer.  Cancer  Immunol  Immunother 
2009;58:449-59. 
 
20.  Nishimura  H,  Honjo  T,  Minato  N.  Facilitation  of  β  selection  and  modification  of 
positive selection  in the thymus  of PD -1-deficient  mice.  J Exp  Med  2000;191(5):891-7. 
 
21.  Liotta  F,  Gacci  M,  Frosali  F,  Querci  V,  Vittori G,  Lapini A,  et  al.  Frequency  of 
regulatory T cells in peripheral  blood and in tumour- infiltrating  lymphocytes correlates 
with poor prognosis in  renal  cell carcinoma.  BJU Intern  2010;107:1500-6. 
 22.  Ropponen KM, Eskelinen  MJ, Lipponen PK, Alhava E, Kosma  V-M. Prognostic value of  
tumour- infiltrating  lynmphocytes (TILs) in colorectal  cancer.  J Pathol 1997;182:318-24. 
 
23.  Dudley ME, Wunderlich JR, Yang  JC, Sherry  RM, Topalian  SL, Restifo  NP, et al. 
Adoptive cell transfer therapy  following  non-myeloablative but lymphodepleting 
chemotherapy for  the treatment of patients  with refractory  metastatic  melanoma.  J Clin 
Oncol 2005;23(10):2346-57. 
 
24.  Hunder NN, Wallen  H, Cao J, Hendricks DW,  Reilly  JZ, Rodmyre R, et al. Treatment  of 
metastatic  melanoma  with autologous CD4+  T cells against  NY-ESO -1. N Engl  J Med 
2008;358(25):2698-703. 
 
25.  Ölcher  M, Braun  M, Friedrichs  N, Rudlowski C, Bercht  E, Fimmers  R, et al. Foxp3+ 
cell infiltration  and granzyme B+/Foxp3+ cell  ratio are associated  with outcome in 
neoadjuvant chemotherapy- treated  ovarian  carcinoma.  Cancer  Immunol Immunother 
2010;59:909-19. 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 87 of 133 
  
26.  Okazaki  T,  Maeda  A,  Nishimura  H,  Kurosaki  T,  Honjo  T.  PD-1  immunoreceptor 
inhibits  B cell receptor -mediated signaling  by recruiting  src homology 2-domain- 
containing tyrosine phosphatase 2 to phosphotyrosine. PNAS 2001;98(24):13866-71 
 
27.  Greenwald  RJ, Freeman  GJ, Sharpe AH. The B7 family  revisted.  Annu Rev Immunol 
2005;23:515-48. 
 
28. Homsi  J, Kashani -Sabet M,  Messina  JL, Daud  A. Cutaneous melanoma:  prognostic 
factors.  Cancer  Control 2005;12(4):223-9. 
 
29.  Iannone R, Gergich  K, Cong C, Kang  P, Daud  A, Dronca R, et al.  Efficacy  and safety of 
MK-3475 in patients with advanced melanoma. Pigment  Cell  Melanoma Res  
2012;25:836-903. 
 
30.  Topalian  SL, Hodi FS, Brahmer  JR, Gettinger  SN, Smith  DC, McDermott DF, et al. 
Safety,  activity,  and immune  correlates  of Anti-PD-1 antibody in cancer.  N Engl  J Med 
2012:doi: 10.1056/NEJMoa1200690. 
 
31.  Lyford -Pike S, Peng  S, Young GD, et al.   Evidence for a role of the PD-1:PD- L1 
pathway in immune resistance of  HPV- associated  head  and neck  squamous cell carcinoma.  
Cancer  Res 2013;73(2): Published online January  3. 
 
32.  Eisenhauer  EA, Therasse  P, Bogaerts  J, Schwartz  LH, Sargent  R, Ford  R, et al.  New 
response evaluation  criteria  in solid  tumors: Revised  RECIST  guideline (version 1.1). 
Eur J Cancer  2009;45(2):228-47. 
 33.  Wolchok JD, Hoos A, O’Day  S, Weber  JS, Hamid  O, Lebbe  C, et al.  Guidelines for the 
evaluation  of immune  therapy  activity  in solid  tumors: immune -related  response criteria. 
Clin Cancer  Res 2009;15(23):7412-20. 
 
34.  Blum  JL, Jones SE, Buzdar AU, LoRusso PM, et al. Multicenter  Phase II Study of 
Capecitabine in Paclitaxel -Refractory  Metastatic  Breast  Cancer.  J Clin Oncol 17: 485-
493, 1999 
 
35.  Martin  M, Ruiz  A, Munoz M, Balil A, Garcia- Mata J, Calvo  L, et al. Gemcitabine  plus 
vinorelbine monotherapy in patients  with metastatic  breast  cancer  previously treated 
with anthracyclines  and taxanes:  final results  of the phase III Spanish Breast  Cancer 
Research  Group (GEICAM) trial.  Lancet  Oncol. 2007;8(3):219. 
 36. Sledge  GW,  Neuberg  D, Bernardo P, Ingle  JN, Martino  S, et al.  Phase  III Trial  of 
Doxorubicin, Paclitaxel,  and the Combination of Doxorubicin and  Paclitaxel  as Front- 
Line Chemotherapy for  Metastatic  Breast  Cancer:  An Intergroup Trial  (E1193).   J Clin 
Oncol. 2003;21(4):588. 
 
37.  Stewart  JSW,  Ezra E.W.  Cohen EEW,  Licitra  L, Van Herpen  CML,  et al. Phase III 
Study of Gefitinib  Compared  With  Intravenous Methotrexate for Recurrent  Squamous 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 88 of 133 
 Cell Carcinoma of the  Head  and Neck.  J Clin  Oncol. 2009;27(11):1864. 
 
38. Vermorken JB, Trigo  J, Hitt R, Koralewski  P, Diaz -Rubio E,  et al.   Open -Label, 
Uncontrolled, Multicenter  Phase II  Study  to  Evaluate the Efficacy  and Toxicity  of  
Cetuximab As  a Single  Agent in Patients  With  Recurrent and/or Metastatic Squamous Cell 
Carcinoma of  the Head  and Neck  Who Failed  to Respond to Platinum- Based Therapy. 
J Clin  Oncol. 2007;25(16):2171.  
 
39.  Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov  L, et al.  Phase III Trial  of 
Vinflunine Plus Best Supportive Care Compared  With  Best Supportive Care Alone 
After  a Platinum-Containing Regimen in Patients  With  Advanced  Transitional Cell 
Carcinoma of the  Urothelial  Tract.  J Clin  Oncol. 2009;27(27):4454 
 
40.  Sweeney  CJ, Roth  BJ, Kabbinavar FF, Vaughn  DJ, Arning M, et al.  Phase II Study of 
Pemetrexed  for Second -Line Treatment  of Transitional Cell Cancer  of the Urothelium.  J 
Clin Oncol. 2006;24(21):3451. 
 
41.  Clopper C and Pearson  ES. The use of confidence or fiducial  limits  illustrated  in the 
case of the binomial.  Biometrika  1934;26:404-413. 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 89 of 133 
  12.0  APPENDICES 
 
12.1  ECOG  Performance Status  
 
Grade  Descripti on 
0 Normal activity. Fully active, able to carry on all pre- disease  
performance  without restriction.  
 
1 Symptoms, but ambulatory. Restricted in  physically  strenuous 
activity,  but ambulatory and able to carry  out work  of a light or 
sedentary  nature (e.g.,  light housework, office  work). 
 
2 In bed <50%  of the time.  Ambulatory and capable of all self-care,  
but unable to carry  out any work  activities.  Up and about more  than 
50% of waking  hours. 
3 In bed >50% of the time.  Capable of only limited self -care, confined 
to bed or chair  more  than 50% of waking hours. 
4 100% bedridden. Completely  disabled. Cannot carry  on any self- 
care.  Totally  confined to bed or chair.  
5 Dead.  
* As published in Am. J. Clin. Oncol.:  Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, 
T.E., McF adden,   E.T. ,  Carbone ,   P.P. :  Toxicit y   And  Respons e   Criteria   Of  The  Easter n  
Cooperativ e On cology  Group.  Am  J  Clin  Oncol  5:649-655,  1982 .  The  Easter n  Cooperati ve  
Oncology  Group, Robert Comis M.D., Group Chair. 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 90 of 133 
  
 
12.2  Common Terminology Criteria  for Adverse Events  V4.0 (CTCAE)  
 
The descriptions and grading scales  found in the revised  NCI Common Terminology Criteria for  
Adverse Events (CTCAE)  version 4.0 will be utilized for  adverse event  reporting. 
(http://ctep.cancer.gov/reporting/ctc.html )
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 91 of 133 
  
12.3  Response  Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria forEvaluating 
Response  in Solid  Tumors 
 
RECIST  version 1.1* will be used in this study  for assessment  of tumor  response. While 
either  CT or MRI  may be utilized,  as per RECIST  1.1, CT is the preferred  imaging  technique in 
this study.  
 
* As published in the European Journal of Cancer:  
 
E.A. Eisenhauer, P. Therasse,  J. Bogaerts,  L.H. Schwartz,  D. Sargent,  R. Ford, J. Dancey,  S. 
Arbuck, S. Gwyther,  M. Mooney, L.  Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, 
J. Verweij.  New  response evaluation  criteria  in solid  tumors: Revised  RECIST guideline  
(version  1.1). Eur J Cancer.  2009 Jan;45(2):228-47. 
 
 
  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 92 of 133 
 12.4  New  York  Heart  Association Classification  of Heart  Failure  
 
 
Class  Patie nt Symptom s 
Class  I (Mild)  No li mitation  of physical  activity.  Ordinary  physical activity  does 
not cause undue fatigue,  palpitation,  or dyspnea (shortness of breath) 
Class  II (Mild)  Slight  limitation  of physical  activity.  Comfortable  at rest, but ordinary  
physical  activity  results  in fatigue,  palpitation,  or dyspnea. 
Class  III 
(Moderate) Marked  limitation  of physical  activity.  Comfortable  at rest, but less 
than ordinary activity  causes  fatigue,  palpitation,  or dyspnea. 
Class  IV (Severe)  Unable  to carry  out any physical  activity  without  disco mfort. 
Symptoms of cardiac  insufficiency at rest. If any  physical  activity  is 
undertaken, disco mfort is increased.  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 93 of 133 
 12.5  List of Potent Inhibitors  and Inducers  of P- glycoprotein  (MDR1)  
 
Inhibitors  Inducers  
Amiodarone  
Azithromycin  
Captopril  
Carvedilol  Clarithromycin  
Conivaptan  Cyclosporine  Diltiazem  
Dronedarone  Erythromycin  Felodipine  
Itraconazole  
Ketoconazole  
Lopinavir  Nelfinavir  
Ritonavir  Quinidine  
Ranolazine  
Saquinavir  
Tacrolimus  
Ticagrelor  
Verapamil  Carbamazepine  
Phenytoin 
Rifampicin  
St John’s Wort  
Phenobarbital Salt  
Tipranavir  
Ritonavir 
 
 
The  information  on  potent  inhibitors  and  inducers  of  P-glycoprotein may  evolve,  it  is 
important for the  investigator to assess such status  on concomitant. 
 
 
 
 
  
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 94 of 133 
 12.6. Liquid Genomics Sample Requisition Form  
 
 
 

Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 95 of 133 
  
 

Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 96 of 133 
  
12.7  Laboratory Tests  
 
Hematology Chemistry Urinalysis Other 
Hematocrit Albumin Blood Serum β-human chorionic gonadotropin† 
Hemoglobin Alkaline phosphatase Glucose (β-hCG )† 
Platele t count Alanine aminotransferas e (ALT ) ProteinCr PT (INR) 
WBC (total and differe ntial) Aspartate aminotransferas e (AST ) Specific gravity aPTT 
Red Blood Cell Coun t Lactat e dehydrogenase (LDH ) Microscopi c exam (If abno rmal) Total thriiodothyronine (T3) 
Absolute Neutrophil Coun t Carbon Dioxide ‡ (CO 2 or 
biocar bonate ) results are noted Free tyroxine (T4) 
 Creatinine Urine or serum pregnancy test † Thyroid stimulating hormone (TSH ) 
 Uric Acid  PK 
 Calcium   
 Chloride  Blood for correlati ve studies 
 Glucose  Correlati ve Biopsies 
 Phosphorus   
 Potassium   
 Sodium   
 Magnesiu m   
 Total Bilirubin   
 Direct Bilirubin (If total bilirubin is 
elevated above the upper limit o f 
normal)   
 Total protein   
 Blood Urea Nitrogen   
† Perform on wom en of childbearing potential only. If urine pregnancy results cannot be confirmed as negative, a serum pregnancy test will be required. 
‡ If considered standard of care in your region. 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 97 of 133 
 12.8  Evaluating Adverse Events  
 
An investigator  who is a qualified  physician,  will evaluate all adverse  events  as to: 
 
V4.0 CTCA E 
Gradin g Grade 1 Mild; asymptomatic or mid symptoms; clinica l or diagnosti c observation s only; interventio n not indicated . 
 Grade 2 Moderate ; minimal, local or noninvasiv e interventio n indicated ; limiting age-appropriat e instru mental ADL . 
 Grade 3 Sever e  or  medically  significant  but  not  immediately   life-threatening ;  hospitalizatio n   or  prolongatio n   or  hospitalizatio n   indicated; 
disabling; limiting self-care ADL. 
 Grade 4 Life threatenin g consequences ;  urgen t interventio n  indicated. 
 Grade 5 Deat h related to AE 
Seriousness A serious advers e even t is any advers e even t occurr ing at any dose or during any use of Merck produc t that: 
†Resu lts in death ; or 
†Is life threaten ing; or place s the subject , in the view of the investigator , at immediat e risk of death from the even t as it occurre d (Note : This does not includ e an 
advers e even t that, had it occurre d in a more sever e form, might have cause d death.) ; or 
†Resu lts in a persistent or significant disability/incapac ity (substantia l disruptio n of one’s abilit y to conduc t normal life functions) ; or 
†Resu lts in or prolongs an existing inpat ient hosp italization  (hospitalizatio n  is define d as an inpatien t admission , regardles s of lengt h of stay, even if the 
hospitalizatio n  is a precautionar y  measur e for continue d observation . (Note : Hospitalizatio n  [including hospitalizatio n  for an electiv e procedure ] for a preexisting 
conditio n which has not worsene d does not constitut e a seriou s adverse event.) ; or 
†Is a congen ital anomaly/birth  defec t (in offsprin g of subjec t takin g the produc t regardles s of time to diagno sis);or 
Is a new cancer ; (that is not a conditio n of the study ) or 
(For Merck Only. BIPI does not list criteria for overdose) Is an overdos e (whethe r accidenta l or intentional) .  Any advers e even t associate d with an overdos e is 
considere d a seriou s advers e event . An overdos e that is not associate d with an advers e even t is considere d a non-serious even t of clinical interest and must be repor ted 
   Other importan t medica l event s that may not resul t in death , not be life threatening , or not requir e hospitalizatio n  may be considere d a seriou s advers e even t when, 
based upon appropriat e medica l judgment, the even t may jeopardiz e the subjec t and may requir e medica l or surgica l interventio n to preven t one of the outcom es listed 
previousl y (designate d abov e by a †). 
Durat ion Recor d the start and stop dates of the advers e event . If less than 1 day, indicat e the appropriat e lengt h of time and units  
Action taken Did the advers e even t cause the Merck produc t to be discontinued ? 
Relationsh ip to 
test drug  Did the Merck produc t cause the advers e even t? The determina tion of the likelihood that the Merck produc t cause d the advers e even t will be provided by an 
investigato r who is a qualifie d physician . The investigator’ s  signed/date d initial s on the sourc e document or w orkshee t that support s the causalit y noted on the AE form, 
ensure s that a m edicall y qualifie d assessm ent of causalit y was done . This initiale d docu ment must be retaine d for the require d regulator y time frame. The criteria below 
are intende d as referenc e guidelines to assist the investigato r in assessing the likelihoo d of a relationshi p between the test drug and the advers e even t based upon the 
availabl e infor mation.  
The following component s are to be used to assess the relationshi p between the Merck produc t and the AE ; the greater the correlation w ith the component s and 
their respectiv e elements (in number and/o r intensity) , the more likely the Merck produc t cause d the advers e even t (AE): 
Exposure Is there evidenc e that the subjec t was actuall y expose d to the Merck produc t such as: reliabl e history , acceptabl e complianc e assess ment (pill count , 
diary , etc.), expecte d pharmacologi c effect , or measure ment of drug/ metabolit e in bodil y speci men? 
Time Course Did the AE follow in a reasonab le tempora l sequenc e from admin istration  of the Merck produc t? 
Is the time of onset of the AE compatibl e with a drug-induce d effec t (applie s to trials with investigationa l  medicina l product) ? 
Likel y Cause Is the AE not reasonab ly explained by another etiology such as under lying disease , other drug(s) /vaccine(s) , or other host or environmental factor s 
Products :  MK- 3475/A fatinib Protocol Version 3.0 
 Version Date : 09/10/18 
Page 98 of 133 
  
 
Relationship to 
Merck product 
(continued)  The followin g component s  are to be used to asses s the relationshi p  betwee n the test drug and the AE: (continued) 
Decha llenge Was the Merck produc t discontinue d or dose/exposure/frequenc y reduced ? 
If yes, did the AE resolve or im prove ? 
If yes, this is a positiv e dechallenge . If no, this is a negative dechallenge.  
(Note : This criterio n is not applicabl e if: (1) the AE resulte d in death or permanen t disability ; (2) the AE resolved/i mprove d despit e continuation of 
the Merck product ; or (3) the trial is a single -dose drug trial) ; or (4) Merck product(s ) is/are only used one time.) 
Recha llenge Was the subjec t re-expose d to the Merck produc t in this study ? 
If yes, did the AE recur or worsen? 
If yes, this is a positiv e rechallenge. If no, this is a negative rechallenge. 
(Note : This criterio n is not applicabl e if: (1) the initia l AE resulte d in death or permanen t disability , or (2) the trial is a single- dose drug trial); or 
(3) Merck product(s ) is/are used only one time). 
NOTE : IF A RECHALLENG E IS PLANNE D  FOR AN ADVERS E EVEN T W HICH WAS SERIOU S AND W HICH MAY HAVE BEEN 
CAUSE D BY THE MERCK PRODUCT , OR IF REEXPOSURE TO THE MERC K PRODUC T POSE S ADDITIONAL POTE NTIAL 
SIGNIFICAN T RISK TO THE SUBJECT , THEN THE RECHALLE NGE MUST BE APPROVE D IN ADVANCE BY THE U.S. CLINICA L 
MONITO R AS PER DOS E MODIFICATIO N GUIDELINE S  IN THE PROTOCOL. 
 Cons istenc y 
with Tria l 
Treat ment 
Profil e Is the clinical/pathologica l presentatio n of the AE consisten t with previou s knowledg e regardin g the Merck produc t or drug class pharmacolog y 
or toxicology?  
The assess ment of relationshi p will be reporte d on the case repor t forms /worksheet s by an investigato r who is a qualifie d physicia n accordin g to his/he r best clinica l judgment, includin g 
consideratio n of the abov e elements. 
Recor d one of the following Use the following scale of criteria as guidanc e (not all criteria must be presen t to be indicative of a Merck produc t relationship). 
Yes, there is a reasonab le 
possibility of M erck product 
relationship . Ther e is evidenc e of exposur e to the Merck product . The temporal sequenc e of the AE onset relativ e to the administratio n of the Merck produc t 
is reasonable.  The AE is m ore likely explaine d by the Merck produc t than by anothe r cause. 
No, there is not a reasonable possibility 
Merck product relationshi p Subjec t  did  not  receive  the  Merck  produc t  OR  temporal  sequenc e  of the  AE  onset  relativ e  to administratio n  of the  Merck  produc t  is not 
reasonabl e OR the AE is more likely explained by another  cause than the Merck product .  (Also entered for a subjec t with overdos e withou t an 
associate d AE.) 
 
 Final  18-Dec-2014  
Version 5.0  9
 Pembroliz umab Event  of Clinical  Interest  Guidance Docu ment  
  
 
 
12.9  Event of Clinical Interest Guidance Document  
 
 
PEMBROLIZUMAB PROGRAM  
(MK-3475)  
 
 
 
EVENT OF CLINICAL INTEREST  
 
GUIDANCE DOCUMENT  
   
Version 5.0 
 
For Instructional Purpose Only 
 
   
  
*Ensure that you are using the most current version of this document.  
 
 Final  18-Dec-2014  
Version 5.0  1
 Pembroliz umab Event  of Clinical  Interest  Guidance Docu ment  
  
 
 Final  18-Dec-2014  
Version 5.0  1
 Pembroliz umab Event  of Clinical  Interest  Guidance Docu ment  
 REVISION HISTORY LOG  
 
 
Version  Effective  
Date * Revision  
Author   
Action  
1 08-Aug-2012  Kevin Gergich  Initial Release of guidance document for MK -3475  
2 07-June-2013  Marty Huber,  
Kevin Gergich, 
Holly Brown  Revised title, formerly was “MK -3475 Immune -Related  
Adverse Event Identification, Evaluation and 
Management  
Guidance Document  for Investigators”  
 
Revised the format of irAE Guidance document, 
including layout, font, sectioning, etc. for consistency 
with Sponsor Events of Clinical Interest guidance 
documents.  
 
Modified Categories for irAEs:  
– Replaced GI with Colitis category.  
– Removed Neurologic category.  
– Added Renal category. 
 
Removed detail in the irAE Guidance document that can 
be located in the Investigator’s Brochure for MK -3475. 
 
Removed details regarding non -MK-3475 compounds. 
Added ECI reporting guidelines.  
Included a Table Events of Clinical Interest: Immune - 
Related Adverse Events that includes the key terms.  
– Also placed a pull -out quick- review sheet in the  
Appendix.  
 
Updated background, diagnosis and course of treatment 
details for irAEs.  
 
 Final  18-Dec-2014  
Version 5.0  1
 Pembroliz umab Event  of Clinical  Interest  Guidance Docu ment  
 3 10-Sep-2014  Marty Huber , 
Kevin Gergich,  
Holly Brown  Renamed the document: “Pembrolizumab Program (MK - 
3475) - Events of Clinical Interest Guidance Document”.  
 
Introduced generic name: pembrolizumab (MK -3475) 
and inserted throughout the document.  
 
Updated Overview – Section 1  
- Clarified the scope of the document and the reporting 
window for ECIs  
 
- Updated Table 1 with medDRA Preferred Terms for 
adverse events to correspond with reporting of terms to 
clinical database, rearranged the order, and updated the 
reporting criteria.  
 
-  Updated the dose modification/discontinuation section 
to clarify discontinuation and hold terminology.  
 
Updated Section 2 – ECI Reporting Guidelines 
 
   
 
 Final  18-Dec-2014  
Version 5.0  1
 Pembroliz umab Event  of Clinical  Interest  Guidance Docu ment  
    – Clarified that ECIs must be reported to Merck 
within 24  
hours regardless of attribution to study treatment or 
etiology.  
 
Updated Section 3  
–   For All Sections, removed the Course of Action 
for 
Grade 1 events.  
 
-   Section 3.1 Pneumonitis 
– Moved Pneumonitis to beginning of ECI 
Section  
– Updated management guidelines for Grade 2 
and 
Grade 3 -4 events  
 
- Section 3.2 Colitis: 
- Updated AE terms and ECI criteria, updated 
course of action language for clarity  
 
- Section 3.3 Endocrine: 
- Updated ECI criteria and updated course of 
action language for clarity.  
- Added subsections for hypophysitis, 
hype rthyroidism and hypothyroidism to clarify 
management guidelines.  
 
- Section 3.4 Hematologic: 
- New section added. 
 
- Section 3.5: Hepatic: 
- Updated terms and added additional guidance 
for reporting of DILI ECI; updated course of action 
for clarity  
 
- Sect ion 3.6 Neurologic: 
- New section added. 
 
- Section 3.7 Ocular: 
- Changed the name of this section from Eye to  
Ocular  
- Added the term “iritis”, updated ECI 
guidance, and updated course of action language for 
clarity  
 
    
     
 
    
         
        
 
 Final  18-Dec-2014  
Version 5.0  1
 Pembroliz umab Event  of Clinical  Interest  Guidance Docu ment  
  
   
   - Section 3.11 Infusion Reactions:  
- New section added. 
 
- Section 3.12: Follow-up to Resolution: 
- New section added. 
 
- Section 4: 
- References updated. 
 
- Section 5: 
- ECI table updated for consistency with Table 
1. 
 
- Section 6: Appendix 2 – Past Medical History 
Related to  
Dermatologic Event:  New section added.  
 
         
      
 
         
   4 04-Dec-2014  Scot 
Ebbinghaus, 
Oswaldo 
Bracco,  
Holly Brown, 
Kevin Gergich  - Table 1  
- Updated Endocrine (reported as ECI if  ≥ 
Grade 3 or ≥ Grade 2 and resulting in dose 
modification or use of systemic steroids to treat the 
AE) Section  
to include:  
- Hyperglycemia, if ≥Grade 3 and associated 
with ketosis or metabolic acidosis (DKA)  
- Created new section in Table 1 – Endocrine 
(reported as ECI) and added:  
- Type 1 diabetes m ellitus (if new onset)  
- Hepatic: Clarified Transaminase elevations as:  
- Transaminase elevations (ALT and/or AST)  
- Section 3.2 Colitis 
- Updated the duration of diarrhea requirments under 
the Course of Action for Grade 2 and Grade  
3 
- Section 3.3 Endocrine 
- Clarified Course of Action for 
hyperthyroidism and hypothyroidism  
         
         
 
    
       5 18-Dec-2014  Holly  Brown  
Kevin Gergich  - Section 3.3 Endocrine  
- Updated the Course of Action for 
Hypophysitis  
         *Ensure that you are using the most current version of this document. 
 
 
Final  18-Dec-2014  
Version 5.0  5  
 Pembrolizumab Event of Clinical Interest Guidance Document  
 
 
TABLE OF CONTENTS  
 
 1. OVERVIEW ............................................................................................................................... 6 2. ECI REPORTING GUIDELINES .............................................................................................. 8 
3. ECI CATEGORIES AND TERMS ............................................................................................ 8 3.1 Pneumonitis .......................................................................................................................... 9 3.2 Colitis .................................................................................................................................. 10 3.3 Endocrine ............................................................................................................................ 12 3.4 Hematologic ........................................................................................................................ 15 3.5 Hepatic ................................................................................................................................ 16 3.6 Neurologic........................................................................................................................... 18 3.7 Ocular.................................................................................................................................. 19 3.8 Renal ................................................................................................................................... 20 3.9 Skin ..................................................................................................................................... 21 3.9.1. Immediate Evaluation for Potential Skin ECIs ........................................................... 22 3.10 Other ................................................................................................................................. 23 3.11 Infusion Reactions ............................................................................................................ 24 3.12 Follow-up to Resolution ................................................................................................... 26 4. REFERENCES ......................................................................................................................... 27 5. APPENDIX 1 –Events of Clinical Interest (ECI) – Reference Table ...................................... 28 
6. APPENDIX 2 – Past  Medical History Related to Dermatologic Event ................................... 29 
7. APPENDIX 3 – Presentation of the Dermatologic Event ........................................................ 30 
8. APPENDIX 4 – Focused Skin Examination............................................................................. 32 
 
 
Final  18-Dec-2014  
Version 5.0  6  
  
 
1. OVERVIEW  
 
 The purpose of this document is to provide study sites with guidance on the identification and management of  
Events of Clinical Interest for the MK-3475 (also known as pembrolizumab) program.  Based on the literature review [1 -11], and consideration of mechanism of action of 
pembrolizumab, potential immune- related adverse events (irAEs) are the primary Event of 
Clinical Interest (ECI). Immune -related AEs are adverse events associated with the treatment of 
patients with immunotherapy treatments that appear to be associated with the immune therapy’s mechanism of action. Based on these potential irAEs, the sponsor has defined a list of specific adverse event terms (ECIs) that are selected adverse experiences that must be reported to 
Merck within 24 hours from the time the Investigator/physician is aware of such an occurrence, 
regardless of whether or  not the investigator/physician considers the event to be related to study 
drug(s). In addition, these ECIs require additional detailed information to be collected and entered in the study database. ECIs may be identified through spontaneous patient report and / or upon review of subject data. Table 1 provides the list of terms and reporting requirements for AEs that must be reported as ECIs for MK-3475 protocols.  Of note, the requirement for reporting of ECIs applies to all arms, including comparators, of MK - 
3475 clinical trials  
 Given that our current list of events of clinical interest is not comprehensive for all potential immune -related events, it is possible that AEs other than those listed in this document may be 
observed in patients receiving pembrolizumab. Therefore  any  Grade  3  or  higher  event  that  the  investigator/physician considers  to  be immune-related should be reported as an ECI regardless of whether the specific event term is in Table 1 and reported to Merck within 24 
hours from the time the Investigator/phy sician is aware of such an occurrence. Adverse events 
that are both an SAE and an ECI should be reported one time as an SAE only, however the event must be appropriately identified as an ECI as well in in the database.   
  
 
 
Final  18-Dec-2014  
Version 5.0  7  
 Table 1: Events of Clinical Interest  
Pneumonitis (reported as ECI if ≥ Grade 2)  
Acute interstitial pneumonitis  Interstitial lung disease  Pneumonitis  
Colitis (reported as ECI if ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to 
   Intestinal Obstruction  Colitis  Colitis microscopic  
Enterocolitis  Enterocolitis hemorrhagic  Gastrointestinal perforation  
Necrotizing colitis  Diarrhea   
Endocrine (reported as ECI if ≥ Grade 3 or ≥ Grade 2 and resulting in dose modification or use of systemic 
steroids to treat  
  Adrenal Insufficiency  Hyperthyroidism  Hypophysitis  
Hypopituitarism  Hypothyroidism  Thyroid disorder  
Thyroiditis  Hyperglycemia, if ≥Grade 3 and associated with ketosis or metabolic acidosis 
(DKA)  
Endocrine (reported as ECI)  
Type 1 diabetes mellitus (if new onset)    
Hematologic (reported as ECI if ≥ Grade 3 or any grade resulting in dose modification or use of systemic steroids 
to treat the  
 Autoimmune hemolytic anemia  Aplastic anemia  Thrombotic Thrombocytopenic Purpura  
(TTP)  
Idiopathic (or immune) 
Thrombocytopenia  Purpura  (ITP)  Dissemi nated Intravascular 
Coagulation (DIC)  Haemolytic Uraemic Syndrome (HUS)  
Any Grade 4 anemia regardless of underlying mechanism  
Hepatic (reported as ECI if ≥ Grade 2, or any grade  resulting in dose modification or use of systemic steroids to treat 
  Hepatitis  Autoimmune hepatitis  Transaminase elevations (ALT and/or 
 Infusion Reactions (reported as ECI for any grade)  
Allergic reaction  Anaphylaxis  Cytokine release syndrome  
Serum sickness  Infusion reactions  Infusion -like reactions  
Neurologic (reported as ECI for any grade)  
Autoimmune neuropathy  Guillain -Barre syndrome  Demyelinating polyneuropathy  
Myasthenic syndrome    
Ocular (report as ECI if ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to treat 
  Uveitis  Iritis   
Renal (reported as ECI if ≥ Grade 2)  
Nephritis  Nephritis autoimmune  Renal Failure  
 
Renal failure acute  Creatinine elevations (report as ECI if ≥Grade 3 or  any grade resulting in dose  
modification or use of systemic steroids to treat the AE)  
 
 
Final  18-Dec-2014  
Version 5.0  8  
 Skin (reported as ECI for any grade)  
Dermatitis exfoliative  Erythema multiforme  Stevens -Johnson syndrome  
Toxic epidermal necrolysis    
Skin (reported as ECI if ≥ Grade 3)  
Pruritus  Rash  Rash generalized  
Rash maculo -papular    
Any rash considered clinically significant in the physician’s judgment  
Other (reported as ECI for any grade)  
Myocarditis  Pancreatitis  Pericarditis  
Any other Grade 3 event which is considered immune -related by the physician  
 
 Each of the events above is described within this guidance document, along with site requirements for reporting these events to the Sponsor.  The information collected should be entered into the narrative field(s) of the Adverse Event module in the database (please note, if narrative entry into the database is not available, please use the narrative text box on the 1727/AER Form).   If additional Medical History or Concomitant Medications are reported, the Medical History and Concomitant Medication modules in the database must be updated.  In addition, the guidelines include recommendations on the management of these ECIs. These guidelines are intended to be applied when the physician determines the events to be related to pembrolizumab. Note:
 if after the evaluation the event is determined not to be related, the 
physician is instructed to follow the ECI reporting guidance but does not need to follow the treatment guidance (below). Therefore, these recommendations should be seen as guidelines and the treating physician should exercise individual clinical judgment based on the patient.  For any question of dose modification or other treatment options, the specific language in the protocol 
should be followed.  Any questions pertaining to the collection of this information or 
management of ECIs should be directed to your local Sponsor contact. 
 
Dose Modification/Discontinuation  
 
The treatment guidance provides specific direction when to hold and/or discontinue pembrolizumab for each immune related adverse event.  Of note, when the guidance states to 
“discontinue” pembrolizumab this is the permanent discontinuation of treatment with pembrolizumab. “Hold” means to stop treating with pembrolizumab but resumption of tr eatment 
may be considered assuming the patient meets the criteria for resumption of treatment.  
  
2. ECI REPORTING GUIDELINES  
ECIs are selected non -serious and serious adverse experiences that must be reported to Merck  
within 24 hours  regardless of attribu tion to study treatment.  The AEs listed in this document 
and any event that meets the ECI criteria (as noted) in Table 1 or in the respective protocol 
 
 
Final  18-Dec-2014  
Version 5.0  9  
 (event term and Grade) must be reported regardless  of physician -determined causality with study 
medicati on and whether or not considered immune- related by the  physician  (unless otherwise 
specified).   Physicians/study coordinators/designated site personnel are required to record these 
experiences as ECIs on the Adverse Experience electronic Case Report Forms  (eCRFs) (or on 
paper) and to provide supplemental information (such as medical history, concomitant medications, investigations, etc.) about the event. 
 – Please refer to the Data Entry Guidelines (DEGs) for your protocol.  
– Please refer to protocol for d etails on reporting timelines and reporting of Overdose and 
Drug Induced  
Liver Injury (DILI).  
3. ECI CATEGORIES AND TERMS  
This  section describes the  ECI  categories and  outlines subject management guidelines when an  
ECI  is reported.   
3.1 Pneumonitis  
 
The following AE terms, if considered ≥ Grade 2, are considered ECIs and should be reported to the Sponsor within 24 hours of the event:  – Pneumonitis – Interstitial lung disease  
– Acute interstitial pneumonitis  
 If symptoms indicate possible new or worsening cardiac abnormalities additional testing and/or a cardiology consultation should be considered.  All attempts should be made to rule out other causes such as metastatic disease, bacterial or viral infection .  It is important that patients with a sus pected diagnosis of pneumonitis be 
managed as per the guidance below until treatment -related pneumonitis is excluded. 
Treatment of both a potential infectious etiology and pneumonitis in parallel may be warranted. Management of the treatment of suspected pneumonitis with steroid treatment 
should not be delayed for a therapeutic trial of antibiotics.  If an alternative diagnosis is 
established, the patient does not require management as below; however the AE should be 
reported regardless of etiology.  
Course of Action  
 
Grade 2 events:  
– Report as ECI  
– Hold pembrolizumab. – Consider pulmonary consultation with bronchoscopy and biopsy/BAL. – Consider ID consult 
 
 
Final  18-Dec-2014  
Version 5.0  1
  
 – Conduct an in person evaluation approximately twice per week 
– Consider frequent Chest X- ray as pa rt of monitoring 
– Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg/day prednisone or equivalent.  When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. – Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks. – Second episode of pneumonitis – discontinue pembrolizumab if upon re- challenge the 
patient develops a second episode of Grade 2 or higher pneum onitis.  
 Grade 3 and 4 events: – Report as ECI  
– Discontinue pembrolizumab. – Hospitalize patient 
– Bronchoscopy with biopsy and/or BAL is recommended. – Immediately  treat  with  intravenous  steroids  (methylprednisolone 125  mg  IV).  When  symptoms  improve to Grade 1 or less, a high dose oral steroid (prednisone 1 to 2 mg/kg once per 
day or dexamethasone 4 mg every 4 hours) taper should be started and continued over no less than 4 weeks. – If IV steroids followed by high dose oral steroids does not reduce initial symptoms within 48 to 72 hours, treat with additional anti- inflammatory measures. Discontinue additional anti-
inflammatory measures upon symptom relief and initiate a prolonged steroid taper over 45 to 60 days. If symptoms worsen during ster oid reduction, initiate a retapering of steroids starting at a 
higher dose of 80 or 100 mg followed by a more prolonged taper and administer additional anti-inflammatory measures, as needed  
– Add prophylactic antibiotics for opportunistic infections.   
3.2 Colitis  
 
The following AE terms, if considered ≥ Grade 2 or resulting in dose modification or use of systemic steroids to treat the AE, are considered ECIs and should be reported to the Sponsor within 24 hours of the event:  – Colitis  
– Colitis microscopic 
– Enterocolitis  
– Enterocolitis hemorrhagic – Gastrointestinal perforation  
– Intestinal obstruction  
– Necrotizing colitis  
– Diarrhea  
 All attempts should be made to rule out other causes such as metastatic disease, bacterial or parasitic infection, viral gastroenteritis, or the first manifestation of an inflammatory bowel 
 
 
Final  18-Dec-2014  
Version 5.0  1
  
 disease by examination for stool leukocytes, stool cultures, a Clostridium difficile titer and 
endoscopy.   However the AE should be reported regardless of etiology.  
Course of Action  
 
Grade 2 Diarrhea/Colitis (4 -6 stools/day over baseline, dehydration requiring IV fluids < 24 
hours, abdominal pain, mucus or blood in stool): – Report as ECI  
– Hold pembrolizumab. – Symptomatic Treatment 
– For Grade 2 diarrhea that persists for greater than 3 days, and for diarrhea with blood and/or mucus, o Consider GI consultation and endoscopy to confirm or rule out colitis o Administer oral corticosteroids (prednisone 1-2 mg/kg QD or equivalent) – When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. – Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks. – If symptoms worsen or persist > 3 days treat as Grade 3  Grade 3 Diarrhea/Colitis (or Grade 2 diarrhea that persists for > 1 week):  
– Report as ECI  
– Hold pembrolizumab. – Rule out bowel perforation. Imaging with plain films or CT can be useful. – Recommend consultation with Gastroenterologist and confirmation biopsy with endoscopy. – Treat with intravenous steroids (methylprednisolone 125 mg) followed by high dose oral steroids (prednisone 1 to 2 mg/kg once per day or dexamethasone 4 mg every 4 hours)   When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Taper over 6 to 8 weeks in patients with diffuse and severe ulceration and/or bleeding. – Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks. –  If IV steroids followed by high dose oral steroids does not reduce initial symptoms within 48 to 72 hours, consider treatment with additional anti- inflammatory measures as described in 
the literature [5]. Discontinue additio nal anti -inflammatory measures upon symptom relief and 
initiate a prolonged steroid taper over 45 to 60 days. If symptoms worsen during steroid reduction, initiate a retapering of  
steroids starting at a higher dose of 80 or 100 mg followed by a more prolonged taper and administer  
additional anti- inflammatory measures as needed.  
  Grade 4 events:  
 
 
Final  18-Dec-2014  
Version 5.0  1
  
 –  Report as ECI  
–  Permanently discontinue pembrolizumab. 
–  Manage as per Grade 3.  
   
3.3 Endocrine  
 
 The following AE terms, if considered ≥Grade 3 or if ≥Grade 2 and require holding/discontinuation/ modification of pembrolizumab dosing, are considered ECIs and should be reported to the Sponsor within 24 hours of the event:  – Adrenal insufficiency – Hyperthyroidism 
– Hypophysitis – Hypopituitarism  
– Hypothyroidism – Thyroid disorder – Thyroiditis  
 All attempts should be made to rule out other causes such as brain metastases, sepsis and/or infection. However the AE should be reported regardless of etiology.  
Hypophysitis or other symptomatic endocrinopathy other th an hypo - or hyperthyroidism  
 Grade 2 -4 events: 
– Report as ECI if appropriate – Hold pembrolizumab – Rule out infection and sepsis with appropriate cultures and imaging. – Monitor thyroid function or other hormonal level tests and serum chemistries more frequently until returned to baseline values. – Pituitary gland  imaging should be  considered (MRIs with  gadolinium and  selective cuts  of  the pituitary can show enlargement or heterogeneity and confirm the diagnosis). – Treat with prednisone 40 mg p.o. or equivalent per day.  When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.  Replacement of appropriate hormones may be required as the steroid dose is tapered. – Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks. – Hypophysitis with  clinically  significant  adrenal  insufficiency  and  hypotension, dehydration, and electrolyte abnormalities (such as hyponatr emia and hyperkalemia) constitutes 
adrenal crisis.  
– Consultation with an endocrinologist may be considered.   
 
 
Final  18-Dec-2014  
Version 5.0  1
  
 Hyperthyroidism and Hypothyroidism  
 
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated 
based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. 
 
Grade 2 hyperthyroidism, Grade 2-4 hypothyroidism events: – Report as ECI if appropriate (see Table 1)  
– Monitor thyroid function or other hormonal level tests and serum chemistries more frequently until returned to baseline values. – Thyroid hormone and/or steroid replacement therapy to manage adrenal insufficiency. – Therapy with pembrolizumab can be continued while treatment for the thyroid disorder is instituted.  
– In hyperthyroidism, non- selective beta -blockers (e.g. propranolol) are suggested as initial 
therapy.  
– In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or liothyroinine, is indicated per standard of care. – Consultation with an endocrinologist may be considered.  Grade 3 hyperthyroidism events: – Report as ECI  
– Hold pembrolizumab. – Rule out infection and sepsis with appropriate cultures and imaging. – Treat with an initial dose of methylprednisolone 1 to 2 mg/kg intravenously followed by 
oral prednisone 1 to 2 mg/kg per day. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks.  Grade 4 hyperthyroidism events: – Report as ECI  
– Discontinue pembrolizumab. – Manage as per Grade 3  
  
Type 1 diabetes mellitus (if new onset) and ≥ Grade 3 Hyperglycemia  
 
The following AE terms are considered ECIs and should be reported to the Sponsor within 24 hours of the event:  – Type I diabetes mellitus (T1DM), if new onset, including diabetic ketoacidosis (DKA)  
– Grade 3 or higher hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis (DKA).  
 
 
 
Final  18-Dec-2014  
Version 5.0  1
  
 Immune- mediated diabetes may present as new onset of Type 1 diabetes or an abrupt w orsening 
of pre - existing diabetes associated with laboratorial evidence of beta cell failure. All attempts 
should be made to rule out other causes such as type 2 diabetes mellitus (T2DM), T2DM 
decompensation, steroid-induced diabetes, physiologic stress-induced diabetes, or poorly controlled pre-existing diabetes (either T1DM or T2DM), but events meeting the above criteria should be reported as ECIs regardless of etiology. The patients may present with hyperglycemia (abrupt onset or abrupt decompensation) with clinical evidence of diabetic ketoacidosis or laboratory evidence of insulin deficiency, such as ketonuria, laboratory evidence of metabolic acidosis, or low or undetected c-peptide.   
Course of Action  
 T1DM should be immediately treated with insulin.  
 
T1DM or Grade 3 -4 Hyperglycemia events:  
- Report as ECI if appropriate (see Table 1)  
- Hold pembrolizumab for new onset Type 1 diabetes mellitus or Grade 3- 4 hyperglycemia 
associated with evidence of beta cell failure, and resume pembrolizumab when patients are clinically and metabolically stable.  
- Insulin  replacement  therapy  is  recommended  for  Type  I  diabetes  mellitus  and  for  
Grade  3 -4 hyperglycemia associated with metabolic acidosis or ketonuria.  
- Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated hemoglobin, and C- peptide.  
- Consultation with an Endocrinologist is recommended. - Consider local testing for islet cell antibodies and antibodies to GAD, IA -2, ZnT8, and 
insulin may be obtained.    
3.4 Hematologic  
 
The following AE term, if considered Grade ≥3 or requiring dose modification or use of systemic steroids to treat the AE, are considered an ECI and should be reported to the Sponsor within 24 hours of the event:  – Autoimmune hemolytic anemia  
– Aplastic anemia  
– Disseminated Intravascular Coagulation (DIC)  
– Haemolytic Uraemic Syndrome (HUS)  
– Idiopathic (or immune) Thrombocytopenia Purpura (ITP) – Thrombotic Thrombocytopenic Purpura (TTP) – Any Grade 4 anemia regardless of underlying mechanism  
 
 
Final  18-Dec-2014  
Version 5.0  1
  
 All attempts should be made to rule out other causes such as metastases, sepsis and/or infection.    
Relevant diagnostic studies such as peripheral blood smear, reticulocyte count, LDH, haptoglobin, bone marrow biopsy or Coomb’s test, etc., should be considered to confirm the diagnosis. However the AE should be reported regardless of etiology.   
Course of Action  
 
Grade 2 events:  
– Report as ECI  
– Hold pembrolizumab – Prednisone 1- 2 mg/kg daily may be indicated  
– Consider Hematology consultation. Permanently  discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.  Grade 3 events:  
– Report as ECI  
– Hematology consultation. 
– Hold pembrolizumab  Discontinuation should be considered as per spe cific protocol 
guidance.  
– Treat with methylprednisolone 125 mg iv or prednisone 1-2 mg/kg p.o. (or equivalent) as appropriate – Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks.  Grade 4 events:  
– Report as ECI  
– Hematology consultation  
– Discontinue pembrolizumab for all solid tumor indications; refer to protocol for hematologic malignancies.  
– Treat with methylprednisolone 125 mg iv or prednisone 1-2 mg/kg p.o. (or equivalent) as appropriate   
3.5 Hepatic  
 
The following AE terms, if considered ≥ Grade 2 or greater (or any grade with dose modification or use of systemic steroids to treat the AE), are considered ECIs and should be reported to the Sponsor within 24 hours of the event:  – Autoimmune hepatitis  
– Hepatitis  
– Transaminase elevations  
 
 
 Fi n al  1 8 -D ec -2 0 1 4  
V ersi o n 5. 0  1
  
 All atte m pts s h o ul d be ma de t o r ule o ut ot her ca us es s uc h as metastatic disease, i nfecti o n or 
ot her he patic diseases. H o we ver t he A E s h o ul d be re p orte d r e gar dless of eti ol o g y. 
 
Dr u g I n d uce d Li ver I nj ur y ( DI LI)  
 
I n a d diti o n, t he e ve nt m ust be re p orte d as a Dr u g I n d uce d Li ver I nj ur y ( DI LI) E CI, if t he patie nt 
meets t he la b orat or y criteria f or p ote ntial DI LI defi ne d as:  
  A n  ele vate d ala ni ne tr a ns a mi nase ( A L T) or as p art ate tra nsa mi nas e ( A S T) l a b val ue t hat is 
gr eater t ha n or e q u al t o t hree ti mes ( 3 X) t he u p per li mit of n or mal ( U L N) a n d  
   A n ele vate d t otal bilir u bi n la b val ue t hat is greater t ha n or e q ual t o t w o ti mes ( 2 X) U L N 
a n d  
  At t he sa me ti m e, a n al kali ne p h os p hatase ( A L P) l a b val ue t hat is less t ha n 2 X U L N, 
  As  a res ult of wit hi n - pr ot oc ol- s pecific t esti n g or u nsc he d ule d testi n g.  
 
N ote  t hat a n y he p atic i m m u ne E CI meeti n g DI LI criteria s h o ul d o nl y be r e p orte d o nce as a DI LI 
e ve nt.  
 
C o urse of  Acti o n  
 
Gra de 2 e ve nts:  
– Re p ort as E CI  
–  H ol d pe m br oliz u ma b w he n A S T or A L T > 3. 0 t o 5. 0 ti mes U L N a n d/ or t otal bilir u bi n 
> 1. 5 t o 3. 0 ti mes 
U L N.  
–  M o nit or li ver f u ncti o n tests m ore fre q u e ntl y u ntil ret ur ne d t o bas eli ne val u es (c o nsi der 
wee kl y).  
o Treat wit h 0. 5- 1 m g/ k g/ da y m et h yl pr e d nis ol o ne or oral e q ui vale nt a n d w he n L F T ret ur ns 
t o gra d e 1 or b aseli ne, ta per ster oi ds o ver at least 1 m o nt h, c o nsi der pr o p h yl actic a nti bi otics f or 
o p p ort u nistic i nfecti o ns, a n d res u me p e m br oliz u ma b per pr ot o c ol 
– Per ma ne ntl y dis c o nti n ue f or i na bilit y t o re d u ce c ortic oster oi d d ose t o 1 0 m g or less of 
pre d nis o ne or e q ui vale nt per da y wit hi n 1 2 wee ks. 
–  Per ma ne ntl y dis c o nti n ue pe m br oliz u ma b f or patie nts wit h li ver metastasis w h o be gi n 
treat me nt wit h  
Gra de 2 ele vati o n of A S T or A L T, a n d A S T or A L T i ncreas es ≥ 5 0 % r elati ve t o baseli ne a n d 
lasts ≥ 1 wee k. 
 
Gra de 3 e ve nts:  
– Re p ort as E CI  
–  Disc o nti n ue pe m br oliz u ma b w he n A S T or A L T > 5. 0 ti mes U L N a n d/ or t otal bilir u bi n 
> 3. 0 ti mes 
U L N.  
–  C o nsi der a p pr o priate c o ns ultati o n a n d li ver bi o p s y t o esta blis h eti ol o g y of h e patic i nj ur y, 
if necessar y  
 
 
Final  18-Dec-2014  
Version 5.0  1
  
 – Treat with high -dose intravenous glucocorticosteroids for 24 to 48 hours. When 
symptoms improve to Grade 1 or less, a steroid taper with dexamethasone 4 mg every 4 hours or 
prednisone at 1 to 2 mg/kg should be started and continued over no less than 4 weeks. – If serum transaminase levels do not decrease 48 hours after initiation of systemic steroids, oral mycophenolate mofetil 500 mg every 12 hours may be given. Infliximab is not recommended due to  its potential for hepatotoxicity.  
  – Several courses of steroid tapering may be necessary as symptoms may worsen when the 
steroid dose is decreased.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks.  Grade 4 events:  
– Report as ECI  
– Permanently discontinue pembrolizumab – Manage patient as per Grade 3 above  
  
3.6 Neurologic  
 
The following AE terms, regardless of grade, are considered ECIs and should be reported to the Sponsor within 24 hours of the event:  – Autoimmune neuropathy – Demyelinating polyneuropathy – Guillain -Barre syndrome 
– Myasthenic syndrome  All attempts should be made to rule out other causes such as metastatic disease, other medications or infectious causes. However the AE should be reported regardless of etiology.   
Course of Action  
 
Grade 2 events:  
– Report as ECI  
– Moderate (Grade 2) – consider withholding pembrolizumab. 
– Consider treatment with prednisone 1-2 mg/kg p.o. daily as appropriate – Consider Neurology consultation. Consider biopsy for confirmation of diagnosis. – Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks.  Grade 3 and 4 events: – Report as E CI 
 
 
Final  18-Dec-2014  
Version 5.0  1
  
 – Discontinue pembrolizumab 
– Obtain neurology consultation. Consider biopsy for confirmation of diagnosis – Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent once per day. If condition worsens consider IVIG or other immunosuppressive therapies as per local guidelines  
 When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.    
3.7 Ocular  
 
The following AE terms, if considered Grade ≥2 or requiring dose modification or use of systemic steroids to treat the AE, is considered an ECI and should be reported to the Sponsor within 24 hours of the event:  – Uveitis  
– Iritis  
 All attempts should be made to rule out other causes such as metastatic disease, infection or other ocular disease (e.g. glaucoma or cataracts). However the AE should be reported regardless of etiology.   
Course of Action  
 
Grade 2 events:  
– Evaluation by an ophthalmologist is strongly recommended. – Treat with topical steroids such as 1% pred nisolone acetate suspension and iridocyclitics. 
– Discontinue  pembrolizumab  as  per  protocol  if  symptoms  persist  despite  treatment  
with  topical immunosuppressive therapy.  Grade 3 events:  
– Evaluation by an ophthalmologist is strongly recommended – Hold pembrolizumab and consider permanent discontinuation as per specific protocol guidance.  
– Treat with systemic corticosteroids such as prednisone at a dose of 1 to 2 mg/kg per day.   When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. – Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks.    
 
 
Final  18-Dec-2014  
Version 5.0  1
  
 Grade 4 events:  
– Evaluation by an ophthalmologist is strongly recommended  
– Permanently discontinue pembrolizumab. 
– Treat with corticosteroids as per Grade 3 above  
  
3.8 Renal  
 
The following AEs if ≥ Grade 2 are considered ECIs and should be reported to the Sponsor within 24 hours of the event:  – Nephritis  
– Nephri tis autoimmune  
– Renal failure  
– Renal failure acute  
 Creatinine elevations ≥ Grade 3 or any grade with dose modification or use of systemic steroids to treat the AE. 
 All attempts should be made to rule out other causes such as obstructive uropathy, progression of disease, or injury due to other chemotherapy agents.  A renal consultation is recommended. However the AE should be reported regardless of etiology.   
Course of Action  
 
Grade 2 events:  
– Hold pembrolizumab – Treatment with prednisone 1-2 mg/kg p.o. daily. – Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks.  Grade 3 -4 events: 
– Discontinue pembrolizumab – Renal consultation with consideration of ultrasound and/or biopsy as appropriate – Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone IV or equiva lent 
once per day.  
 When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.   
  
 
 
Final  18-Dec-2014  
Version 5.0  2
  
 3.9 Skin  
 
Rash and Pruritus 
 
The following AEs should be considered as ECIs, if ≥ Grade 3 and should be reported to the Sponsor within 24 hours of the event:  – Pruritus  
– Rash  
– Rash generalized  
– Rash maculo -papular 
– In addition to CTCAE Grade 3 rash, a ny rash that is considered clinically significant, in 
the physician's judgment, should be treated as an ECI. Clinical significance is left to the physician to determine, and could possibly include rashes such as the following: o rash with a duration >2 weeks; 
OR 
o rash that is >10% body surface area; OR 
o rash that causes significant discomfort not relieved by topical medication or temporary cessation  
of study drug.  Classic acneiform rash from afatinib < grade 3 need not be reported to sponsor. 
 
Other Skin ECIs  
 
The following AEs should always be reported as ECIs, regardless of grade, and should be 
reported to the 
Sponsor within 24 hours of the event:  – Dermatitis exfoliative  
– Erythema multiforme  
– Steven’s Johnson syndrome – Toxic epidermal necrolysis  
 Please note, the AE should be reported regardless of etiology.  
Course of Action  
 
Grade 2 events:  
– Symptomatic treatment should be given such as topical glucocorticosteroids (e.g., betamethasone  
0.1% cream or hydrocortisone 1%) or urea- containing creams i n combination with oral anti-
pruritics  
(e.g., diphenhydramine HCl or hydroxyzine HCl). – Treatment with oral steroids is at physician’s discretion for Grade 2 events.  
 
 
 
Final  18-Dec-2014  
Version 5.0  2
  
 Grade 3 events:  
– Hold pembrolizumab. 
– Consider Dermatology Consultation and biopsy for confirmation of diagnosis. – Treatment with oral steroids is recommended, starting with 1 mg/kg prednisone or equivalent once per day or dexamethasone 4 mg four times orally daily.  When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks.  Grade 4 events:  
– Permanently discontinue pembrolizumab. – Dermatology co nsultation and consideration of biopsy and clinical dermatology 
photograph. – Initiate steroids at 1 to 2 mg/kg prednisone or equivalent.  When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.   
3.9.1. Immediate Evaluation for Potential Skin ECIs  
A. Photographs : 
Every attempt should be made to get a photograph of the actual ECI skin lesion or rash as soon 
as possible . Obtain appropriate consent for subject photographs if a consent form 
addendum is  required by your IRB/ERC.  
– Take digital photographs of: o the head (to assess mucosal or eye involvement), o the trunk and extremities, and o a close-up of the skin lesion/rash. 
– If possible, a ruler should be placed alongside the site of a skin occurre nce as a fixed 
marker of distance.  
– The time/date stamp should be set in the 'ON' position for documentation purposes. – Photographs should be stored with the subject’s study records. – The Sponsor may request copies of photographs. The local study contac t (e.g., CRA) will 
provide guidance to the site, if needed.  
B. Past Medical History : 
Collect past medical history relevant to the event, using the questions in Appendix 2 (Past Medical History Related to Dermatologic Event) as a guide. Any preexisting con ditions not 
previously reported (e.g., drug allergy) should be entered into the Medical History eCRF.  
C. Presentation of the Event:  
Collect information on clinical presentation and potential contributing factors using the questions in Appendix 3 (Presentation of the Dermatologic Event) as a guide. This information should be summarized and entered in narrative format in the AE eCRF. Please use the available free- text fields, such as 
Signs and Symptoms. Note pertinent negatives where applicable to reflect that the information 
 
 
Final  18-Dec-2014  
Version 5.0  2
  
 was collected. Any treatments administered should be entered on the Concomitant Medication 
eCRF.  
D. Vitals Signs and Standard Laboratory Tests:  
Measure vital signs (pulse, sitting BP, oral temperature, and respiratory rate) and record on the Vital Signs eCRF.  Perform standard laboratory tests (CBC with manual differential and serum chemistry panel, including LFTs).  
E. Focused Skin Examination:  
Perform a focused skin examination using the questions in Appendix 4 (Focused Skin Examination)  as a guide. Information should be summarized and entered on the Adverse 
Experience eCRF as part of the narrative.  
F. Dermatology Consult  
Refer the subject to a dermatologist as soon as possible. – For a “severe rash” , the subject must be seen within 1-2 days of reporting the event. 
– For clinically significant rash , the subject should be seen within 3-5 days . 
 The  dermatologist  should  submit  a  biopsy  sample  to  a  certified  dermatopathology  laboratory  or  to  a pathologist experienced in reviewing skin specimens.  The site should provide the dermatologist with all relevant case history, including copies of clinical photographs and laboratory test results.   
3.10 Other  
The following AEs, regardless of grade, are considered ECIs and should be reported to the 
Sponsor within 24 hours of the event:  – Myocarditis  
– Pericarditis  
– Pancreatitis  
– Any additional Grade 3 or higher event which the physician considers to be immune related  All  attempts should be  made  to  rule  out  other  causes. Therapeutic specialists should be  
consulted as appropriate. However the AE should be reported regardless of etiology.   
Course of Action  
 
Grade 2 events or Grade 1 events that do not improve with symptomatic treatment: – Withhold pembrolizumab. – Systemic  corticosteroids may be indicated.  
– Consider biopsy for confirmation of diagnosis. – If pembrolizumab held and corticosteroid required, manage as per grade 3 below.  Grade 3 events:  
– Hold pembrolizumab 
 
 
Final  18-Dec-2014  
Version 5.0  2
  
 – Treat with systemic corticosteroids at a dose of 1  to 2 mg/kg prednisone or equivalent 
once per day.  
– When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks. – Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks. Otherwise, pembrolizumab treatment may be restarted and the dose modified as specified in the protocol  Grade 4 events:  
– Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equiva lent 
once per day.  
– Discontinue pembrolizumab  
3.11 Infusion Reactions  
 
The following AE terms, regardless of grade, are considered ECIs and should be reported to the Sponsor within 24 hours of the event: – Allergic reaction  
– Anaphylaxis  
– Cytokine release syndrome 
– Serum sickness  
– Infusion reactions – Infusion- like reactions  
 Please note, the AE should be r eported regardless of etiology.  
 
Course of Action  
 
Refer to infusion reaction table in the protocol and below.  
  
 
 
Final  18-Dec-2014  
Version 5.0  2
  
 Infusion Reactions 
 
NCI CTCAE Grade  Treatment  Premedication at 
subsequent dosing  
Grade 1  
Mild reaction; infusion 
interruption not indicated;  
   Increase monitoring of vital signs 
as 
medically indicated until the 
     
    
  None  
Grade 2  
Requires infusion interruption but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics, IV fluids); prophylactic medications indicated for < =24 hrs Stop Infusion.  
Additional appropriate medical therapy may include but is not limited to:  
IV fluids Antihistamines  
NSAIDS Acetaminophen Narcotics  
Increase monitoring of vital signs as medically indicated until the subject is  
deemed medically stable in the opinion of the investigator.  
If symptoms resolve within one hour of stopping drug infusion, the infusion may 
be restarted at 50% of the original 
infusion rate (e.g. from 100 mL/hr 
   
      
     
 
     
  
     
   
   
   
   
 Subject may be 
premedicated  
1.5h (± 30 minutes) prior 
to infusion of pembrolizumab with : 
 Diphenhydramine 50 mg p.o. (or equivalent dose of antihistamine).  
 Acetaminophen 500-1000 mg p.o. (or equivalent dose of antipyretic).  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief 
interruption of infusion); recurrence of symptoms 
following initial improvement; 
hospitalization indicated for other clinical sequelae (e.g., renal impairment, pulmonary infiltrates)  
Grade 4:  
Life-threatening; pressor or 
ventilatory support indicated Stop Infusion.  
Addit ional appropriate medical 
therapy may include but is not limited to:  
IV fluids Antihistamines  
NSAIDS Acetaminophen Narcotics Oxygen  
Pressors Corticosteroids Epinephrine  Increase monitoring of vital signs as medically indicated until the subject is deemed medically stable 
in the opinion of the investigator. 
Hospitalization may be indicated.  
   
    
  No subsequent dosing  
Appropriate resuscitation equipment should be available in the roo m and a physician readily available during the  
period of drug administration.  
For Further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) 
at http://ctep.cancer.gov  
 
 
Final  18-Dec-2014  
Version 5.0  2
  
   
 
 
Final  18-Dec-2014  
Version 5.0  2
  
  
3.12 Follow- up to Resolution  
 
 Subjects should be followed to resolution. The Adverse Experience eCRF should be updated with information regarding duration and clinical course of the event. Information obtained from the consulting specialist, including diagnosis, should be recorded in the appropriate AE fields. Free-text fields should be used to record narrative information: 
 – Clinical course of the event – Course of treatment  
– Evidence supporting recovery – Follow-up to the clinical course  Any treatm ents administered for the event should also be entered in the Concomitant Medication 
eCRF.  
     
  
 
 
Final  18-Dec-2014  
Version 5.0  2
  
 4. REFERENCES  
 
 
1.   Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.  Nature Reviews 
Cancer  2012; 12:252-264. 
 2.   Weber JS Practical  Management of Immune-Related Adverse Events from Immune Checkpoint 
Protein  Antibodies for the Oncologist. American Society of Clinical Oncology 2012; 
1092-9118/10/1-10. 
 3.   Weber JS, Ka¨hler KC, and Hauschild A. Management of Immune- Related Adverse Events and 
Kinetics of  Response With Ipilimumab. J Clin Oncol 30. 2012.
 
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.41.6750.  
 4.   Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved Survival with 
Ipilimumab in  Patients with Metastatic Melanoma. N Engl J Med 363:711 -723, 2010. 
 5.   Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
Activity, and Immune Correlates of Anti- PD-1 Antibody in Cancer. N Engl J Med 2012; 
366:2443-2454. 
 6.   Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, et al. Safety and Activity of Anti–PD -L1 
Antibody in Patients with Advanced Cancer. N Engl J Med 2012; 366:2455-2465. 
 7.   Weber J, Thompson JA, Hamid O, et al: A randomized, double-blind, placebo-controlled, phase 
II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591-5598, 2009. 
 8.   Lemech C and Arkenau HT. Novel Treatments for Metastatic Cutaneous Melanoma and the 
Management of Emergent Toxicities. Clinical Medicine Insights: Oncology 2012:6 53–66. 
 9.   Phan GQ, Weber JS, and Sondak VK.  CTLA-4 Blockade with Monoclonal Antibodies in 
Patients with  Metastatic Cancer: Surgical Issues. Annals of Surgical Oncology 15(11):3014–
3021. 
 10. Bristol- Myers Squibb: YERVOY (ipilimumab): Serious and fatal immune -mediated adverse 
reactions — YERVOY Risk Evaluation and Mitigation S trategy 
(REMS). http://www.yervoy.com/hcp/rems.aspx
 
 11. Bristol-Myers Squibb: YERVOY   (ipilimumab) prescribing information revised March 2011.
 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf  
 
  
 
 
Final  18-Dec-2014  
Version 5.0  2
  
 5. APPENDIX 1 –Events of Clinical Interest (ECI) – Reference Table 
 
Pneumonitis (reported as ECI if ≥ Grade 2)  
Acute interstitial pneumonitis  Interstitial lung disease  Pneumonitis  
Colitis (reported as ECI if ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to treat 
  Intestinal Obstruction  Colitis  Colitis microscopic  
Enterocolitis  Enterocolitis hemorrhagic  Gastrointestinal perforation  
Necrotizing colitis  Diarrhea   
Endocrine (reported as ECI if ≥ Grade 3 or ≥ Grade 2 and resulting in dose modification or use of systemic 
steroids to treat  
  Adrenal Insufficiency  Hyperthyroidism  Hypophysitis  
Hypopituitarism  Hypothyroidism  Thyroid disorder  
Thyroiditis  Hyperglycemia, if ≥Grade 3 and associated with ketosis or metabolic acidosis 
 Endocrine (reported as ECI)  
Type 1 diabetes mellitus (if new onset)    
Hematologic (reported as ECI if ≥ Grade 3 or any grade resulting in dose modification or use of systemic steroids 
to treat the  
 Autoimmune hemolytic anemia  Aplastic anemia  Thrombotic Thrombocytopenic Purpura  
(TTP)  
Idiopathic (or immune) 
Thrombocytopenia  Purpura  (ITP)  Disseminated Intravascular 
Coagulation  (DIC)  Haemolytic Uraemic Syndrome (HUS)  
Any Grade 4 anemia regardless of underlying mechanism  
Hepatic (reported as ECI if ≥ Grade 2, or any grade resulting in dose modification or use of systemic steroids to treat 
  Hepatitis  Autoimmune hepatitis  Transaminase elevations (ALT and/or 
 Infusion Reactions (reported as ECI for any grade)  
Allergic reaction  Anaphylaxis  Cytokine release syndrome  
Serum sickness  Infusion reactions  Infusion -like reactions  
Neurologic (reported as ECI for any grade)  
Autoimmune neuropathy  Guillain -Barre syndrome  Demyelinating polyneuropathy  
Myasthenic syndrome    
Ocular (report as ECI if ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to treat 
  Uveitis  Iritis   
Renal (reported as ECI if ≥ Grade 2)  
Nephritis  Nephritis autoimmune  Renal Failure  
Renal failure acute  Creatinine elevations (report as ECI if ≥Grade 3 or any grade resulting in dose  
modification or use of systemic steroids to treat the AE)  
Skin (reported as ECI for any grade)  
Dermatitis exfoliative  Erythema multiforme  Stevens -Johnson syndrome  
Toxic epidermal necrolysis    
 
 
Final  18-Dec-2014  
Version 5.0  2
  
 Skin (reported as ECI if ≥ Grade  3) 
Pruritus  Rash  Rash generalized  
Rash maculo -papular    
Any rash considered clinically significant in the physician’s judgment  
Other (reported as ECI for any grade)  
Myocarditis  Pancreatitis  Pericarditis  
Any other Grade 3 event which is considered immune -related by the physician  
 
 
  
  
 
 
Final  18-Dec-2014  
Version 5.0  3
  
 6. APPENDIX 2 – Past Medical History Related to Dermatologic Event  
 
Past Medical History : 
Any preexisting conditions not previously reported (e.g., drug allergy) should be entered into the Medical  History eCRF.  
 1. Does the subject have any allergies? □ Yes □ No  
 If yes, please obtain the following information:  a. Any allergy to drugs (including topical or ophthalmic drugs)? □ Yes □ No  List the drug name(s) and describe the type of allergic response (e.g. rash, anaphylaxis, etc):   ____ 
_______________________________________________________________________________  b. Any allergy to external agents, such as laundry detergents, soaps, poison ivy, nickel, etc.?  □ Yes □  No 
 Describe the agent and type of allergic response: _______
_________________________________ 
_______________________________________________________________________________  c. Any allergy to food? □ Yes □ No  
Describe the food  and type of allergic response:        
__________________________________________________________________________  d. Any allergy to animals, insects? □ Yes □ No  
Describe the allergen and type of allergic response:        
__________________________________________________________________________  e. Any other allergy? □ Yes □ No  
 Describe the allergen and type of allergic response: 
  _______________________________ 
 2. Does the subject have any other history of skin reactions, skin eruptions, or rashes? □ Yes □ No  If so what kind? 
  _____________________________________________________________ 
 3. Has the subject ever been treated for a skin condition? □ Yes □ No  If so what kind? 
  _____________________________________________________________ 
 4. Is the current finding similar to a past experience? □ Yes □ No  
 
 
 
Final  18-Dec-2014  
Version 5.0  3
  
 7. APPENDIX 3 – Presentation of the Dermatologic Event  
 
 
Presentation of the event:  
Collect information on clinical presentation and potential contributing factors. Key information 
should be summarized and entered on the Adverse Experience eCRF. Any treatments administe red 
should be entered on the Concomitant Medication eCRF.  1. What is the onset time of the skin reaction, skin eruption, or rash relative to dose of study drug?  _________________________________________________________________________  2. Has the subject contacted any known allergens? □ Yes □ No  If so what kind? 
  _____________________________________________________________ 
 3. Has the subject contacted new, special, or unusual substances (e.g., new laundry detergents, soap, personal care product, poison ivy, etc.)? □ Yes □ No  If so what kind? 
  _____________________________________________________________ 
 4. Has the subject taken any other medication (over the counter, prescription, vitamins, and supplement)? □ Yes □ No  
 If so what kind? 
  _____________________________________________________________ 
 5. Has the subject consumed unaccustomed, special or unusual foods? □ Yes □ No  If so what kind? 
  _____________________________________________________________ 
 6. Does the subject have or had in the last few days any illness? □ Yes □ No  If so what kind? 
  _____________________________________________________________ 
 7. Has the subject come into contact with any family or house members who are ill? □ Yes □ No  If so who and what? 
 
 _________________________________________________________________________ 
 8. Has the subject recently been near children who have a skin reaction, skin eruption, or rash (e.g., Molluscum  Contagiosum )? □ Yes □ No 
 9. Has the subject had recent sun exposure? □ Yes □ No  10. For the current rash, have there been any systemic clinical signs? □ Yes □ No 
 
 
Final  18-Dec-2014  
Version 5.0  3
  
  
If so what kind?   ___________________________________________________________ 
 i. Anaphylaxis? □ Yes □ No ii. Signs of hypotension? □ Yes □ No iii. Signs of dyspnea? □ Yes □ No iv. Fever, night sweats, chills? □ Yes □ No  11. For the current rash, has the subject needed subcutaneous epinephrine or other systemic catecholamine therapy? □ Yes □ No  
 If so what kind? 
  ___________________________________________________________ 
 12. For the current rash, has the subject used any other medication, such as inhaled bronchodilators, antihistaminic medication, topical corticosteroid, and/or systemic corticosteroid? □ Yes □ No  List medication(s) and dose(s): 
  _______________________________________________ 
_____________________________________________________________________________  13. Is the rash pruritic (itchy)? □ Yes □ No    
  
 
 
Final  18-Dec-2014  
Version 5.0  3
  
 8. APPENDIX 4 – Focused Skin Examination  
 
 
Focused Skin Examination:  
Key information should be summarized and entered on the Adverse Experience eCRF. 
 
Primary Skin Lesions Description  
Color:    
 General description:  
    Describe the distribution of skin reaction, skin eruption, or rash on the body:     Is skin reaction, skin eruption, or rash resolving or continuing to spread?     Any associated signs on physical   
   
 
 